Chemical-Scale Studies of G Protein-Coupled Receptors and Ligand-Gated Ion Channels by Van Arnam, Ethan Buggie
  
Chemical-Scale Studies of G Protein-Coupled Receptors and 
Ligand-Gated Ion Channels 
 
 
Thesis by 
Ethan Buggie Van Arnam 
 
 
 
In Partial Fulfillment of the 
Requirements for the Degree of 
Doctor of Philosophy 
 
 
 
 
California Institute of Technology 
Pasadena, California 
2014 
(Defended December 12, 2013) 
	   ii	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2014 
Ethan Buggie Van Arnam 
All Rights Reserved 
	   iii	  
 
 
Dedicated to my parents: 
Jean and Peter Van Arnam 
 
	   iv	  
Acknowledgements 
I expected a rich scientific experience at Caltech, but never imagined how 
personally fulfilling my time here would be.  For that I have a great number of people to 
thank.  First and foremost, I want to extend heartfelt thanks to my graduate advisor 
Dennis Dougherty.  I appreciate the extensive freedom he gives his students and yet the 
compassion and personal dedication he devotes to each one of us.  Dennis is a supremely 
talented communicator, and I especially value the lessons I've learned about speaking, 
writing, and teaching from him.  I also appreciate the support he has given me and the 
confidence he has instilled in me to tackle hard scientific problems and to explore a new 
field after Caltech. 
 Henry Lester, a longtime collaborator of the Dougherty group, is an inexhaustible 
source of suggestions for new experiments and novel approaches to scientific problems.  I 
value his scientific rigor and his dedication to his students.  I also want to thank the 
members of my thesis committee, Peter Dervan, Doug Rees, and David Tirrell for their 
support and suggestions, both with regards to my graduate research and my career. 
 The Dougherty group has been a fantastic place to work (and a fantastic place at 
times to hang out and not work too).  I really look forward to keeping in touch with 
everyone I overlapped with in the group. When I first arrived in lab, Ariele Hanek, Kiowa 
Bower, and Kristin Gleitsman had saintly patience while I was learning the ropes, passed 
on endless sage advice, and made me feel welcome.  I’m very glad I got to know Jai 
Shanata, who always brought a valuable quantitative rigor to scientific discussions and 
whose worldview is refreshingly optimistic.  Sean Kedrowski answered so, so, many of 
my chemistry questions and put up with all assortment of canned fish and other exciting 
	   v	  
lunch items that I brought in.  I really enjoyed sitting next to him for three years.  Angela 
Blum and Nyssa Puskar, with whom I overlapped for a good deal of grad school, have 
great integrity and are supremely capable researchers.  Kay Limapichat helped me 
immensely to get started on fluorescence experiments and was generous with time and 
with materials she worked long to prepare.  Noah Duffy is a hell of a human being.  He 
always has an open mind, really thinks things through, and can fix absolutely anything. 
 Kristina Daeffler, Ximena da Silva, Maggie Thompson, and I all entered Caltech 
together and had the wisdom to join the Dougherty group.  Maggie has remained a good 
friend and I deeply admire her bravery to teach middle school science.  Ximena (da Silva 
Tavares Bongoll de Rossi) has the longest name of anyone I know.  Kristina and I both 
cut our teeth on GPCR projects and have commiserated on more than one topic on more 
than one occasion. 
 Tim Miles knows how to chart his own path and excel at it.  I’ve appreciated his 
friendship and look forward to watching what he does in the future.  We were ever so 
fortunate to land Michael Post in the group.  He’s carrying the nicotinic receptor torch 
forward and smiles seem to erupt everywhere he goes.  Oliver Shafaat and Fan Liu have 
orders of magnitude more mathematical competence than I do.  I really enjoyed my 
GPCR collaborations with Fan and all of our conversations.  The future involves photons 
for Kayla Busby, Matt (Jefferson) Davis, and Paul (David?) Walton.  These folks are 
breaking new ground, which made my last year in the group a lot more intellectually 
stimulating.  They made it a whole lot more fun too.  Betty Wong is bravely taking on 
some fluorescence work, and is more than up to the task.  She hasn’t been in the group 
long, but everybody agrees she’s a force for good. 
	   vi	  
 Finally, Matt Rienzo and Clint Regan were my companions in the south bay of 
desks for the last few years and I’ll deeply miss them.  Clint is steering the 
photochemistry ship – making good progress and knowing the right questions to ask.  
Matt can do very hard chemistry and very hard biology and is a very good person as well. 
 I had the privilege of working with three truly outstanding undergraduates in lab 
during my graduate career: Jessica Swallow, Emily Blythe, and Jessica Hsu.  All learned 
the ropes in lab effortlessly and accomplished much, were great to work with, and were 
often many steps ahead of me. 
 Friends in the Los Angeles area showed me that this is an awesome place to live 
and is going to be an especially hard place to leave.  Michael Van Vliet has been a 
fantastic friend and a much needed beacon of normalcy beyond the Caltech community.  
All of my cycling friends gave me a window into this city I would never have seen 
otherwise and are all fantastic people.  My roommates Alex Goldberg, James McKone, 
and Judy Lattimer have been great friends and deserve a medal for putting up with my 
eccentricities. 
 Finally, I want to thank my family, who I don't thank nearly enough.  My parents 
have always supported me unconditionally and serve as the strongest role models I could 
ever ask for. 
	   vii	  
Abstract 
This dissertation describes studies of G protein-coupled receptors (GPCRs) and 
ligand-gated ion channels (LGICs) using unnatural amino acid mutagenesis to gain high 
precision insights into the function of these important membrane proteins.  
Chapter 2 considers the functional role of highly conserved proline residues within 
the transmembrane helices of the D2 dopamine GPCR.  Through mutagenesis employing 
unnatural α-hydroxy acids, proline analogs, and N-methyl amino acids, we find that lack 
of backbone hydrogen bond donor ability is important to proline function.  At one proline 
site we additionally find that a substituent on the proline backbone N is important to 
receptor function. 
In Chapter 3, side chain conformation is probed by mutagenesis of GPCRs and the 
muscle-type nAChR.  Specific side chain rearrangements of highly conserved residues 
have been proposed to accompany activation of these receptors.  These rearrangements 
were probed using conformationally-biased β-substituted analogs of Trp and Phe and 
unnatural stereoisomers of Thr and Ile.  We also modeled the conformational bias of the 
unnatural Trp and Phe analogs employed. 
Chapters 4 and 5 examine details of ligand binding to nAChRs.  Chapter 4 describes 
a study investigating the importance of hydrogen bonds between ligands and the 
complementary face of muscle-type and α4β4 nAChRs.  A hydrogen bond involving the 
agonist appears to be important for ligand binding in the muscle-type receptor but not the 
α4β4 receptor.  Chapter 5 describes a study characterizing the binding of varenicline, an 
actively prescribed smoking cessation therapeutic, to the α7 nAChR.  Additionally, 
	   viii	  
binding interactions to the complementary face of the α7 binding site were examined for 
a small panel of agonists.  We identified side chains important for binding large agonists 
such as varenicline, but dispensable for binding the small agonist ACh. 
 Chapter 6 describes efforts to image nAChRs site-specifically modified with a 
fluorophore by unnatural amino acid mutagenesis.  While progress was hampered by high 
levels of fluorescent background, improvements to sample preparation and alternative 
strategies for fluorophore incorporation are described. 
 Chapter 7 describes efforts toward a fluorescence assay for G protein association 
with a GPCR, with the ultimate goal of probing key protein-protein interactions along the 
G protein/receptor interface.  A wide range of fluorescent protein fusions were generated, 
expressed in Xenopus oocytes, and evaluated for their ability to associate with each other. 
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* Portions of this chapter are adapted from a review article in preparation (Van Arnam, E. B. and 
Dougherty, D. A.) 	  
Chapter 1: Introduction* 
 
1.1  Signaling across a membrane: the chemical underpinning of neuroscience 
Nature has evolved exquisite mechanisms for cells to sense the world beyond the 
boundaries of their plasma membranes.  Small molecule chemical signals are recognized 
by a broad array of membrane-spanning receptor proteins, which couple an extracellular 
ligand binding event to an intracellular response.  Such proteins enable communication 
among adjacent cells, within tissues, and across organisms.  Cellular communication 
mediated by membrane receptors is played out on the grandest scale in the human brain, 
which comprises 1012 highly interconnected neurons.  There, neurotransmitters relay 
across synapses to bind receptors, which initiate signal propagation to the next neuron: 
this is the basic chemical underpinning of thought, emotion, and awareness.  Myriad 
receptors and neurotransmitters play roles in synaptic transmission.  Key families of 
membrane receptors are the ligand-gated ion channels (LGICs) and G protein-coupled 
receptors (GPCRs).   
 
1.2  Ligand-gated ion channels 
Ligand-gated ion channels are multimeric membrane-spanning proteins that open a 
transmembrane ion-conducting pore upon binding their cognate ligand.  A key family of 
these proteins involved in synaptic transmission is the nicotinic acetylcholine receptors 
(nAChRs), cation-selective channels gated by the neurotransmitter acetylcholine (ACh).  
These receptors are pentamers and can be comprised of a wide range of subunits, either in 
a homomeric or heteromeric fashion.  The prototypical nAChR, the muscle-type receptor, 
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assembles with a fixed subunit composition of (α1)2β1γδ (fetal form: in adults the ε 
subunit substitutes for γ).  The remainder of the nAChRs, the neuronal receptors, can be 
found throughout the central and peripheral nervous systems, though some have been 
found in non-neuronal cells as well.  Neuronal nAChRs can be comprised of the subunits 
α2-α10 and β2-β4, of which homomeric α7 receptors and receptors containing α4 and β2 
subunits are the dominant subtypes expressed in the brain.14  
 
Figure 1.1.  (A) Torpedo nAChR cryo-EM structure.1 (B) Acetylcholine binding protein structure.2 (C) 
Aromatic box residues of the nAChR binding site. 
In these pentameric receptors, each subunit contains four membrane-spanning α-
helices and a large, primarily β-sheet, N-terminal extracellular domain.  The five subunits 
arrange pseudo-symmetrically around a pore lined by the second transmembrane helix, 
and ligand-binding sites are found at subunit interfaces in the extracellular domain.  
While we lack a nAChR crystal structure, the global architecture of these proteins is now 
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well established from a wealth of biochemical studies and from several informative 
model structures.  A cryo-EM structure of the Torpedo ray nAChR is available at 4 Å 
resolution for the closed receptor (Figure 1.1A).1  Crystal structures of homologs within 
the same superfamily of pentameric receptors corroborate the global architecture, 
including structures of the C. elegans channel GluCl and the bacterial channels ELIC and 
GLIC.3-6  Comparison of structures thought to represent an open pore conformation 
(GluCl, GLIC) to those in closed-channel conformations (ELIC, nAChR cryo-EM) 
support a gating model7,8 in which twisting of the extracellular domain modulates the tilt 
of the second and third transmembrane helices to open the ion-conducting pore. 
 Our knowledge of nAChR ligand-binding sites has been buoyed by structures of 
invertebrate acetylcholine binding proteins (AChBPs) (Figure 1.1B).  These soluble 
proteins have proven amenable to crystallization, and share structural homology and 20 – 
25% sequence identity with the nAChR extracellular domain.  AChBP structures reveal 
that binding site aromatic residues conserved across nAChRs are arranged into an 
“aromatic box” (Figure 1.1C).  Components of this box are contributed from four 
different structural loops (named loop A through loop D) and also from both subunits that 
meet at the binding site.  This box comprises a pocket for ligand binding, and numerous 
AChBP structures have been reported in complex with pharmacologically-relevant 
ligands, suggesting specific ligand-binding interactions (Figure 1.2).10  One key ligand-
binding interaction suggested by AChBP and corroborated by mutagenesis studies is a 
cation-π interaction between an agonist cationic group and the side chain of a tryptophan 
on loop B (TrpB).7,8  Additionally, agonists that have a N+H group can form a hydrogen 
bond to the backbone carbonyl of TrpB.9  Finally, AChBP structures suggest that the  
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Figure 1.2.  A binding model for nicotine at nAChRs.  (A) Crystal structure of nicotine bound to AChBP.  
(B) Schematic of the binding model.  Reproduced with permission from reference 11. 
hydrogen bond-accepting group common to most nAChR agonists interacts with a water 
molecule held between backbone groups of a conserved Leu and a conserved Asn that lie 
across the subunit interface from TrpB.  Mutagenesis confirms that the Leu backbone NH 
can be important for ligand binding.10,11 
 However, functional studies reveal that these ligand-receptor interactions can be 
variable across receptor subtypes.  For example, the muscle-type receptor and the α4β2 
and α4β4 neuronal receptors typically utilize a cation-π interaction to TrpB.  The α7 
neuronal nAChR, however, binds agonists through cation-π interactions to a tyrosine on 
loop A (TyrA) and a tyrosine on loop C (TyrC2).12  The Leu backbone NH is important 
to ligand binding in α4β2 and muscle-type receptors, but appears dispensable to ligand 
binding in α4β4 and α7 receptors.10,11,13  Such distinctions likely contribute to the unique 
pharmacology of different nAChRs and could help guide rational design of subtype-
selective pharmaceuticals targeting these receptors.  
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1.3  G protein-coupled receptors 
The largest family of membrane receptors (and indeed the largest class of membrane 
proteins in humans) are the G protein-coupled receptors, of which an estimated 720 – 800 
are encoded in the human genome.14  While GPCRs comprise a sprawling class of 
proteins responding to diverse stimuli and inducing varied downstream responses, several 
structural features and principles of signaling are common among all GPCRs.  All are 
characterized by a bundle of seven transmembrane helices and (with the exception of the 
receptor rhodopsin, which responds to light) are activated by ligand binding.  GPCR 
activation begins with ligand binding to a pocket in the extracellular half of the 
transmembrane helical core (Figure 1.3A), which induces a conformational change in the 
receptor.  This new receptor conformation modulates an associated guanine nucleotide-
binding protein (G protein), causing the G protein to exchange bound GDP for GTP and 
assume its active, signaling state.  The activated G protein dissociates into its Gα and Gβγ 
subunits (Figure 1.3B), which can affect various cellular targets (Figure 1.3C), such as  
 
 
 
 
 
Figure 1.3.  Schematic of GPCR signaling.  (A) Ligand binding initiates GPCR signaling.  (B) Activation 
of the G protein by GDP/GTP exchange induces dissociation of Gα and Gβγ subunits.  (C) Gα and Gβγ 
subunits can activate cellular signaling partners.  (D) GTP hydrolysis terminates signaling by inducing 
reassociation of Gα and Gβγ. 
	   6	  
adenylate cyclase, phospholipase Cβ, or potassium channels, inducing complex signaling 
pathways.  GTP hydrolysis causes the Gα and Gβγ subunits to reassociate, ending 
signaling (Figure 1.3D). 
 
Figure 1.4.  (A) Structure of the inactive β2 adrenergic GPCR (β2AR) bound to an antagonist.15  (B) 
Structure of the β2AR in its active conformation bound to an agonist and its cognate G protein, Gs.16  TM6, 
the helix that undergoes the most dramatic conformational rearrangement upon activation, is denoted with 
an asterisk in both structures. 
Since the seminal crystal structure of rhodopsin in 2000,17 considerable structural 
information has emerged for GPCRs, including structures of over 15 distinct receptors 
and structures capturing different conformational states.18  In a landmark achievement, a 
crystal structure was obtained for the β2 adrenergic GPCR in an active conformation in 
complex with its cognate G protein, Gs (Figure 1.4).16  All GPCRs share the same general 
topology with an extracellular N-terminus, intracellular C-terminus, and seven 
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intervening transmembrane helices (TMs) in a roughly counterclockwise arrangement 
when viewed from the extracellular face, numbered TM1 – TM7.  The main ligand-
binding pocket typically sits between TMs 3, 5, and 6 on the extracellular half of the 
receptor, beneath extracellular loop 2 (EL2).  
 While the specifics of ligand binding vary from receptor to receptor, mounting 
evidence from both crystallography and from biochemical studies suggests that receptor 
activation among the various classes of GPCRs involves common conformational 
changes in the transmembrane helical bundle, allowing for activation of the G protein at 
the receptor’s intracellular face.18,19  Briefly, agonist binding induces subtle changes at 
the extracellular half of the helical bundle, accompanied by more marked spreading of the 
intracellular end, most notably of TM6 and TM7.  Outward displacement of the 
intracellular end of TM6 is critical to expose an important G protein binding site (Figure 
1.4).18  
 
1.4  Methods for interrogating ion channel and GPCR function 
1.4.1  Electrophysiology as an assay for ion channels and GPCRs 
The studies described in this dissertation probe the function of ion channels and 
GPCRs in vivo using Xenopus laevis oocytes as an expression system.  These physically 
large (~ 1 mm diameter) cells can be readily injected with mRNA or other material.  In 
this eukaryotic in vivo expression system, complex membrane proteins are competently 
translated, folded, modified, and trafficked to the plasma membrane. 
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 These cells provide a convenient vehicle in which to assay surface-expressed 
membrane proteins by electrophysiology.  Using two-electrode voltage clamp 
electrophysiology, passage of ions across the plasma membrane through ion channels can 
be recorded as an electrical current.  Hence, we can directly assay ligand-gated ion 
channels by applying agonist to cells and recording responses from open channels.  For 
GPCRs, we use an indirect assay that relies on G protein activation of an ion channel.  
Gi/o-type G proteins are activated by select GPCRs (including the D2 dopamine and M2 
acetylcholine receptors considered in this dissertation) and can in turn activate G protein-
coupled inwardly rectifying potassium (GIRK) channels (Figure 1.3C).20  Coexpression 
of GIRK with the GPCR of interest thus enables a straightforward assay for these 
receptors by electrophysiology via GIRK activation. 
For both GPCRs and ligand-gated ion channels, we assay receptor function by 
assembling a dose-response curve from current responses to progressively greater 
concentrations of agonist (Figure 1.5A, B).  This curve is fit to the Hill equation (Figure 
1.5C), which gives an EC50, the dose that affording a half-maximal response, and the Hill 
coefficient, nH, which represents ligand binding cooperativity.  The EC50 is a metric of 
receptor function; mutations that increase EC50 relative to the wild-type receptor (Figure 
1.5B, red curve) are referred to as a “loss of function,” since a larger agonist 
concentration is required to give the same response, while those that lower the EC50 
(Figure 1.5B, green curve) are referred to as “gain of function” mutations. 
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Figure 1.5.  (A) Current responses to a range of agonist concentrations.  (B) Dose-response curves.  The 
black curve represents the wild-type receptor while the red curve represents a loss-of-function mutant and 
the green curve a gain-of-function mutant.  (C) Hill equation.  Imax is the maximal current response to 
agonist, EC50 is the agonist concentration that gives half-maximal current response, and nH is the Hill 
coefficient. 
 
1.4.2  Unnatural amino acid mutagenesis 
 Unnatural amino acid mutagenesis expands the palette of amino acids available 
for structure-function studies.  Through site-specific incorporation of unnatural amino 
acids, we can engineer novel functionalities into proteins or introduce much more subtle 
modifications to protein structure than are possible from the 20 naturally occurring 
residues, including modifications to the protein backbone.  This powerful tool allows us 
to bring a physical organic chemistry problem solving approach to the study of complex 
membrane proteins.  Unnatural amino acids can serve as highly specific probes of ligand 
binding interactions such as hydrogen bonds, cation-π interactions, and ion pairs, can 
serve as probes of local conformational changes, and can act as site-specific biophysical 
probes such as fluorophores. 
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 To site-specifically incorporate unnatural amino acids, we use the nonsense 
suppression method for ribosomal incorporation.21  The mRNA codon corresponding to 
the amino acid of interest is replaced with a nonsense (stop) codon and a suppressor 
tRNA with the corresponding anticodon is supplied.  This tRNA is acylated with the 
desired unnatural amino acid, which gets incorporated into the protein at the site of 
interest (Figure 1.6).  tRNA acylation is typically accomplished in two steps.  A 
dinucleotide corresponding to the last two positions of the complete 76mer tRNA’s 3’ 
terminus is chemically acylated with the amino acid of interest.  This acylated 
dinucleotide is then ligated a truncated 74mer tRNA to yield the desired complete 
acylated tRNA.  To discourage hydrolysis of the amino acid off of the tRNA, the 
unnatural amino acid typically bears a photolabile protecting group on its α-amino group, 
which is cleaved immediately before use of the tRNA. 
Figure 1.6.  Nonsense suppression method for ribosomal incorporation of an unnatural amino acid into a 
protein. 
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 For unnatural amino acid mutagenesis in vivo, we simply inject Xenopus oocytes 
with the appropriate mRNA and suppressor tRNA.  The native translational machinery of 
the cell accepts these components to translate the protein of interest bearing the unnatural 
residue (Figure 1.7).  It should be noted that the suppressor tRNA has been engineered to 
be orthogonal to cellular aminoacyl-tRNA synthetases, to limit in vivo reacylation of the 
tRNA with a natural amino acid.22,23  
 
Figure 1.7.  Unnatural amino acid mutagenesis by nonsense suppression applied to receptors expressed in 
Xenopus oocytes. 
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1.4.3  Probing receptor function with fluorescence 
 Fluorescent probes are incredibly powerful tools for the study of biological 
systems, allowing for location and conformation of biomolecules to be interrogated.  
While crystallography has clarified the structure of GPCRs and ligand-gated ion channels 
and suggested both inactive and active conformations of some of these proteins, many 
questions remain with regard to conformational changes involved in the activation of 
these receptors.  Fluorescence is an ideal tool to probe the conformational repertoire of 
these proteins and its kinetics.  Specifically, Förster resonance energy transfer (FRET) 
can monitor conformation by serving as a “molecular ruler” between two appropriate 
fluorophores.  Fluorescence energy from a donor dye is transferred nonradiatively to an 
acceptor dye with an efficiency that depends sharply on the separation of these 
fluorophores, r, (FRET efficiency is proportional to 1/r6).   
 A major challenge for FRET studies is the selective incorporation of fluorophores 
into the protein(s) of interest in a nonperturbing fashion.  Fluorescent proteins have the 
advantage of facile genetic incorporation into a protein of interest, but have relatively low 
brightness and photostability and are very large (~27 kDa), so they may perturb 
function.24  Small molecule fluorophores have the advantage of smaller size and can have 
high brightness and photostability, but are generally more difficult to incorporate site-
specifically.  Unnatural amino acid mutagenesis by nonsense suppression offers an 
attractive option for site-selective fluorophore incorporation as an amino acid side chain.  
Both small molecule fluorophores incorporated as unnatural amino acid side chains and 
genetically encoded fluorescent proteins are applied to the study of membrane receptors 
in this dissertation. 
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1.5  Summary of dissertation work  
 This dissertation describes six studies on GPCRs and ligand-gated ion channels, 
primarily structure-function analyses of these proteins using unnatural amino acid probes. 
Chapter 2 describes a study investigating the functional role of highly conserved 
proline residues within the transmembrane helices of the D2 dopamine GPCR.  Through 
mutagenesis employing unnatural α-hydroxy acids, proline analogs, and N-methyl amino 
acids, we find that lack of backbone hydrogen bond donor ability is important to proline 
function.  At one proline site we additionally find that a substituent on the proline 
backbone N is important to function. 
Chapter 3 describes studies that probe side chain conformation by mutagenesis of 
GPCRs and the muscle-type nAChR.  Specific side chain rearrangements have been 
proposed to accompany activation of these receptors.  These rearrangements were probed 
using conformationally-biased β-substituted analogs of Trp and Phe and unnatural 
stereoisomers of Thr and Ile.  We also modeled the conformational bias of the unnatural 
Trp and Phe analogs employed. 
Chapters 4 and 5 examine details of ligand binding to nAChRs.  Chapter 4 describes 
a study investigating the importance of hydrogen bonds to the complementary face of the 
muscle-type and α4β4 nAChRs.  A hydrogen bond involving the agonist appears to be 
important for ligand binding in the muscle-type receptor, but not the α4β4 receptor.  
Chapter 5 describes a study characterizing the binding of varenicline, an actively 
prescribed smoking cessation therapeutic, to the α7 nAChR.  Additionally, binding 
interactions to the complementary face of the α7 binding site were examined for a small 
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panel of agonists.  We identified side chains important for binding large agonists such as 
varenicline, but dispensable for binding the small agonist ACh. 
 Chapter 6 describes efforts to image nAChRs site-specifically modified with a 
fluorophore by unnatural amino acid mutagenesis.  Progress was hampered by high levels 
of fluorescent background.  Improvements to sample preparation and alternative 
strategies for fluorophore incorporation are described. 
 Chapter 7 describes attempted development of a fluorescence assay for G protein 
association with a GPCR, with the ultimate goal of probing key protein-protein 
interactions along the G protein/receptor interface.  A wide range of fluorescent protein 
fusions were generated, expressed in Xenopus oocytes, and evaluated for their ability to 
associate with each other using a FRET assay. 
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Chapter 2: Dissecting the functions of conserved prolines within 
transmembrane helices of the D2 dopamine receptor* 
 
2.1  Abstract 
G protein–coupled receptors (GPCRs) contain a number of conserved proline 
residues in their transmembrane helices, and it is generally assumed these play important 
functional and/or structural roles. Here we use unnatural amino acid mutagenesis, 
employing α-hydroxy acids and proline analogs, to examine the functional roles of five 
proline residues in the transmembrane helices of the D2 dopamine receptor. The well–
known tendency of proline to disrupt helical structure is important at all sites, while we 
find no evidence for a functional role for backbone amide cis–trans isomerization, 
another feature associated with proline. At most proline sites, the loss of the backbone 
NH is sufficient to explain the role of the proline. However, at one site – P2105.50 – a 
substituent on the backbone N appears to be essential for proper function. Interestingly, 
the pattern in functional consequences that we see is mirrored in the pattern of structural 
distortions seen in many GPCR crystal structures. 
 
2.2  Introduction 
Proline stands apart from the other 19 canonical amino acids.  Its cyclic side chain 
uniquely shapes protein structure and facilitates protein dynamics.  As proline’s side 
chain substantially restricts its backbone psi angle and removes a backbone hydrogen 
bond donor, proline disrupts the regular structures of both α-helices and β-sheets and can 
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introduce flexibility into these structures.1-4  Further, proline’s backbone N–substitution 
biases its peptide bonds to the cis conformer, relative to other peptide bonds.  The cis–
trans isomerization of proline peptide bonds is well documented to mediate protein 
folding and mature protein function.5  Here we examine which of the above properties 
contribute to function of the D2 dopamine G protein–coupled receptor (GPCR) at 
conserved proline sites within its transmembrane α-helices (TMs), using conventional 
and unnatural amino acid mutagenesis. 
Transmembrane proline residues are a characteristic feature of GPCRs and are 
found in five of the D2 receptor’s seven TMs.  These prolines are also highly conserved; 
three (P2015.50, P3886.50, and P4237.50) are the most conserved residue of their respective 
helix among Class A GPCRs and the remaining two (P892.59, P1694.59) are conserved 
among aminergic GPCRs. (Superscripts refer to Ballesteros–Weinstein numbering, in 
which the most conserved residue of helix X is denoted X.50).6 A wealth of conventional 
mutagenesis studies has already established that these prolines play some significant 
functional role in GPCRs.7-14  Proline kinks have long been hypothesized to mediate the 
helical movements involved in GPCR activation, acting as pivot points, hinges, and/or 
swivels to expose a G protein binding site at the intracellular end of the helical 
bundle.15,16  A recent crystal structure of the closely related D3 dopamine receptor 
confirms that the prolines investigated here are associated with helical kinks, especially 
prominent in TMs 2, 6, and 7 (Figure 2.1).17  P1694.59 sits only one helical turn from the 
N–terminus of TM4, although the pre–proline turn is indeed kinked relative to the rest of 
the helix. Interestingly in the D3 and other GPCR crystal structures, TM5 is only slightly 
kinked, but instead possesses a prominent bulge in the helical turn preceding P2015.50.17-22  
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Figure 2.1.  Two views of the crystal structure of the D3 dopamine receptor (PDB: 3PBL), highlighting the 
prolines considered here.17 Numbering is for the corresponding residues in the D2 receptor. 
Proline’s ability to distort helices most obviously comes from its lack of backbone 
hydrogen bond donor ability, which frees its would–be hydrogen bond acceptor, the 
backbone carbonyl of the residue i–4 from proline (Figure 2.2).  Additionally, the proline 
side chain introduces a steric clash with the i–4 carbonyl.  The net effect is usually 
manifested as a kink, which often frees the carbonyl i–3 to proline as well.2,5,23,24   
Figure 2.2.  Hydrogen bonding patterns in an α–helix for (left to right) a typical amino acid; proline; an N–
methyl amino acid; and an α–hydroxy acid. 
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Since the 19 other canonical amino acids are ill suited to probe the unique 
properties of proline, unnatural amino acid mutagenesis is an especially valuable tool to 
dissect the basis for a given proline’s functional importance.  As structural information on 
GPCRs continues to accrue, the subtle and high precision probes provided by unnatural 
residues will become increasingly valuable.  Tests of detailed structural environments and 
specific functional roles are significantly facilitated by the unnatural amino acid 
methodology.    
Here we compare the effect of replacing each of 5 TM prolines of the D2 receptor 
with unnatural α–hydroxy acids, and an N–methyl amino acid (Figure 2.2).  We also 
consider cyclic proline analogs and conventional amino acids that correspond to the α–
hydroxy acids.  Unnatural α–hydroxy acids introduce a backbone ester that, like the 
proline peptide bond it replaces, is not a hydrogen bond donor (Figure 2.2).  N–Me–Ala, 
effectively proline lacking its side chain Cγ, shares N–substitution (and thus lack of 
hydrogen bond donor ability) with proline, but has greater conformational freedom.  
Finally, proline analogs (Figure 2.3) that vary the size of the ring or introduce 
substituents can probe tolerance for subtle changes to the proline side chain as well as 
cis–trans isomerization.  Pipecolic acid (Pip) and azetidine–2–carboxylic acid (Aze), six– 
and four–membered ring analogs of proline, respectively, have a greater cis bias relative 
to proline, while 2–methylproline (2–Me–Pro) is substantially more trans–biased.5,6 
   
Pip Aze 2-Me-Pro 
Figure 2.3.  Unnatural proline analogs employed in this study 
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2.3  Results 
2.3.1  Experimental approach 
We utilized a recently optimized electrophysiological readout of the D2 receptor 
that yields quantitative dose–response relationships from receptor activation of 
coexpressed GIRK1/4 channels in Xenopus laevis oocytes and is amenable to unnatural 
amino acid mutagenesis by nonsense suppression.7-14,25  All unnatural amino acid and 
hydroxy acid mutations, as well as the valine mutants noted, were generated by nonsense 
suppression, while all other mutants were expressed conventionally.  A wild–type rescue 
experiment (incorporating Pro by nonsense suppression) at each proline site yields an 
EC50 within two–fold of the wild–type value, validating the ability to perform nonsense 
suppression at all residues considered here.   
Because of the indirect nature of the measurement, interpretation of EC50 requires 
some caution.  A detailed discussion of this issue has been presented elsewhere.15,16,26  
For present purposes, we consider EC50 values that differ by a factor of greater than 2 to 
be distinguishable in this assay.  
2.3.2  Strategy and general observations 
Previously, we have characterized three distinct phenotypes for functionally 
important proline residues in ligand–gated ion channels.  In the M1 transmembrane helix 
of both the α subunit of the muscle–type nicotinic acetylcholine receptor and the 5–HT3A 
receptor, a conserved proline in the middle of the helix can be replaced by a range of α–
hydroxy acids, giving essentially wild–type behavior.17,27,28  In contrast, incorporating 
any canonical amino acid other than proline gave a nonfunctional receptor.  A second 
phenotype was seen in the M2–M3 loop of the 5–HT3A receptor.17-22,29  In this system, 
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cis–trans isomerization of a proline peptide bond is critical for receptor gating, as 
revealed by a series of cyclic proline analogs with varying cis preferences.  Finally, we 
have characterized an important proline–aromatic interaction in the Cys loop of the 
muscle–type nicotinic acetylcholine receptor, in which the hydrophobicity of a Phe side 
chain preceding proline is important for receptor function.30  We seek to determine which 
of these phenotypes is most applicable to the transmembrane prolines of the D2 receptor, 
and we began by incorporating α–hydroxy acids at each site. 
For the most part, incorporation of an α–hydroxy residue is not strongly 
perturbing; all but one of the hydroxy acid mutants we could characterize gave EC50s 
within 5-fold of wild type (Figure 2.4, Table 2.1).  In addition, each conventional amino 
acid residue is typically much more perturbing than its unnatural α–hydroxy acid analog.  
This trend suggests the importance of lacking a hydrogen bond donor at these sites.  N–
Me–Ala provides an alternative way to remove the backbone NH group, and it is also 
well–tolerated at all sites.  Given the results for α-hydroxy residues and N–Me–Ala, it is 
not surprising that various cyclic proline analogs, which are much more similar to 
proline, are well–tolerated at all transmembrane proline sites, yielding EC50s within 5-
fold of wild type. 
Mutations of proline to the conventional amino acids Ala, Val, and Leu range 
from modestly perturbing to dramatically perturbing (EC50 shifts of 3.5–fold to >2000–
fold from wild type), with the exception of P892.59, discussed below.  Generally, Gly is 
less perturbing than the other natural amino acids, with the glaring exception of 
P2015.50G.  These conventional mutants provide a useful reference to which we can 
compare the α–hydroxy mutants. 
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Figure 2.4.  Results for incorporating α–hydroxy acids; their amino acid analogs; Gly; and N–Me–Ala.  At 
four sites, indicated by a ≈, EC50 is too large to determine accurately.  * = no current detected. 
 
The P892.59 site, despite >70% conservation among aminergic receptors, accepts 
diverse mutations with only modest functional consequences.  All mutations made, 
including conventional mutations, give wild–type EC50s or relatively small shifts from 
wild type.  Evidently, this site does not require the unique side chain and hydrogen 
bonding properties conferred by proline, and we will not consider it further here. 
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Table 2.1.  Conventional amino acid, hydroxy acid, and N-Me-Ala mutations.  EC50 and Hill coefficient 
(nH) are ± SEM for goodness of fit to the Hill equation. 
Site Mutation EC50 (nM) nH n 
wild type  39 ± 1 1.12 ± 0.03 71 
Pro892.59 Proa 24 ± 1 1.14 ± 0.04 30 
 Gly 35 ± 3 1.3 ± 0.1 12 
 Ala 65 ± 4 1.32 ± 0.08 10 
 Valb 53 ± 7 1.2 ± 0.2 11 
 Leu 114 ± 5 1.33 ± 0.07 10 
 Aah 140 ± 10 0.94 ± 0.05 12 
 Vah 47 ± 1 1.20 ± 0.02 13 
 Lah 136 ± 4 1.19 ± 0.03 13 
 N-Me-Ala 46 ± 2 1.11 ± 0.04 19 
Pro1694.59 Proa 41 ± 2 1.17 ± 0.05 49 
 Gly 180 ± 10 1.00 ± 0.06 14 
 Ala 1310 ± 80 1.12 ± 0.06 12 
 Valb 1150 ± 70 1.03 ± 0.05 12 
 Leu >2000c  14 
 Aah 59 ± 3 1.20 ± 0.07 15 
 Vah 76 ± 4 1.42 ± 0.09 14 
 Lah 102 ± 2 1.27 ± 0.03 27 
 N-Me-Ala 40 ± 2 1.22 ± 0.06 11 
Pro2015.50 Proa 24 ± 1 1.07 ± 0.04 37 
 Gly >2000c  17 
 Ala 600 ± 50 1.09 ± 0.09 17 
 Val >2000c  20 
 Leu NDd   
 Aah 180 ± 10 1.3 ± 0.1 9 
 Vah 330 ± 10 1.01 ± 0.04 14 
 Lah NDd   
 N-Me-Ala 16 ± 1 1.15 ± 0.08 14 
Pro3886.50 Proa 46 ± 2 1.18 ± 0.04 34 
 Gly 67 ± 3 1.24 ± 0.06 9 
 Ala 230 ± 10 1.25 ± 0.06 14 
 Valb >2000c  15 
 Leu 1000 ± 100 0.87 ± 0.07 10 
 Aah 58 ± 2 1.43 ± 0.07 15 
 Vah 185 ± 6 1.31 ± 0.05 9 
 Lah 35 ± 2 1.12 ± 0.07 25 
 N-Me-Ala 92 ± 4 1.26 ± 0.06 12 
Pro4237.50 Proa 35 ± 2 1.13 ± 0.06 43 
 Gly 61 ± 5 1.19 ± 0.09 16 
 Ala 140 ± 10 1.4 ± 0.1 10 
 Valb 170 ± 8 1.01 ± 0.04 16 
 Leu NDd   
 Aah 21 ± 2 1.4 ± 0.1 8 
 Vah 45 ± 3 1.10 ± 0.05 16 
 Lah NDd   
 N-Me-Ala 21.5 ± 1 1.25 ± 0.06 10 
aExpression of the wild type receptor with the natural amino acid incorporated by nonsense suppression 
bConventional mutant generated by nonsense suppression 
cResponse of naïve oocytes to dopamine doses ≥ 100 µM obscures complete dose-response data 
dNo dopamine-induced current detected for dopamine concentrations up to 1 mM 
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2.3.3  1694.59, 3886.50, 4237.50: Importance of lacking a backbone hydrogen bond donor 
For the TM4, 6, and 7 proline sites, we observe hydroxy acid mutations (to Aah, 
Vah, or Lah; “ah" signifying α–hydroxy) in all cases to be less perturbing than the 
corresponding conventional amino acid mutations (to Ala, Val, or Leu) (Figure 2.4, Table 
2.1).  In fact, most of the hydroxy acid mutants for these sites (P1694.59Aah, P1694.59Vah, 
P3886.50Aah, P3886.50Lah, P4237.50Aah, and P4237.50Vah) have EC50s that are not 
meaningfully different from wild type (i.e., within the margin of error we can expect 
from this assay).  As hydroxy acids and proline both lack backbone hydrogen bond 
donors, this property alone may account for proline’s functional role at these sites.  
However, hydroxy acids do introduce additional perturbations, including weakening the 
hydrogen bond acceptor strength of the preceding residue’s backbone carbonyl, and an 
electrostatic repulsion by the introduced main chain oxygen with the i–4 carbonyl. 
An alternative way to remove the backbone NH of a peptide bond is with N–Me–
Ala, which contains a fragment of the proline ring and does not significantly perturb the 
backbone carbonyl.  At the helix 4, 6, and 7 prolines, N–Me–Ala is not largely 
perturbing, being essentially equivalent to Aah and producing EC50s within 2.5-fold of 
wild type.  This suggests that the carbonyl mutation associated with α-hydroxy residues is 
not a large factor in these helices.  
Given the tolerance for α-hydroxy and N–methyl residues, it is not surprising that 
the proline analogs Aze and Pip are also well tolerated in helices 4, 6, and 7 (Table 2.2).  
As described in previous work, Aze and Pip show different intrinsic cis–trans preferences 
than Pro.5  The minimal impact of these mutations at these sites indicates that cis–trans 
isomerization is not an essential component of receptor function.  While varying ring size 
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does not substantially alter function, introducing a methyl substituent at proline’s α 
carbon (2–Me–Pro) does produce measurable EC50 shifts at the 3886.50 and 4237.50 sites, 
but not at 1694.59. 
Table 2.2.  Proline analog mutations.  EC50 and Hill coefficient (nH) are ± SEM for goodness of fit to the 
Hill equation. 
Site Mutation EC50 (nM) nH n 
Pro892.59 Pip 26 ± 2 1.04 ± 0.04 11 
 Aze 26 ± 3 1.3 ± 0.1 11 
 2-Me-Pro 64 ± 3 1.25 ± 0.05 9 
Pro1694.59 Pip 19 ± 2 1.00 ± 0.09 12 
 Aze 25 ± 3 1.1 ± 0.1 17 
 2-Me-Pro 37 ± 3 1.3 ± 0.1 18 
Pro2015.50 Pip 34 ± 2 1.14 ± 0.06 21 
 Aze 41 ± 2 0.90  ± 0.03 10 
 2-Me-Pro 160 ± 10 0.95 ± 0.07 15 
Pro3886.50 Pip 82 ± 5 1.12 ± 0.07 17 
 Aze 47 ± 3 1.26 ± 0.07 11 
 2-Me-Pro 131 ± 5 0.77 ± 0.02 15 
Pro4237.50 Pip 80 ± 5 1.27 ± 0.09 10 
 Aze 15 ± 2 1.1 ± 0.1 12 
 2-Me-Pro 128 ± 7 0.95 ± 0.04 12 
 
Interestingly, Gly is less perturbing than the other conventional amino acids at 
these sites.  We do note, however, that the P4237.50G mutant gave currents that were 
generally small, suggesting either poor expression or diminished receptor efficacy.  
While no P4237.50 mutants produced dramatic EC50 shifts, cells injected with appropriate 
mRNA and tRNA for the Leu and Lah mutants gave no response in our assay; evidently 
the leucine side chain is not tolerated.   
2.3.4  2015.50: N–substitution as well as lack of a hydrogen bond donor are important 
The 2015.50 site shows a qualitatively distinct pattern from the other prolines 
considered here.  As before, α-hydroxy residues are less perturbing than their α–amino 
analogs.  Unlike the other proline sites, however, no hydroxy acid mutation to P2015.50 
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yields a wild–type EC50. P2015.50Aah and P2015.50Vah are loss of function by 4– and 8–
fold, respectively, while we were unable to characterize the P2015.50Lah mutant (though 
the same was true of the Leu mutant).  Interestingly, N–Me–Ala is minimally perturbing, 
perhaps even gain of function, and the proline analogs Pip and Aze are wild type.  Taken 
together, these data suggest that simply deleting the hydrogen bonding ability of the 
backbone NH is not sufficient to produce a functional receptor.  A substituent on the N is 
also necessary, and it can be either a ring (Pro, Pip, Aze) or a methyl (N–Me–Ala). 
Also in contrast to the TM4, 6, and 7 sites, Gly is highly disruptive at 2015.50, more so 
than Ala.  Together with the fact that no hydroxy acid tested gave a wild–type EC50 at 
this site, these findings suggests a more specific need for proline here, not merely a 
generic requirement for a helix–breaking residue. 
 
2.4  Discussion 
In the present work, we have used nonsense suppression techniques and the assay 
system we recently developed to evaluate an array of unnatural residues at five new sites 
of the D2 dopamine receptor.  Our results establish the generality of this protocol for 
evaluating GPCR function with unnatural residues.  
In particular, we have probed five conserved proline sites located in the 
transmembrane region of the D2 receptor.  Transmembrane prolines are not uncommon, 
and are frequently considered to play important functional roles by introducing structural 
perturbations and/or increased conformational flexibility to the helix.4,15  In previous 
work we established several types of unnatural residues to probe proline function: α-
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hydroxy acids to evaluate the role of backbone hydrogen bonding,27,28 and a series of 
proline analogs to evaluate any role for cis–trans isomerization around the proline 
peptide bond.29  In many ways, the prolines considered here respond to our various 
mutations in a common fashion, although we find that P2015.50 shows a functional 
phenotype that is distinct from the other residues.  
Not surprisingly, P892.59, which is located in a helix that is not intimately involved 
in ligand binding nor conformational changes, is generally tolerant of mutations and does 
not show any obvious trends in the mutagenesis data. 
Three prolines on more critical helices – P1694.59, P3886.50, and P4237.50 – share a 
functional phenotype. Conventional amino acids are modestly to substantially disruptive, 
but their corresponding α-hydroxy acids significantly restore function.  N–Me–Ala and 
the proline analogs Pip and Aze are also well tolerated.  Taken together, these results 
indicate that the key function of proline at these sites is to disrupt the α helix by removing 
the key backbone NH.  Any strategy that accomplishes this, including cyclic residues, α-
hydroxy residues, or N–methyl residues, produces receptors with essentially wild type 
function.  Interestingly, glycine is also well tolerated.  Glycine is well known to have an 
especially low propensity for helical structures relative to other amino acids (second–
lowest only to proline),31,32 a property believed to stem both from its high conformational 
entropy and from its minimal burial of solvent accessible surface area in helices.33  The 
good tolerance of Gly at these sites suggests a generic functional requirement for a helix 
breaker at these sites.  Proline appears to accomplish this by lack of a backbone hydrogen 
bond donor, but Gly can achieve the same end by different means. 
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Structurally, all three prolines seem to play a similar role also.  In various 
structures of GPCRs, helices 4, 6, and 7 all display a significant kink associated with the 
proline.17-21  Movements of helices 6 and 7 are considered to be critical to receptor 
activation, with the kinks playing a prominent role.16  Indeed, a recent crystal structure 
thought to represent an active conformation of the β2 adrenergic receptor shows 
displacement of TM6 accomplished by a slight “unwinding” of the helical turn preceding 
the proline at position 6.50.34  The movement originates at residue 6.46, the would–be 
backbone hydrogen bond acceptor to position 6.50, potentially providing a direct link 
between proline 6.50’s lack of hydrogen bond donor ability and functionally important 
helix flexibility. 
Because the α-hydroxy residues do not seriously compromise receptor function at 
these sites (the way their α–amino analogs do), we can use the α–hydroxy data to 
consider the effects of side chain variation. The largest perturbations are seen for Lah at 
P1694.59 and Vah at P3886.50.  This suggests that the 1694.59 site is sensitive to size, while 
3886.50 is sensitive to β-branching.  No response was detected for cells injected with 
appropriate mRNA and tRNA for P4237.50L and P4237.50Lah mutations, suggesting this 
site is especially sensitive to steric bulk.  Supporting this notion, in the D3 receptor 
crystal structure, the P4237.50 side chain points directly at TM1, while P1694.59 and 
P3886.50 are directed more toward the lipid bilayer.17  Curiously, the P4237.50G mutant 
gives small signals (though a near-wild-type EC50), suggesting this site may play an 
important role in GPCR folding, transport, and/or function, possibilities we cannot 
differentiate with our assay. 
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P2015.50 shows a different pattern in response to the array of mutations considered 
here. α–Hydroxy residues are more strongly perturbing, while N–Me–Ala and the cyclic 
proline analogs Pip and Aze are wild type. This suggests that simply removing the NH is 
not enough to achieve the function of the native proline residue.  There must be a 
substituent on the backbone N.  Consistent with this, glycine is highly perturbing at 
P2015.50, in contrast to the other sites.   
It is clear from Figure 2.1 that the structural perturbation associated with the 
proline of helix 5 is distinct from what is seen in helices 2, 4, 6, and 7.  Instead of a 
prominent kink, helix 5 has a bulge.  It has been proposed that this bulge is functionally 
significant, as residues in the bulge directly contact ligands in the agonist binding site.  
Specifically, the side chain of S1975.46, which is i–4 relative to P2015.50 and located at the 
center of the bulge, is thought to contribute a hydrogen bond that is important to agonist 
binding.35,36  Evidently, the steric effect of proline’s N–substitution is key to producing 
this bulge. 
 
2.5  Conclusions 
In all functionally important transmembrane proline sites we have investigated to 
date – the TM 4, 5, 6, and 7 prolines in this study and the M1 transmembrane proline of 
two different ligand–gated ion channels – we find that lack of a backbone hydrogen bond 
donor is important for function.27,28 A general phenotype has emerged in which loss of 
function mutations to conventional amino acids are mitigated by the corresponding α–
hydroxy acids.  In contrast, α–hydroxy residues produced nonfunctional human 5–HT3 
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receptors when replacing a proline that appears to undergo cis–trans isomerization.29 This 
proline lies not in an α–helix, but in a loop/turn region, where cis–trans isomerization 
seems much more plausible. 
We do observe variations on the general transmembrane proline phenotype.  
Unlike the D2 receptor’s TM4, 6, and 7 prolines, the requirement for lacking a backbone 
hydrogen bond donor is absolute at the ion channel M1 proline sites; conventional amino 
acids, including glycine, produced completely nonfunctional channels.27,28 The TM5 
proline of the D2 receptor additionally requires N–substitution for fully wild–type 
function.  Taken together, these studies establish the power of unnatural amino acid 
methodology for dissecting out the various consequences of the proline residue’s unique 
structural features. 
 
2.6  Experimental 
2.6.1  Molecular biology 
In these experiments, the cDNA for GIRK1 and GIRK4 was in pBSMXT 
plasmids and for the D2 receptor (human long form) was in the pGEMhe plasmid.  Site–
directed mutagenesis was performed using the Stratagene QuikChange protocol to 
generate the appropriate codon.  For unnatural amino acid mutants and conventional 
mutants generated by nonsense suppression, the site of interest was mutated to the TAG 
stop codon.  Plasmids were linearized with the appropriate restriction enzymes (the GIRK 
plasmids with SalI and the D2 receptor with NheI or SbfI).  Receptor mRNA was 
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prepared by in vitro runoff transcription using the Ambion T7 mMessage mMachine kit 
and GIRK1 and GIRK4 mRNA was prepared with the T3 kit.   
Hydroxy or amino acids, all commercially available, were appended to the 
dinucleotide dCA and enzymatically ligated to truncated 74mer THG73 tRNA as 
previously described.37,38 The 74mer tRNA was prepared using the Ambion T7 
MEGAshortscriptTM kit by transcription from a DNA oligonucleotide template with its 5’ 
terminal two nucleotides bearing methoxy groups at the ribose C2’ position to enhance 
RNA transcript homogeneity, as described in the literature.39 Crude tRNA–amino acid or 
tRNΑ–hydroxy acid product was used without desalting, and the product was confirmed 
by matrix–assisted laser desorption ionization time–of–flight mass spectrometry on a 3–
hydroxypicolinic acid matrix.  Deprotection of the NVOC group on the tRNA–amino 
acids or NB group on tRNA–Aah was carried out by 5–min photolysis on a 1 kW xenon 
lamp with WG–335 and UG–11 filters immediately prior to injection.  tRNA–Vah and –
Lah were unprotected and were injected directly. 
2.6.2  Oocyte preparation and RNA injection   
Stage V–VI oocytes of Xenopus laevis were harvested and injected with RNAs as 
described previously.37 For nonsense suppression experiments, each cell was injected 
with 15 ng each of GIRK1 and GIRK4 mRNA approximately 64 hours before recording, 
then 4 – 30 ng receptor mRNA and approximately 25 – 60 ng appropriate tRNA 
approximately 48 hours before recording.  Mutants yielding small responses required a 
second injection of receptor mRNA and appropriate tRNA 24 hours before recording.   
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For wild type experiments, each cell received a single injection of 0.16 ng receptor 
mRNA and 10 ng each of GIRK1 and GIRK4 mRNA approximately 48 hrs before 
recording.  Conventional amino acid mutants (except those generated by nonsense 
suppression) were prepared identically, except 1 ng receptor mRNA was required.  Small 
responses were obtained for P4237.50G, which required 10 ng receptor mRNA.  Injection 
volumes for each injection session were 25 – 75 nL per cell. 
As a negative control for suppression experiments at each site, unacylated full 
length tRNA was co–injected with mRNA in the same manner as charged tRNA.  These 
experiments yielded negligible responses for all sites.  Wild–type recovery conditions 
(injecting tRNA–Pro and appropriate mRNA) were injected alongside mutant nonsense 
suppression conditions to control for data variability. 
2.6.3  Electrophysiology   
Oocyte recordings were made in two–electrode voltage clamp mode using the 
OpusXpressTM 6000A (Axon Instruments).  Recording buffers were ND96 (96 mM NaCl, 
2 mM KCl, 1 mM MgCl2, 5 mM HEPES, 1.8 mM CaCl2, pH 7.5) and high K+ ringer (96 
mM NaCl, 24 mM KCl, 1 mM MgCl2, 5 mM HEPES, 1.8 mM CaCl2, pH 7.5).  Solution 
flow rates were 2 mL min-1 and drug application flow rates were 2.5 mL min-1. Initial 
holding potential was –60 mV.  Data were sampled at 125 Hz and filtered at 50 Hz.  Cells 
were subjected to a ND96 pre–wash for 10 s, a high K+ application for 50 s to establish 
basal currents, and dopamine application in high K+ ringer for 25 s, followed by high K+ 
and ND96 washings for 45 s and 90 s in duration, respectively.  Dopamine–induced 
currents were measured over the basal K+ current as described previously.25 Dopamine 
(Sigma–Aldrich) solutions in high K+ ringer were prepared immediately before recording 
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by dilutions from a 1 M stock in ddi water.  Dose–response data were obtained for a 
minimum of eight concentrations of dopamine, for a minimum of two cell batches, and 
for a minimum of 8 cells total.  Dose–response relations were fitted to the Hill equation, 
INorm = 1/(1+(EC50/A))nH, where INorm is the normalized current peak at [dopamine] = A, 
EC50 is the concentration of agonist that elicits a half–maximum response, and nH is the 
Hill coefficient.  EC50 values were obtained by averaging the INorm values for each cell at 
a given dose and fitting those averaged INorm data to the Hill equation.  
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Chapter 3: Probing side chain conformations and rearrangements in 
receptor binding sites 
 
3.1  Abstract 
 The large-scale gating motions of ligand-activated transmembrane receptors are 
likely correlated with motions at the ligand binding site, such as side chain 
rearrangements upon ligand binding.  In GPCRs and in nAChRs, the nature of these 
conformational changes, and the precise orientation of side chains in the ligand-bound, 
active state, have been widely debated.  Activation models have been proposed, such as 
the rotamer toggle switch model for GPCR activation, though there is little experimental 
evidence to support them.  Crystallography and molecular dynamics of these systems 
have offered some insight, though have largely complicated, rather than clarified, models 
of gating at the binding site.  Here we present several mutagenesis approaches to study 
side chain conformations and rearrangements.  Rotamer-biased β-methyl analogs of Trp 
and Phe, and other unnatural analogs, were employed at several sites in the muscle-type 
nAChR and in the D2 dopamine and M2 acetylcholine GPCRs.  These data provide some 
suggestive evidence for specific side chain geometries, corroborated by modeling of the 
conformational bias of these unnatural side chains.  However, much of the data cannot be 
reconciled with proposed steric clashes or activation models, underscoring the difficulty 
of rationalizing conformation by mutagenesis. 
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3.2  Introduction 
 Gating of GPCRs and nAChRs is initiated by ligand binding, and ultimately 
results in substantial conformational changes of the receptor that enable association with 
a G protein (in the case of GPCRs) or opening of an ion-conducting pore (in the case of 
nAChRs).  Presumably these large-scale gating motions are coupled to smaller scale 
rearrangements of the binding site, which also assumes active and inactive states.  The 
structural details of these active and inactive states of the binding site are debated in both 
of these systems. 
3.2.1 GPCR activation 
 In GPCRs, receptor activation is characterized by an outward displacement of the 
intracellular end of transmembrane helix 6 (TM6), which creates a binding site for the G 
protein.1  This is thought to be a conserved mode of activation among GPCRs and was 
originally proposed on the basis of site-directed spin labeling,2 disulfide crosslinking,3 
and fluorescence experiments.4  TM6 displacement upon activation has also been borne 
out by crystallography of Rhodopsin and of the β2 adrenergic receptor, both of which 
have been captured in both inactive and active states, the latter in complex with its 
cognate G protein.5-8  These structures also indicate more subtle movements of the 
intracellular ends of TM5 and TM7. 
 Presumably, a local rearrangement in TM6 at or near the ligand-binding site gets 
propagated into the larger conformational changes observed.  Much attention has been 
focused on the highly conserved CWxPx(Y/F) motif in the middle of TM6, centered 
around the helical kink associated with P6.50 (residue numbering follows the Ballesteros-
Weinstein scheme, in which the most conserved residue of helix X is denoted X.50).9  
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Based on biased Monte Carlo simulations and mutagenesis of the β2 adrenergic receptor, 
Javitch and co-workers (expanding upon a proposal by Weinstein and co-workers10) 
proposed that the binding site residues C6.47, W6.48, and F6.52 form a rotamer toggle 
switch, in which receptor activation involves a correlated “switch” of these residues’ 
sidechain χ1 rotamers (Figures 3.1 and 3.2).11  The authors further propose that the 
rotamer switching, including a gauche(-) to trans transition of the W6.48 χ1 angle, 
increases the TM6 kink angle, inducing the key displacement of the intracellular end of 
TM6.  These residues line the binding site and ligand binding would presumably induce 
the rotamer switching. 
Figure 3.1.  (A) Angles describing a residue’s conformation, shown for Trp.  (B) χ1 rotamer definitions  
Figure 3.2.  The TM6 rotamer toggle switch model for GPCR activation, involving changes in χ1 for 
residues C6.47, W6.48, and F6.52. 
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NMR and fluorescence experiments on rhodopsin suggest rotamer switching or 
some other local rearrangement of the W6.48 side chain upon receptor activation,12,13 and 
molecular dynamics simulations of rhodopsin show rotamer switching of W6.48.14  In 
detailed molecular dynamics experiments on the A2A receptor that draw upon multiple 
ligand-bound crystal structures, Voth and co-workers have proposed a model in which 
receptor activation is intimately connected to rotamer transitions of W6.48.  The 
proposed rotamer transitions are the same as those suggested by Javitch: a gauche(-) to 
trans switch in χ1 and a 180° flip in χ2.15  
However, crystal structures that are thought to represent active GPCR 
conformations consistently show binding sites essentially unchanged from the putative 
inactive structures (Figure 3.3).8,16,17  A slight lateral displacement of W6.48 toward TM5 
has been observed, especially in rhodopsin structures (Figure 3.3B), but no rotamer 
changes are seen.  A different orientation of the W6.48 side chain is observed in a 
structure of the M2 acetylcholine receptor (Figure 3.3D), but this is an antagonist-bound, 
inactive structure.18  Thus the role of TM6 side chain rearrangements in GPCR activation 
remains unresolved.  Interestingly, a different “switch” was observed one helical turn 
below W6.48 in crystal structures of the β2 adrenergic receptor.  F6.44 moves laterally 
past the I3.40 side chain “gate” (I3.40 undergoes a rotamer transition).  The experiments 
described in this chapter interrogate the rotamer toggle switch and the F6.44/I3.40 switch 
in the D2 dopamine receptor and also interrogate W6.48 in the M2 muscarinic 
acetylcholine receptor. 
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Figure 3.3.  W6.48 conformations seen in GPCR crystal structures.  Binding sites are shown with W6.48 
and co-crystallized ligand. 
 
3.2.2  nAChR activation 
Activation of nAChRs and other pentameric receptors opens the ion-conducting 
transmembrane pore approximately 60 Å away from the ligand binding site.  This is 
thought to occur through a twisting of the extracellular domain, which induces a tilting of 
TM2 and TM3 to open the pore.  This general gating mechanism has been borne out both 
computationally, through normal mode analysis of an α7 receptor model,19 and by 
crystallography, through structures of pentameric bacterial channels in open and closed 
pore conformations.20-22   
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Other structural data have guided our understanding of gating motions at the 
ligand binding site.  Mollusc-derived acetylcholine binding proteins (AChBPs) with 
homology to the extracellular domain of nAChRs have been crystallized at high 
resolution, offering a structural template for the ligand binding region of these receptors.  
Structures of several variants of this protein are available, in complex with antagonists, 
partial agonists, and full agonists.23  A consensus model has emerged in which agonist 
binding induces closure of the C loop around the ligand binding site.  Very subtle 
changes have been observed for ligand binding residues, for example, in apo versus 
agonist-bound structures of an AChBP/α7 receptor chimera: subtle side chain 
displacements are seen for TyrC1, TyrA, and TrpD.24  However, as AChBPs simply bind 
acetylcholine and do not open a transmembrane pore, it is unclear how well, if at all, 
these binding site “gating” motions are applicable to nAChRs. 
Other insights into nAChR gating have come from cryo-EM structures of the 
Torpedo nAChR in native membrane.  One recent structure obtained from rapid freezing 
after exposure to acetylcholine corroborates some gating motions, including C loop 
closure and pore opening (though these changes were not observed in all subunits).25  The 
resolution of this structure (~6 Å) is too low for insight into side chain geometry.  A 
higher resolution (4 Å) structure is available for the closed, ligand-free receptor.26  This 
structure reveals an extended C loop and a more open binding site, relative to AChBP 
structures, suggesting side chain rearrangements that must occur upon ligand binding 
(Figure 3.4).  In particular, TrpD is seen in a different side chain rotamer, and the critical 
cation-π binding residue TrpB shows a displacement as well.  The nAChR experiments in 
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this chapter interrogate the mouse muscle-type nAChR (α2βγδ), which has very high 
homology to the Torpedo nAChR. 
 
Figure 3.4.  The nAChR binding site in a cryo-EM structure of the inactive receptor shows different side 
chain conformations for TrpB and TrpD, compared to an agonist-bound AChBP structure. 
 
3.2.3  Probing side chain conformation by mutagenesis 
Here we use mutagenesis to probe side chain conformation in these 
transmembrane receptor systems.  In one approach, we assess the effect of appending a 
charged amine to the Trp side chain using 5-aminomethyltryptophan, a novel amino acid 
that was synthesized for these experiments.  The tolerance of this significant structural 
and electrostatic perturbation helps inform the positioning of the W6.48 side chain within 
GPCR binding sites.  In another approach, we employ conformationally-biased unnatural 
side chains to probe for rotameric transitions upon receptor activation.  For Phe and Trp, 
we use conformationally constrained β-methyl analogs – a method introduced by Victor 
Hruby to study the orientation of aromatic side chains.27  The β-methyl group (in either 
(R) or (S) stereochemistry, Figure 3.5) alters the conformational landscape of these amino 
acids, changing their side chain rotamer preferences.  This reshaping of the χ1, χ2 
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conformational landscape was modeled by Hruby using molecular mechanics 
calculations on a model peptide,27 and we performed similar calculations here to produce 
energy maps for these unnatural side chains.   
Figure 3.5.  β-methyl amino acids employed in this chapter 
 
We probed the W6.48 site of the M2 muscarinic GPCR and the W6.48, F6.51, 
and F6.52 sites of the D2 dopamine GPCR to test the rotamer toggle switch hypothesis.  
We also used β-methyltryptophan to probe the TrpB and TrpD sites of the muscle-type 
nAChR, to test for rotamer transitions of these residues.  To explore possible steric 
effects of the introduced methyl groups with adjacent residues, we performed double 
mutants of the β-methyl analog and potentially clashing side chains.  Finally, a similar 
approach was applied using the allo isomers of β-branched amino acids Thr and Ile – 
unnatural analogs with inverted stereochemistry at the β carbon.  These were used as 
probes of Thr and Ile rotamer transitions. 
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3.3  Results and Discussion 
3.3.1  Mutagenesis probing conformational rearrangements of C6.47 upon D2 dopamine 
receptor activation 
In their study proposing the rotamer toggle switch model for GPCR activation, 
Javitch and co-workers supported their model though mutagenesis of the β2 adrenergic 
receptor.11  In their model (Figure 3.2), C6.47 adopts the trans rotamer in the inactive 
state, contacting W6.48, and switches to the gauche(-) rotamer in the active state.  
Mutation of C6.47 to Ser, which has a similar rotamer distribution to Cys in an α-helix, 
largely preserved wild type function in the β2 receptor.  They rationalized that since the 
“inactive” trans rotamer is highly disfavored for Thr, a C6.47T mutation would promote 
receptor activation.  Indeed, the C6.47T mutant of the β2 receptor showed enhanced 
constitutive activity (basal signaling in the absence of agonist) and a reduced EC50.  We 
sought to test these and other mutations in the D2 dopamine receptor to probe the 
proposed rotamer toggle switch in that system. 
 In the D2 dopamine receptor we also observe a small gain of function for the 
C6.47T mutant and a borderline loss of function for C6.47S (Table 3.1) – consistent with 
the Javitch results for the β2 receptor. To test the hypothesis that the C6.47T mutation 
causes a gain of function because it favors the “active” gauche(-) rotamer, we evaluated 
allo-threonine (aThr) at this position, which has opposite stereochemistry at the β carbon.  
On the basis of simple conformational analysis (Figure 3.6), the “inactive” trans rotamer 
of aThr should be favored and the active gauche(-) rotamer disfavored, relative to Thr.  
Surprisingly, the aThr mutation gives an even larger gain of function than C6.47T, 
inconsistent with this model.  C6.47A, which removes all side chain functionality, also 
gives a gain of function.  This latter observation could be consistent with the Javitch 
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model, in that no interaction with W6.48 is possible to stabilize the inactive state.  
Overall, this data set does not lend strong support for the Javitch model of C6.47’s role in 
activation.  The nature of an interaction between C6.47 and the W6.48 side chain is 
unclear. While the native Cys would be anticipated to undergo a sulfur-π-type interaction, 
a comparable interaction is not very favorable for the –OH of Ser and Thr.  As such, it is 
difficult to anticipate how these mutants would adapt to the toggle switch model.  
Table 3.1.  C6.47 mutations in the D2 dopamine receptor.  Dopamine EC50 and Hill coefficient (nH) are ± 
SEM for goodness of fit to the Hill equation.  
 EC50 (µM Dopamine) Fold Shift nH n 
wt 0.043 ± 0.001  1.13 ± 0.02 57 
C6.47S 0.072 ± 0.002 1.7 1.17 ± 0.04 20 
C6.47A 0.010 ± 0.002 1 / 4.3 1.1 ± 0.1 5 
C6.47T 0.0152 ± 0.0009 1 / 2.8 1.07 ± 0.06 28 
C6.47Thra 0.014 ± 0.001 1 / 3.1 1.12 ± 0.08 11 
C6.47aThr 0.0082 ± 0.0004 1 / 5.2 1.21 ± 0.06 14 
aExpression of the wild type receptor with the natural amino acid incorporated by nonsense suppression 
 
 
Figure 3.6.  Conformational analysis indicates that the putative “inactive” trans χ1 rotamer will be more 
accessible to aThr than to Thr. 
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Also casting doubt on this model, C6.47 is found in the “inactive” trans rotamer 
in the crystal structure of rhodopsin in the inactive state (the structural template for the 
Javitch study), but is actually found in the putative “active” gauche(-) rotamer (pointing 
away from W6.48) in many other “inactive” GPCR crystal structures.  These include 
antagonist-bound structures of the β2 adrenergic receptor and the D3 dopamine 
receptor.5,7,28  As such, the role of C6.47 in activation of the D2 receptor and other 
GPCRs remains unclear. 
3.3.2  Investigating the role of a F6.44/I3.40 switch in activation of the D2 dopamine 
receptor 
 GPCR crystal structures thought to represent active conformations have not 
shown any of the side chain transitions predicted by the rotamer toggle switch model.  
However, for the β2 adrenergic receptor, the closest homolog to the D2 receptor for 
which we have an active state crystal structure, another switch was found.  One turn 
below W6.48, F6.44 was observed to slide laterally, with the lower half of TM6 
following it.  This rigid body rotation contributes to the large displacement of TM6 to 
accommodate the G protein.  The F6.44 side chain does not undergo a conformational 
change, but rather moves past I3.40, which serves as a “swinging gate,” adopting a new 
side chain rotamer to follow the Phe side chain in the active state (Figure 3.7).  These 
residues, especially F6.44, are highly conserved.  Previous mutagenesis studies have 
pointed to the importance of F6.44 for receptor activation in the β2 adrenergic receptor, 
among other systems, and computational work has supported the idea of a F6.44/I3.40 
activation “switch.”29-31  In particular, previous studies in the M3 muscarinic receptor, the 
β2 adrenergic receptor, and the α1B-adrenergic receptor have shown that mutating F6.44 
	   
47	  
to smaller side chains such as Leu, Val, or Ala results in a gain of receptor function 
and/or an increase in constitutive activity.29,31,32 
Figure 3.7.  F6.44/I3.40 activation switch revealed by structures of the β2-adrenergic receptor.  Inactive 
(blue) and active (green) structures are overlaid. 
 To investigate the role of these residues in the D2 dopamine receptor, we also 
characterized the F6.44L mutant, for which a gain of function was observed, consistent 
with the results described above from other systems (Table 3.2).  This could reflect a 
weakening of the inactive state “lock” imposed by the interaction of F6.44 with I3.40.  
We saw no EC50 shift for the 3,4,5-trifluorophenylalanine mutant of F6.44, indicating that 
side chain electrostatics are unimportant and suggesting no involvement in significant 
aromatic-aromatic interactions with F5.47, W6.48, or other nearby residues. 
 At the I3.40 site, we observed a significant loss of function for the I3.40V mutant 
– simply a methyl group deletion from the native Ile side chain. Such sensitivity confirms 
the importance of this side chain, but as this methyl contacts F6.44 in both active and  
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Table 3.2.  Mutations to F6.44 and I3.40 in the D2 dopamine receptor.  Dopamine EC50 and Hill coefficient 
(nH) are ± SEM for goodness of fit to the Hill equation.  
 EC50 (µM Dopamine) Fold Shift Hill n 
wt 0.043 ± 0.001  1.13 ± 0.02 57 
F6.44L 0.013 ± 0.001 1 / 3.3 1.3 ± 0.1 5 
F6.44Phea 0.047 ± 0.005  1.0 ± 0.1 5 
F6.44F3-Phe 0.046 ± 0.003 1.0 1.3 ± 0.1 4 
I3.40V 0.280 ± 0.020 6.5 1.10 ± 0.08 5 
I3.40A NDb    
I3.40Ilea 0.034 ± 0.002  1.13 ± 0.09 9 
I3.40aIle 0.059 ± 0.007 1.7 0.95 ± 0.10 10 
aExpression of the wild type receptor with the natural amino acid incorporated by nonsense suppression 
bNo dopamine-induced current detected 
 
inactive states of the putative “switch,” it is difficult to ascribe these data a mechanistic 
significance. No response was detected from the I3.40A mutant (Table 3.2). Finally, to 
probe the potential role of a rotamer switch, Ile was mutated to allo-isoleucine (aIle), the 
Ile analog with inverted stereochemistry at the β carbon.  I3.40 undergoes a trans to 
gauche(-) rotamer transition upon activation in the β2 receptor crystal structures.  aIle is 
expected to favor the trans rotamer and disfavor gauche(-), by the same logic applied to 
aThr in section 3.3.1 above, and thus should be deleterious to receptor function.  A very 
small loss of function was measured, below the 2-fold threshold we typically consider to 
be meaningful for this assay, so it is difficult to rule on the importance of the rotamer 
transition based on this data point.  Of course, the stereochemistry inversion also alters 
the packing of this side chain with its neighbors.   
Overall, these various mutagenesis results could be consistent with a F6.44/I3.40 
rotamer switch, and indicate some functional importance of these residues. However, our 
observations are certainly insufficient to confirm the presence of this “switch” in the D2 
dopamine receptor. 
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3.3.3  Synthesis and use of 5-aminomethyltryptophan to probe the W6.48 site in GPCRs 
It remains unclear what conformation W6.48 assumes in the active state of 
various GPCRs, and whether rotamer switching has a role in activation.  We reasoned 
that we could learn about the Trp’s orientation by measuring the tolerance for a 
significant structural perturbation added to the W6.48 side chain.  We chose to introduce 
an aminomethyl group at the 5-position of the indole, a group that will be positively 
charged at physiological pH.  We further envisioned that by also introducing a negative 
charge in the receptor (i.e., Asp or Glu) near the Trp side chain, we might create a salt 
bridge involving W6.48 (Figure 3.8).  If such a salt bridge could be engineered and was 
functionally tolerated, this would help inform the preferred orientation of the W6.48 side 
chain. 
 
 
 
 
Figure 3.8.  Scheme for an engineered salt bridge involving 5-aminomethyltryptophan to test for W6.48 
rotamer switching 
In particular, we were interested in probing W6.48 in the M2 muscarinic 
acetylcholine receptor and in the D2 dopamine receptor.  Inactive, antagonist-bound 
crystal structures are available for the M2 receptor and for the D3 dopamine receptor, a 
very close homolog to the D2 receptor.18,28  Interestingly, these structures show different 
orientations of W6.48: the usual “vertical” Trp orientation in the D3 structure, and a 
“tilted” orientation with a different χ2 rotamer in the M2 structure (Figure 3.3, C and D).  
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We wondered whether these different orientations seen by crystallography would be 
reflected in different functional tolerance for 5-aminomethyltryptophan (5-NH2CH2Trp). 
5-NH2CH2Trp was synthesized employing a Friedel-Crafts-type indole coupling 
(Scheme 3.1).33  5-Aminomethyl-indole was Boc protected, and this species (1), was 
coupled to ethyl 3-bromo-2-hydroxyiminopropanoate.33  The hydroximine (2) was 
reduced by an aluminum/mercury amalgam, and the Boc group removed by 
trifluoroacetic acid.  This racemic diamine (4) was protected with 
nitroveratryloxycarbonyl (NVOC) groups and the ester was hydrolyzed.  Reaction with 
chloroacetonitrile gave the cyanomethyl ester 7, which was coupled to dCA and ligated to 
tRNA by standard methods. 
Scheme 3.1.  Synthesis of 5-aminomethyltryptophan 
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5-NH2CH2Trp was surprisingly well tolerated at the W6.48 site in the M2 
receptor, giving an EC50  less than 2-fold shifted from wild type (Table 3.3).  In contrast, 
no response was detected from efforts to incorporate W6.48[5-NH2CH2Trp] in the D2 
receptor under otherwise identical conditions.  It is unclear whether the mutation 
rendered the receptor nonfunctional or reduced receptor expression levels.  The salt 
bridge conceived for W6.48 in the “active” conformation (Figure 3.8) suggested by the 
rotamer toggle switch pairs 5-NH2CH2Trp with Y5.48E.  No response was detected for 
this double mutant either, and again, it is unclear whether low expression or lack of 
receptor function is the reason, though the Y5.48E single mutant gave a very large loss of 
function. 
Table 3.3.  5-Aminomethyltryptophan mutations to W6.48 in the M2 acetylcholine and D2 dopamine 
receptors.  EC50 and Hill coefficient (nH) are ± SEM for goodness of fit to the Hill equation. 
M2 Acetylcholine Receptor EC50 (µM ACh) Fold Shift nH n 
W6.48Trpa 0.27 ± 0.01  1.32 ± 0.06 7 
W6.48[5-NH
2
CH
2
Trp] 0.47 ± 0.09 1.7 1.5 ± 0.4 4 
D2 Dopamine Receptor EC50 (µM Dopamine) Fold Shift nH n 
W6.48Trpa 0.025 ± 0.002  1.00 ± 0.06 8 
W6.48[5-NH2CH2Trp] 
 
NDb    
Y5.48E 6 ± 2 240 0.56 ± 0.05 4 
Y5.48E W6.48[5-NH2CH2Trp] NDb    
aExpression of the wild type receptor with the natural amino acid incorporated by nonsense suppression 
bNo dopamine-induced current detected 
 
In the speculative case that the D2 W6.48[5-NH2CH2Trp] mutant expresses but is 
nonfunctional, an interesting contrast emerges with the M2 receptor.  If W6.48 does not 
move upon activation, as suggested by crystallography, 5-NH2CH2Trp is expected to be 
especially deleterious in the D2 receptor, for which the D3 structure suggests a “vertical” 
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orientation.  The cationic amine of dopamine is expected to meet steric and electrostatic 
repulsion from the introduced aminomethyl substitutent (Figure 3.9).   
 
Figure 3.9.  Structures of GPCR binding sites with the 5-aminomethyl substituent modeled onto the W6.48 
side chain.  The approximate predicted location of agonist binding is noted. 
Also supporting this “vertical” tryptophan conformation in the active D2 receptor, 
a functionally important sulfur-π interaction between W6.48 and C3.36 has been 
identified.34  Weakening this interaction by indole fluorination is detrimental to receptor 
function, suggesting that the interaction is present in the active receptor, which would 
require the Trp to maintain its “vertical” conformation.  In contrast, the “tilted” 
orientation of W6.48 in the M2 structure would place the aminomethyl group clear of the 
agonist in a pocket between helices 3, 4, and 5 (Figure 3.9).  This could account for the 
surprisingly good tolerance for this side chain in the M2 receptor.  These data are 
consistent with a lack of Trp movement upon activation, and with different Trp 
conformations in the D2 and M2 receptors, as suggested by crystallography. 
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3.3.4 Synthesis, mutagenesis, and modeling of β-methyltryptophan and β-
methylphenylalanine  
β-methyl analogs of Phe and Trp were employed to probe the conformation of 
aromatic side chains within nAChR and GPCR binding sites.  β-methyl substituents 
introduce conformational constraints to the side chain and have been employed to study 
the conformation of aromatic amino acids in various peptide contexts by Hruby and co-
workers.27 
     3.3.4.1  Synthesis 
In these studies, we employed (2S, 3S) and (2S, 3R) stereoisomers of both β-
methyltryptophan and β-methylphenylalanine.  (2S, 3S)-β-methylphenylalanine 
[hereafter (S)-β-MePhe] was obtained from a commercial supplier (Chem-Impex).  (2S, 
3R)-β-methylphenylalanine [(R)-β-MePhe] and (2S, 3S)-β-methyltryptophan [(S)-β-
MeTrp] were generous gifts from Victor Hruby.  These three compounds were NVOC-
protected, activated as cyanomethyl esters, and coupled to dCA by standard methods 
(compounds 9-14).  (2S, 3R)-β-methyltryptophan [(R)-β-MeTrp] was synthesized by a 
route drawing upon two previously reported syntheses by Hruby (Scheme 3.2).35,36   
Indoleacrylic acid was Boc-protected and the resulting compound (15) was 
coupled to the (S)-4-phenyl-2-oxazolidinone chiral auxiliary via a pivalate ester to yield 
compound 16.  The chiral auxiliary directs installation of the methyl and amine groups 
with good stereoselectivity.  Conjugate cuprate addition of methyl Grignard installed the 
β-methyl group (17).  The azide precursor to the amine was installed via deprotonation 
and electrophilic azide addition with trisyl azide to yield compound 18.  The chiral 
auxiliary was removed via hydrogen peroxide-mediated hydrolysis, and the azide of this 
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compound (19) was reduced to the amine (compound 20) via a Staudinger reduction.  
Removal of the Boc group yielded the amino acid (21), which was NVOC protected 
(compound 22), activated as a cyanomethyl ester (compound 23), and coupled to dCA 
(24) by standard methods. 
Scheme 3.2.  Synthesis of (2S,3R)-β-methyltryptophan  
 
     3.3.4.2  Mutagenesis 
 (R) and (S) β-methyl analogs of both Phe and Trp proved viable for incorporation 
by nonsense suppression; robust currents were measured from receptors expressing these 
unnatural amino acid analogs in both GPCRs and in the muscle-type nAChR.  While very 
large losses of receptor function were recorded for the β-MeTrp analogs at the W6.48 site 
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of the D2 dopamine and M2 acetylcholine GPCRs, these side chains caused little, or no, 
perturbation to nAChR function at the TrpB (αW149) and TrpD (γW55/δW57) sites 
(Table 3.4).  The β-MePhe analogs were well-tolerated at the F6.52 site in the D2 
dopamine receptor.  Additionally, both β-MePhe analogs were incorporated at the TrpD 
site, which interestingly yielded equivalent losses of function, in contrast to the β-MeTrp 
derivatives.  Both conformational and steric effects could contribute to the EC50 shifts 
observed in Table 3.4.  Conformational (rotamer-bias) effects are considered in section 
3.3.4.3 and steric effects are considered in section 3.3.4.4. 
Table 3.4.  β-methyl mutations to W6.48 of the M2 acetycholine receptor, W6.48 and F6.52 of the D2 
dopamine receptor, and TrpB (αW149) and TrpD (γW55/δW57) of the muscle-type nAChR.  EC50 and Hill 
coefficient (nH) are ± SEM for goodness of fit to the Hill equation. 
M2 Acetylcholine Receptor EC50 (µM ACh) Fold Shift nH n 
W6.48Trpa 0.27 ± 0.01  1.32 ± 0.06 7 
W6.48(R)βMeTrp 54 ± 1 200 0.95 ± 0.02 7 
W6.48(S)βMeTrp 73 ± 2 270 0.91 ± 0.02 7 
D2 Dopamine Receptor EC50 (µM Dopamine) Fold Shift nH n 
W6.48Trpa 0.025 ± 0.002  1.00 ± 0.06 8 
W6.48(R)-β-MeTrp 4.3 ± 0.4 170 0.70 ± 0.03 5 
W6.48(S)-β-MeTrp 0.69 ± 0.10 28 1.18 ± 0.16 7 
F6.52Phea 0.052 ± 0.003  1.44 ± 0.08 5 
F6.52(R)-β-MePhe 0.067 ± 0.007 1.3 1.19 ± 0.05 10 
F6.52(S)-β-MePhe 0.127 ± 0.008 2.4 1.12 ± 0.07 7 
Muscle-Type nAChR EC50 (µM ACh) Fold Shift nH n 
αW149Trpa 22 ± 2  1.5 ± 0.1 6 
αW149(R)-β-MeTrp 22 ± 1 1.0 1.6 ± 0.1 4 
αW149(S)-β-MeTrp 17.1 ± 0.4 1 / 1.3 1.39 ± 0.04 7 
γW55/δW57Trpa 23.4 ± 0.7  1.35 ± 0.05 3 
γW55/δW57(R)-β-MeTrp 95 ± 3 4.0 1.44 ± 0.05 4 
γW55/δW57(S)-β-MeTrp 23.6 ± 0.8 1.0 1.30 ± 0.05 5 
γW55/δW57Phe 271 ± 7 12 1.51 ± 0.05 4 
γW55/δW57(R)-β-MePhe 330 ± 20 14 1.35 ± 0.09 4 
γW55/δW57(S)-β-MePhe 290 ± 30 12 1.2 ± 0.1 6 
aExpression of the wild type receptor with the natural amino acid incorporated by nonsense suppression 
 
 
	   
56	  
     3.3.4.3  Conformational effects 
To gain insight into the conformational bias of these β-methyl analogs relative to 
the native Phe and Trp side chains, we performed calculations to map the energy 
landscape of these amino acids as a function of χ1 and χ2.  Using a protocol similar to that 
previously employed by Hruby,27 molecular mechanics calculations (MMFF) were 
performed for each amino acid, capped in the form: Ac-Xaa-NH-Me (where Xaa is the β-
methyl amino acid).  Energies were determined at all angles of χ1 and χ2, in 10° 
increments.  The angles φ and ψ were constrained to either the β-sheet values observed 
for TrpD in the nicotine-bound Ls-AChBP crystal structure37 (φ = -86°, ψ = 120°), or to 
idealized α-helix values (φ = -48°, ψ = -57°) which are closer to the appropriate angles 
for TrpB and for W6.48.  The plots (Figures 3.10 through 3.12) show the same general 
shape as those previously constructed by Hruby,27 and the location of wells in these plots 
generally (though not perfectly) corresponds to the predominant rotamers represented in 
the PDB for Phe and Trp.38 
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Figure 3.10.  Energy maps for Trp, (R)-β-MeTrp, and (S)-β-MeTrp as a function of the side chain 
dihedrals χ1 and χ2, with the backbone constrained to idealized α-helix dihedral values (φ = -48°, ψ = -57°). 
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Figure 3.11.  Energy maps for Trp, (R)-β-MeTrp, and (S)-β-MeTrp as a function of the side chain 
dihedrals χ1 and χ2, with the backbone constrained to the β-sheet dihedral values observed for TrpD in the 
nicotine-bound Ls-AChBP crystal structure37 (φ = -86°, ψ = 120°). 
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Figure 3.12.  Energy maps for Phe, (R)-β-MePhe, and (S)-β-MePhe as a function of the side chain 
dihedrals χ1 and χ2, with the backbone constrained to the β-sheet dihedral values observed for TrpD in the 
nicotine-bound Ls-AChBP crystal structure37 (φ = -86°, ψ = 120°). 
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To evaluate the effect of a β-methyl mutation on the conformational landscape of 
a Trp or Phe side chain, we created “β-methyl effect” plots, in which the plot for the 
parent side chain (Trp or Phe) is subtracted from the plot for one of its β-methyl analogs 
(Figures 3.13 through 3.16).  Note that the two plots from which the difference is taken 
are for different compounds and have different global minima, so the value ΔΔG = 0 
should not be ascribed special significance. 
We can use these plots to make predictions about how β-methyl mutations should 
affect receptor activation on the basis of specific activation models.  We first consider the 
“rotamer toggle switch” activation model for W6.48 in GPCR binding sites (Figure 3.13).  
As W6.48 in the inactive M2 acetylcholine receptor structure was observed in a 
noncanonical conformation unaccounted for in models of GPCR activation, the M2 
receptor is not included in this analysis.  Instead, we consider the D3 dopamine receptor 
structure as a model for the inactive D2 dopamine receptor.  The Javitch/Voth “rotamer 
toggle switch” model for GPCR activation posits a W6.48 χ1 rotamer change from 
gauche(-) to trans and a 180° flip in χ2.11,15  On Figure 3.13A, this is a transition from the 
black ✕ (χ1, χ2 for the canonical inactive W6.48 rotamer seen in the D3 structure) to the 
purple ✕.  The difference in energy between these two (χ1, χ2) points is 0.3 kcal/mol 
greater for (R)-β-MeTrp than for Trp and 0.4 kcal/mol less for (S)-β-MeTrp than for Trp 
(Figure 3.13B, blue values).  Thus, β-methyl substitutions are expected to have modest 
but opposite effects for the two stereoisomers. This stands in stark contrast to the large 
losses of function recorded for both stereoisomers in the D2 dopamine receptor.  Steric 
effects, discussed in section 3.3.4.4, most likely dominate. 
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Figure 3.13.  (A) “β-methyl effect” difference plots for (R) and (S) β-methyls of tryptophan with α-helix 
backbone dihedral constraints.  χ1, χ2 values for W6.48 observed in crystal structures and predicted for the 
active state are denoted with an ✕.  (B) Conformational energy analysis.  Boxed values are energies (in 
kcal/mol) calculated for the indicated χ1, χ2, taken from the corresponding plot in Figure 3.10.  Values 
associated with arrows are energy differences.  Note that the green “methyl effect” values correspond to 
ΔΔG values at the appropriate ✕ in part A.  Blue values are the differential effect of the methyl on 
activation. 
In an alternative model, W6.48 does not move upon activation, as suggested by 
crystal structures of active GPCRs, mutagenesis suggesting a sulfur-π interaction between 
W6.48 and C3.36,34 and perhaps consistent with the 5-NH2CH2Trp results in section 
3.3.3.  In this scenario, β-methyl groups could conceivably have a functional effect if they 
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destabilize the W6.48 conformation observed in inactive GPCR crystal structures (which 
is also the active conformation).  Note that the different W6.48 conformations 
(specifically, different χ2 values) seen in the D3 and M2 structures are indeed 
differentially affected by the β-methyl analogs (Figure 3.13A, black ✕ and green ✕).  
While (R)-β-MeTrp should have a similar effect on both receptors, (S)-β-MeTrp will 
significantly destabilize the M2 tryptophan conformation.  This effect could in part be 
responsible for the larger loss of function observed for (S)-β-MeTrp in the M2 
acetylcholine receptor, compared to the D2 dopamine receptor (Table 3.4). 
In the nAChR, a speculative gating model emerges by comparing agonist-bound 
AChBP structures (presumably the active conformation) to Unwin’s cryo-EM structure of 
the inactive nAChR (Figure 3.4).  An analysis of predicted β-methyl effects for this 
Unwin cryo-EM-to-AChBP activation model is presented in Figures 3.14 through 3.16 
using the same approach applied to GPCR W6.48 activation in Figure 3.13.  For TrpB, 
the inactive to active energy gap is predicted to be 3.4 kcal/mol larger for (R)-β-MeTrp 
than for Trp and 3.4 kcal/mol smaller for (S)-β-MeTrp than for Trp (blue values, Figure 
3.14B).  However, both of these analogs gave wild type function at TrpB (Table 3.4), 
calling into question the validity of this activation model and/or energy analysis.  For 
TrpD, smaller but still significant β-methyl perturbations are predicted (+1.5 kcal/mol for 
(R)-β-MeTrp and -2.2 kcal/mol for (S)-β-MeTrp) (Figure 3.15).  (R)-β-MeTrp did indeed 
give a loss of function for TrpD, as predicted, while the (S) analog was wild type (Table 
3.4).  Interestingly, the loss of function for the (R) analog was not observed for the series 
Phe, (S)-β-MePhe, and (R)-β-MePhe.  However, the energy analysis for the β-methyl Phe 
analogs suggests that (R)-β-MePhe should destabilize activation by 2.6 kcal/mol, even 
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more than (R)-β-MeTrp (Figure 3.16).  Clearly, the predictions made by computational 
work on model systems are inconsistent with our mutagenesis results.  This could reflect 
incorrect assignment of inactive and active Trp conformations, certainly possible for the 
inactive state given the low resolution of the Unwin structure.  Alternatively, steric 
effects in the actual protein are unaccounted for in the model system used for the 
calculations.  We consider the latter possibility in the following section.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14.  (A) “β-methyl effect” difference plots for (R) and (S) β-methyls of tryptophan with α-helix 
backbone dihedral constraints (note that these are the same plots as in Figure 3.13A).  χ1, χ2 values for TrpB 
observed in cryo-EM and crystal structures are denoted with an ✕.  (B) Conformational energy analysis.  
Boxed values are energies (in kcal/mol) calculated for the indicated χ1, χ2, taken from the corresponding 
plot in Figure 3.10.  Values associated with arrows are energy differences.  Note that the green “methyl 
effect” values correspond to ΔΔG values at the appropriate ✕ in part A.  Blue values are the differential 
effect of the methyl on activation. 
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Figure 3.15.  (A) “β-methyl effect” difference plots for (R) and (S) β-methyls of tryptophan with β-sheet 
backbone dihedral constraints.  χ1, χ2 values for TrpD observed in cryo-EM and crystal structures are 
denoted with an ✕.  (B) Conformational energy analysis.  Boxed values are energies (in kcal/mol) 
calculated for the indicated χ1, χ2, taken from the corresponding plot in Figure 3.11.  Values associated with 
arrows are energy differences.  Note that the green “methyl effect” values correspond to ΔΔG values at the 
appropriate ✕ in part A.  Blue values are the differential effect of the methyl on activation. 
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Figure 3.16.  (A) “β-methyl effect” difference plots for (R) and (S) β-methyls of phenylalanine with β-
sheet backbone dihedral constraints.  χ1, χ2 values for TrpD observed in cryo-EM and crystal structures are 
denoted with an ✕.  (B) Conformational energy analysis.  Boxed values are energies (in kcal/mol) 
calculated for the indicated χ1, χ2, taken from the corresponding plot in Figure 3.12.  Values associated with 
arrows are energy differences.  Note that the green “methyl effect” values correspond to ΔΔG values at the 
appropriate ✕ in part A.  Blue values are the differential effect of the methyl on activation. 
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     3.3.4.4  Double mutant cycle analysis to probe steric effects of β-methyl substituents 
To probe for steric effects of the introduced β-methyl substituents, we made β-
methyl mutations in combination with mutations to adjacent side chains.  Double mutant 
cycle analyses could then be used to test for interactions, and perhaps clarify why energy 
analyses in the preceding section failed.  Mutant cycle analysis can determine whether 
two single mutants’ perturbations are functionally coupled or act independently.  This is 
done by calculating a coupling coefficient {Ω  = [EC50 (mut1,2) x EC50 (WT)]/[EC50 
(mut1) x EC50 (mut2)]}, which can in turn be converted to a coupling energy [ΔΔG =        
-RTln(Ω)].  If the two mutations are independent of each other, Ω ∼ 1.  A 
“compensatory” coupling, in which the double mutant is less deleterious than the effect 
of the two single mutants multiplied, will yield Ω < 1 and a positive ΔΔG.  By defining 
specific steric clashes, we can place constraints on the side chain χ1 angle (i.e., in which 
direction the β-methyl group is pointing). 
In the D3 and M2 GPCR crystal structures, the F5.47 side chain is expected to 
clash with both (R) and (S) β-methyl substituents on W6.48, and a clash between the (S)-
β-methyl and the F6.52 side chain is anticipated in the D3 structure (Figure 3.17).  No 
clash with the ligand is predicted for either receptor (neither for the antagonist co-
crystallized in each structure nor for the agonist used to probe each receptor). 
The F5.47L mutation in the M2 receptor, which reduces the size of the side chain, 
caused a large loss of function (Table 3.5).  The EC50 estimates for the double mutants of 
F5.47L with the β-MeTrp analogs predictably indicate large losses of function, though a 
strong “compensatory” coupling is seen: +1.8 kcal/mol with the (S)-β-methyl and +2.4 
kcal/mol with the (R)-β-methyl.  The compensatory nature of the coupling (Ω < 1,  
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Figure 3.17.  Structures of GPCR binding sites with β-methyl substituents modeled onto the W6.48 side 
chain 
Table 3.5.  W6.48/F5.47 double mutants of the M2 acetylcholine receptor.  EC50 and Hill coefficient (nH) 
are ± SEM for goodness of fit to the Hill equation. 
 EC50 (µM ACh) Fold Shift nH n Ω 
ΔΔG 
(kcal/mol) 
W6.48Trpa,b 0.27 ± 0.01  1.32 ± 0.06 7   
W6.48(R)-β-MeTrpa 54 ± 1 200 0.95 ± 0.02 7   
W6.48(S)-β-MeTrpa 73 ± 2 270 0.91 ± 0.02 7   
F5.47L 25 ± 2 93 1.2 ± 0.1 4   
F5.47L W6.48Trp Low Currents      
F5.47L W6.48(R)-β-MeTrp 80 ± 10c 300 1.1 ± 0.1 6 1 / 62.5 +2.4 
F5.47L W6.48(S)-β-MeTrp 310 ± 70c 1100 0.67 ± 0.05 4 1 / 21.8 +1.8 
aData reproduced from Table 3.4 
bExpression of the wild type receptor with the natural amino acid incorporated by nonsense suppression 
cEC50 estimate from truncated dose-response data 
positive ΔΔG) is consistent with the envisioned “bump-hole” pair created in the double 
mutant.  The fact that both methyls couple strongly with the 5.47 side chain suggests that 
the gauche(-) χ1 angle seen for W6.48 in the crystal structure may indeed be the 
approximate χ1 angle of the active receptor, as both proposed steric clashes are evidently 
detrimental to receptor activation.  Further, W6.48 and F5.47 move slightly closer to one 
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another in crystal structures of the active β2 adrenergic receptor and of rhodopsin: the 
Cα-Cα distance decreases by 1.2 Å for the β2 receptor and by 2.5 Å for rhodopsin.  Thus, 
the β-methyl perturbation might be telling us more about subtle repacking upon activation 
rather than about side chain rotamer changes. 
A similar approach to study steric interactions with F5.47 in the D2 dopamine 
receptor was attempted, but the F5.47L mutant gave too large of a loss of function to 
accurately measure an EC50.  However, previously published results for single mutants in 
this region are consistent with a similar steric clash as seen in the M2 receptor.  A 14-fold 
loss of function was recorded for mutation of F5.47 to the bulkier 3,5-
dimethylphenylalanine analog, and an extremely large 1300-fold loss of function was 
recorded for the same mutation to F6.52.34,39  These results are consistent with tight 
packing in this region where the β-methyls were introduced. 
In the muscle-type nAChR, we have identified several potential steric clashes 
between adjacent side chains and the β-methyl groups introduced, using a homology 
model of this receptor based on AChBP that should represent the active state (Figure 
3.18).  Steric clashes in this active conformation of the receptor are predicted to give a 
loss of function.  Little, if any, steric clash is predicted for either β-methyl introduced to 
TrpB, in keeping with the wild type EC50 values measured for both (R) and (S) analogs at 
this site (Figure 3.18A).   
However, it is predicted that extra bulk at the αV91 site will result in a steric clash 
with the (R) β-methyl.  In an effort to verify the χ1 rotamer of TrpB in the active receptor, 
double mutants of αV91 with (R)-β-MeTrp were made, with (S)-β-MeTrp mutations 
serving as controls (Table 3.6).  Lengthening the α91 side chain from Val to Leu had no  
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Figure 3.18.  Two views of the α/γ binding site of the muscle-type nAChR in the presumed active 
conformation from a homology model based on AChBP by Kristin Rule Gleitsman,40 with β-methyl 
substituents modeled onto the side chains of TrpB and TrpD.  Similar conformations are seen at the α/δ 
binding site.  Corresponding residues in the δ subunit are T38, W57, and L121. 
 
Table 3.6.  TrpB (αW149) double mutants of the muscle-type nAChR.  EC50 and Hill coefficient (nH) are ± 
SEM for goodness of fit to the Hill equation. 
  EC50 (µM ACh) Fold Shift nH n Ω ΔΔG (kcal/mol) 
αW149Trpa,b 22 ± 2  1.5 ± 0.1 6   
αW149(R)-β-MeTrpa 22 ± 1 1.0 1.6 ± 0.1 4   
αW149(S)-β-MeTrpa 17.1 ± 0.4 1 / 1.3 1.39 ± 0.04 7   
αV91L αW149Trp 23 ± 1 1.0 1.4 ± 0.1 7   
αV91L αW149(R)-β-MeTrp 63 ± 2 2.9 1.52 ± 0.06 4 2.74 -0.60 
αV91L αW149(S)-β-MeTrp 57 ± 3 2.6 1.46 ± 0.08 4 3.19 -0.69 
αV91I αW149Trp 33 ± 1 1.5 1.39 ± 0.07 7   
αV91I αW149(R)-β-MeTrp 38 ± 2 1.7 1.20 ± 0.05 5 1.15 -0.084 
αV91I αW149(S)-β-MeTrp 108 ± 2 4.9 1.43 ± 0.04 4 4.21 -0.85 
αV91Val αW149Trp b 22.5 ± 0.3  1.57 ± 0.03 8   
αV91Tle αW149Trp 93 ± 2 4.1 1.55 ± 0.05 7   
αV91Tle αW149(S)-β-MeTrp 260 ± 10 12 1.6 ± 0.1 7 3.59 -0.76 
αV91Tle αW149(R)-β-MeTrp NDc      
aData reproduced from Table 3.4 
bExpression of the wild type receptor with the natural amino acid(s) incorporated by nonsense suppression 
cNo current detected from identical expression conditions as αV91Tle αW149(S)-β-MeTrp 
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effect on the wild type receptor, and unexpectedly gave a similar modest 
coupling energy for both (R) and (S) β-methyl analogs.  Also 
unexpectedly, the larger Ile side chain had a meaningful coupling with 
the (S) β-methyl, but not the (R).  Finally, αV91 was mutated to tert-
leucine (Tle), which adds an additional methyl group to the β carbon (Figure 3.19) that is 
expected to clash significantly with an (R) β-methyl on TrpB.  The αV91Tle single 
mutant itself gave a modest loss of function and a measurable +0.76 kcal/mol coupling 
energy was calculated for the Tle/(S)-β-MeTrp double mutant cycle.  The (R)-β-
MeTrp/Tle double mutant gave very little, if any, detectable currents (versus average 
currents of 1.3 µA for the Tle/(S)-β-MeTrp double mutant also measured at 24 hrs post-
injection).  This observation could be consistent with a major perturbation to this key 
residue of the ligand binding site, which would confirm the proposed TrpB χ1 rotamer, 
though it is unknown whether the deficit is in ligand binding, activation, or expression. 
 At the TrpD site, steric clashes are predicted for the (R) β-methyl with the 
γT36/δT38 side chain and for the (S) β-methyl with the γL119/δL121 side chain (Figure 
3.18B).  We wondered whether the loss of function recorded for the (R) β-methyl analog 
was due to a clash with the adjacent Thr.  In support of this hypothesis, double mutant 
cycles with (R)-β-MeTrp in which the Thr side chain was made progressively smaller – 
to Ser, to Ala, and to Gly – gave progressively larger “compensatory” coupling energies 
of +0.069, +0.50, and +0.72 kcal/mol (Table 3.7).  However, moderate coupling energies 
(also positive in sign) were also observed for the same Thr mutations in conjunction with 
(S)-β-MeTrp.  As this β-methyl should not interact with the Thr side chain, the trend 
Figure 3.19.  
Tert-leucine (Tle) 
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described above cannot reasonably be attributed to a specific interaction between the (R) 
β-methyl and the Thr.   
Table 3.7.  TrpD (γW55/δW57) double mutants of the muscle-type nAChR.  EC50 and Hill coefficient (nH) 
are ± SEM for goodness of fit to the Hill equation. 
 EC50  
(µM ACh) 
Fold 
Shift nH n Ω 
ΔΔG 
(kcal/mol) 
γW55/δW57Trpa,b 23.4 ± 0.7  1.35 ± 0.05 3   
γW55/δW57(R)-β-MeTrpa 95 ± 3 4.0 1.44 ± 0.05 4   
γW55/δW57(S)-β-MeTrpa 23.6 ± 0.8 1.0 1.30 ± 0.05 5   
γT36/δT38S γW55/δW57Trp 44 ± 1 1.9 1.24 ± 0.04 5   
γT36/δT38S γW55/δW57(R)β-MeTrp 160 ± 3 6.8 1.40 ± 0.03 6 1 / 1.13 +0.069 
γT36/δT38S γW55/δW57(S)β-MeTrp 22.0 ± 0.6 1 / 1.1 1.32 ± 0.04 4 1 / 2.07 +0.43 
γT36/δT38A γW55/δW57Trp 63 ± 1 2.7 1.35 ± 0.03 5   
γT36/δT38A γW55/δW57(R)β-MeTrp 112 ± 3 4.8 1.45 ± 0.05 4 1 / 2.34 +0.5 
γT36/δT38A γW55/δW57(S)β-MeTrp 40.1 ± 0.8 1.7 1.28 ± 0.03 5 1 / 1.66 +0.29 
γT36/δT38G γW55/δW57Trp 192 ± 3 8.2 1.43 ± 0.03 5   
γT36/δT38G γW55/δW57(R)β-MeTrp 230 ± 10 9.8 1.34 ± 0.07 5 1 / 3.41 +0.72 
γT36/δT38G γW55/δW57(S)β-MeTrp 117 ± 3 5.0 1.27 ± 0.03 5 1 / 1.70 +0.31 
γL119/δL121F γW55/δW57Trp 86 ± 3 3.7 1.73 ± 0.09 3   
γL119/δL121F γW55/δW57(R)β-MeTrp 390 ± 10 17 1.36 ± 0.05 4 1.12 -0.066 
γL119/δL121F γW55/δW57(S)β-MeTrp 142 ± 5 6.1 1.17 ± 0.04 4 1.63 -0.29 
aData reproduced from Table 3.4 
bExpression of the wild type receptor with the natural amino acid incorporated by nonsense suppression 
 
While the TrpD mutation to (S)-β-MeTrp gave a wild type EC50, a modest steric 
clash is predicted with the γL119/δL121 side chain.  We wondered if mutation to a larger 
Phe side chain at this site might induce a functionally significant clash.  The (S)-β-
MeTrp/Phe double mutant cycle indeed yields a coupling (-0.29 kcal/mol), though 
modest, and the sign (negative ΔΔG, Ω > 1) is consistent with an engineered clash.  
Reassuringly, the (R)-β-MeTrp/Phe double mutant cycle has a negligible coupling 
energy. 
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 While a sensible result emerges from this series of mutations of TrpD with 
γL119/δL121, the majority of these nAChR double mutants probing sterics (Tables 3.6 
and 3.7) give unexpected results.  Overall, the lack of predictability suggests that either 
our model of the active receptor’s binding site is incorrect, or that the mutations designed 
to simply alter sterics have unforeseen consequences. 
 
3.4  Conclusions 
The experiments described in this chapter use mutagenesis to probe side chain 
conformation in receptor binding sites, and changes to side chain conformation upon 
receptor activation.  The D2 and M2 GPCR results are most consistent with a model in 
which the W6.48 side chain does not change its conformation upon activation, and 
suggest different χ2 rotamers for W6.48 in the D2 and M2 receptors, consistent with 
crystallography.  However, no definitive conclusions emerge.  The nAChR results are 
largely inconclusive. Thus, even very subtle mutations like those considered here can 
produce ambiguous results when used to probe the complex motions associated with 
integral membrane receptors.  
To be able to interpret the effect of a mutation on a conformational change, there 
are two requirements.  First, a fairly precise description of the protein’s inactive and 
active conformations is necessary (if indeed a two-state model adequately describes the 
system).  From the current limited body of structural data and of proposed activation 
mechanisms for GPCRs and nAChRs, this requirement is a significant challenge. 
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Second, the energetic consequence of the mutation on each state must be 
accurately predicted.  On this point, it is hard to know the true energetic consequence of a 
mutation in the actual receptor.  Steric and electrostatic impacts of the local protein 
environment certainly complicate the simple conformational analysis applied to Thr/aThr 
or Ile/aIle or the more sophisticated χ1, χ2 energy analysis applied to the β-methyl analogs 
in this chapter.  Recently developed molecular dynamics approaches termed 
“metadynamics” allow the energy of an entire system to be determined as a function of a 
set of collective variables, such as χ1, χ2 of a specific residue.41  This effectively allows 
for the construction of plots such as those in Figures 3.10 through 3.12 for a given side 
chain in its actual protein context.  Such an approach has been used by Voth and co-
workers to suggest χ1, χ2 rearrangements of W6.48 in the A2A adenosine GPCR.15  If 
extended to unnatural amino acid analogs at W6.48 or other protein sites, this approach 
could aid the interpretation of experimental data to inform activation mechanisms. 
 
3.5  Experimental 
3.5.1  Molecular biology 
cDNA for the mouse muscle nAChR α1, β1, γ, and δ subunits was in the pAMV 
plasmid, the human D2 dopamine receptor (long isoform) was in the pGEMhe plasmid, 
the human M2 muscarinic acetylcholine receptor was in the pGEM3 plasmid, GIRK1 and 
GIRK4 were in pBSMXT plasmids, and RGS4 was in the pcDNA3.1 plasmid.  Site-
directed mutagenesis was performed using the QuikChange protocol (Agilent 
Technologies).  For nonsense suppression experiments, the site of interest was mutated to 
the amber stop codon, with the exception of muscle-type nAChR αV91, which was 
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mutated to the opal stop codon.  Circular DNA was linearized with the appropriate 
restriction enzyme (NotI for nAChR subunits, NheI or SbfI for the D2 receptor, HindIII 
for the M2 receptor, SalI for GIRK1 and GIRK4, and StuI for RGS4).  After purification 
(Qiagen), linearized DNA was used as a template for runoff in vitro transcription using 
the T7 mMessage mMachine kit (Life Technologies). The amber suppressor tRNA 
THG7342 was used for nonsense suppression at all sites except αV91 in the muscle-type 
nAChR, for which the opal suppressor TQOpS’43,44 was used. 
Amino acids were appended to the dinucleotide dCA and enzymatically ligated to 
the appropriate truncated 74mer suppressor tRNA as previously described.45  Crude 
tRNA-amino acid product was used without desalting, and the product was confirmed by 
MALDI-TOF MS on a 3-hydropicolinic acid matrix.  tRNA-amino acids bearing a 6-
nitroveratryloxycarbonyl protecting group were deprotected prior to injection via 
irradiation with a 500 W Hg/Xe arc lamp, filtered with WG-334 and UG-11 filters prior 
to injection. 
3.5.2  Microinjection 
Stage V–VI Xenopus laevis oocytes were harvested and injected with RNAs as 
described previously.45  For the muscle-type nAChR, oocytes were injected with 10 - 20 
ng mRNA in a 10:1:1:1 ratio of α1:β1:γ:δ for nonsense suppression in the α1 subunit or 
in a 1:1:5:5 ratio for nonsense suppression in the γ and δ subunits, together with ~25 ng 
of the appropriate tRNA.  Oocytes were incubated 18 - 24 hrs before recording. 
For the M2 acetylcholine receptor, approximately 10 ng M2 receptor mRNA (2 
ng for conventional mutagenesis experiments), 10 ng each of GIRK1 and GIRK4 mRNA, 
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and ~25 ng of the appropriate tRNA (for nonsense suppression) were injected 48 hrs prior 
to recording.  An additional ~25 ng tRNA (for nonsense suppression) and 10 ng of RGS4 
mRNA were injected 24 hrs prior to recording. 
For the D2 dopamine receptor, receptor mRNA (4 - 25 ng for suppression 
experiments, 0.16 ng for wild type, and 1 ng for conventional mutagenesis), 10 ng each 
of GIRK1 and GIRK4, and ~25 ng tRNA (for nonsense suppression) were injected 48 hrs 
prior to recording.  For low-expressing mutants generated by nonsense suppression, an 
additional ~25 ng receptor mRNA and ~25 ng tRNA were injected 24 hrs prior to 
recording. 
As a negative control for all suppression experiments, unacylated full length 
tRNA was co-injected with mRNA in the same manner as charged tRNA.  These control 
experiments yielded negligible responses for all sites studied. 
3.5.3  Electrophysiology 
Receptor function was assayed using the OpusXpress 6000A (Molecular Devices, 
Sunnyvale, CA) in two-electrode voltage clamp mode.  The oocytes were clamped at a 
holding potential of -60 mV.  For the muscle-type nAChR, acetylcholine doses in Ca2+-
free ND96 (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 5 mM HEPES, pH 7.5) were applied 
for 15 s followed by a 116 s wash with Ca2+-free ND96.  For the D2 dopamine receptor 
and M2 muscarinic acetylcholine receptor, cells were subjected to a ND96 (96 mM NaCl, 
2 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 5 mM HEPES, pH 7.5) pre–wash for 10 s, a 
high K+ buffer (96 mM NaCl, 24 mM KCl, 1 mM MgCl2, 5 mM HEPES, 1.8 mM CaCl2, 
pH 7.5) application for 50 s to establish basal currents, and agonist application in high K+ 
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ringer for 25 s, followed by high K+ and ND96 washings for 45 s and 90 s in duration, 
respectively.  Agonist–induced currents were measured over the basal K+ current as 
described previously.39  Dopamine solutions in high K+ buffer were prepared 
immediately before recording by dilutions from a 1 M stock in water.  The EC50 and Hill 
coefficient (nH) values for each condition were obtained by fitting the averaged, 
normalized dose-response data to the Hill equation. 
3.5.4  Energy calculations 
Using the Spartan ’08 software package, molecular mechanics (MMFF) energies 
were calculated for the amino acids (R)-β-MeTrp, (S)-β-MeTrp, (R)-β-MePhe, and (S)-β-
MePhe capped in the form: Ac-Xaa-NH-Me (where Xaa is the β-methyl amino acid).  
Energies were determined at all angles of χ1 and χ2, in 10° increments.  For Phe and β-
MePhe, the backbone dihedrals were constrained to φ = -86°, ψ = 120° (β-sheet values 
observed for TrpD in the nicotine-bound Ls-AChBP crystal structure).37  For Trp and β-
MeTrp, the backbone dihedrals were constrained to either φ = -86°, ψ = 120° (β-sheet) or 
to φ = -48°, ψ = -57° (idealized α-helix).  For all calculations, the backbone amide 
dihedrals were constrained to 180°.  The resulting energies, relative to the global 
minimum for each condition, are plotted versus χ1 and χ2 in Figures 3.10 through 3.12.   
A cubic interpolation surface fit of each data set was constructed using MATLAB, from 
which energy values for a specific χ1, χ2 were extracted.  These values are shown in the 
tables in Figures 3.13 through 3.16,.  The “methyl effect” plots (Figures 3.13 through 
3.16) are generated by subtracting the relative energies for the parent amino acid (Trp or 
Phe) from the relative energies of the β-methyl analog. 
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3.5.5  Synthesis 
Synthesis of Boc-5-aminomethyl indole (1).  5-aminomethyl indole (Aldrich, 500 mg, 
3.42 mmol, 1 eq) was dissolved in a solution of H2O (20 mL) and THF (20 mL).  Boc2O 
(Fluka, 0.864 mL, 3.76 mmol, 1.1 eq) was added with stirring, followed by NaOH (3.76 
mL of a 1 M aqueous solution, 3.76 mmol, 1.1 eq), and stirred for 12 hrs.  The THF was 
removed in vacuo and the aqueous layer extracted with dichloromethane (3x), washed 
with brine, dried over MgSO4, and concentrated.  The resulting crude product was 
purified by flash chromatography (2.5:1 hexanes/ethyl acetate).  Compound 1 (786 mg, 
93% yield) was recovered as a clear, colorless tar.  1H NMR (300 MHz, CDCl3) δ 8.51 (s, 
1H), 7.55 (s, 1H), 7.33 (d, J = 8.3 Hz, 1H), 7.16 (m, 1H), 7.12 (d, J = 8.3 Hz, 1H), 6.51 
(ddd, J = 3.0, 2.0, 0.9 Hz, 1H), 4.90 (s, 1H), 4.42 (d, J = 5.5 Hz, 2H), 1.50 (s, 9H). 
Synthesis of hydroxyimine (2).  Ethyl 3-bromo-2-hydroxyiminopropanoate33 (298 mg, 
1.42 mmol, 1 eq) was dissolved in 20 mL dichloromethane.  Boc-5-aminomethyl indole 1 
(700 mg, 2.84 mmol, 2 eq) followed by anhydrous Na2CO3 (226 mg, 2.13 mmol, 1.5 eq) 
were added, and the reaction suspension was stirred for 20 hrs under argon.  
Dichloromethane (25 mL) and H2O (25 mL) were added, and the layers were partitioned.  
The aqueous layer was extracted (3x) with dichloromethane, the combined organics were 
washed with brine, dried over MgSO4, and concentrated.  The crude product was purified 
by flash chromatography (1.25:1 to 1:1.1 hexanes/ethyl acetate) to yield compound 2 
(339 mg, 64% yield). 1H NMR (300 MHz, CDCl3) δ 10.34 (s, 1H), 8.32 (s, 1H), 7.64 (s, 
1H), 7.22 (d, J = 8.2 Hz, 1H), 7.09 (s, 1H), 7.06 (s, 1H), 4.91 (s, 1H), 4.37 (d, J = 4.8 Hz, 
2H), 4.20 (q, J = 7.2 Hz, 2H), 4.05 (s, 2H), 1.47 (s, 9H), 1.23 (t, J = 7 Hz, 3H). 
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Synthesis of Boc-5-aminomethyl-Trp ethyl ester (3).  Hydroximine 2 (300 mg, 0.80 
mmol) was dissolved in a solution of THF (27 mL) and H2O (3 mL).  Aluminum pellets 
(2 g) were treated with 10% NaOH (50 mL) for 3 min, washed (3x) with water, treated 
with 2% Hg2Cl2 (50 mL) for 5 min, washed (3x) with water, and dropped into the 
solution of hydroximine 2.  After 16 hrs stirring, the reaction was filtered through a short 
plug of silica, washing with ethyl acetate, then 5:2 ethyl acetate/methanol, and the 
combined organics were concentrated.  The crude product (327 mg recovered) was 
carried on to the next step without further purification. 
Synthesis of 5-aminomethyl-Trp ethyl ester (4).  Crude amine 3 (100 mg, ~0.28 mmol) 
was dissolved in dichloromethane (1 mL).  Trifluoroacetic acid was added (1 mL) and the 
reaction was stirred for 1 hr under argon, after which the reaction solution was 
concentrated in vacuo.  The crude product (75 mg recovered) was carried on to the next 
step without further purification. 
Synthesis of (NVOC)2-5-aminomethyl-Trp ethyl ester (5).  Crude diamine 4 (75 mg, 
~0.29 mmol, 1 eq) was dissolved in H2O (6 mL).  6-Nitroveratryloxycarbonyl (NVOC) 
chloride (158 mg, 0.574 mmol, 3 eq) dissolved in dioxane (6 mL) was added, and the 
reaction solution was stirred for 4 hrs.  An additional portion of 6-
nitroveratryloxycarbonyl (NVOC) chloride (39 mg, 0.191 mmol, 0.5 eq) dissolved in 
dioxane (1 mL) was added and the reaction solution was stirred for an additional 4 hrs.  
The reaction solution was poured into 75 mL H2O, acidified to pH = 3 with 0.2 M 
aqueous HCl, and extracted (3x) with ethyl acetate.  The combined organics were washed 
with brine, dried over Mg2SO4, and concentrated.  The crude product was purified by 
flash chromatography (2.5:1 ethyl acetate/hexanes, followed by 100% ethyl acetate) to 
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yield compound 5 (48 mg, 20% yield over three steps from hydroximine 2).  1H NMR 
(500 MHz, DMSO-d6) δ 10.84 (s, 1H), 8.01 (d, J = 7.8 Hz, 1H), 7.97 (t, J = 6.0 Hz, 1H), 
7.69 (s, 2H), 7.42 (s, 1H), 7.29 (d, J = 8.3 Hz, 1H), 7.17 (s, 2H), 7.13 (s, 1H), 7.03 (dd, J 
= 8.3, 1.1 Hz, 1H), 5.37-5.26 (m, 4H), 4.29 (d, J = 5.1 Hz, 2H), 4.05 (dd, J = 7.0, 2.2 Hz, 
1H), 3.86-3.74 (m, 14H), 3.14 (dd, J = 14.3, 5.2 Hz, 1H), 3.03 (dd, J = 14.5, 9.2 Hz, 1H), 
1.09 (t, J = 7.1 Hz, 2H). 
Synthesis of (NVOC)2-5-aminomethyl-Trp (6).  (NVOC)2-5-aminomethyl-Trp ethyl 
ester 5 (43 mg, 0.058 mmol, 1 eq) was dissolved in a solution of H2O (1 mL) and dioxane 
(5 mL).  Aqueous 1M NaOH was added (0.5 mL) and the reaction was stirred for 20 hrs 
at room temperature.  Additional 1M NaOH (1 mL) was added and the reaction was 
heated at 40°C for 1.5 hrs, after which the reaction was complete by TLC.  The reaction 
solution was cooled to room temperature, diluted with H2O, and aqueous KHSO4 was 
added until the pH reached 2.5, causing the solution to turn cloudy.  This suspension was 
extracted with dichloromethane (3x) and the combined organics were washed with brine, 
dried over Mg2SO4, and concentrated, to yield the crude product (42 mg recovered), 
which was carried on to the next step without further purification.  LRMS (ESI-) 
calculated for [C32H32N5O14]- ([M-H]-) 710.2, found 710.0. 
Synthesis of (NVOC)2-5-aminomethyl-Trp cyanomethyl ester (7).  Crude (NVOC)2-5-
aminomethyl-Trp 6 (42 mg, ~0.058 mmol, 1 eq) was dissolved in a solution of DMF (1 
mL) and chloroacetonitrile (1 mL, 16 mmol, 270 eq).  Triethylamine (24 µL, 0.17 mmol, 
3 eq) was added and the reaction was stirred at room temperature for 6 hrs.  The reaction 
solution was concentrated in vacuo and the crude product was dissolved in 
dichloromethane.  This solution was washed with 0.2 M aqueous HCl, 1 M aqueous 
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NaHCO3, and brine, dried over MgSO4, and concentrated.  The crude product was 
recrystallized by dissolving in a minimal volume (~1 mL) dichloromethane, diluting with 
hexanes to precipitate the product, and cooling this suspension to 0°C.  The precipitate 
was recovered by filtration, washing with cold hexanes, to yield compound 7 (21 mg, 
47% yield over two steps).  1H NMR (300 MHz, DMSO-d6) δ 10.90 (s, 1H), 8.21 (d, J = 
7.5 Hz, 1H), 7.97 (t, J = 5.8 Hz, 1H), 7.69 (s, 2H), 7.43 (s, 1H), 7.30 (d, J = 8.3 Hz, 1H), 
7.19 (d, J = 1.9 Hz, 1H), 7.17 (s, 1H), 7.11 (s, 1H), 7.04 (d, J = 8.3 Hz, 1H), 5.40-5.27 
(m, 4H), 4.99 (s, 2H), 4.42 (dd, J = 14.1, 7.9 Hz, 1H), 4.29 (d, J = 5.7 Hz, 2H), 3.86-3.79 
(m, 12H), 3.23-3.05 (m, 2H).  13C NMR (126 MHz, DMSO-d6) δ 171.26, 155.78, 155.56, 
153.40, 153.33, 147.67, 147.61, 139.15, 139.04, 135.36, 129.67, 128.07, 127.69, 126.75, 
124.40, 121.13, 116.70, 115.66, 112.07, 111.42, 110.33, 110.13, 109.53, 108.81, 108.12, 
62.67, 62.35, 56.13, 56.06, 54.60, 49.46, 44.62, 26.64. 
Synthesis of (NVOC)2-5-aminomethyl-Trp-dCA (8).  dCA2.2 TBA (10 mg, 8.6 µmol, 
1 eq) and (NVOC)2-5-aminomethyl-Trp cyanomethyl ester 7 (10 mg, 13 µmol, 1.5 eq) 
were dissolved in DMF (0.2 mL) and stirred at room temperature for 22 hrs under argon, 
then stirred at 50°C for 1 hr.  The reaction was purified by HPLC to yield compound 8 
(347 µg, 3% yield).  MALDI-MS calculated for [C51H58N13O26P2]+ ([M+H]+) 1330.31, 
found 1330.54. 
NVOC-(2S,3S)-β-methylPhe cyanomethyl ester (9).  Prepared from (2S,3S)-β-
methylPhe (Chem-Impex) by standard methods as for compounds 22 and 23.  1H NMR 
(300 MHz, CDCl3) δ 7.70 (s, 1H), 7.37-7.17 (m, 5H), 6.88 (s, 1H), 5.50 (dd, J = 34.8, 
15.0 Hz, 2H), 5.12 (d, J = 8.8 Hz, 1H), 4.85-4.62 (m, 3H), 3.94 (s, 3H), 3.92 (s, 3H), 3.42 
(m, 1H), 1.43 (d, J = 7.1 Hz, 3H).  13C NMR (75 MHz, CDCl3) δ 170.42, 155.76, 153.72, 
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148.22, 139.70, 129.19, 127.97, 127.83, 127.52, 113.81, 109.79, 108.23, 64.23, 59.17, 
56.52, 48.94, 41.75, 17.88. 
NVOC-(2S,3S)-β-methylPhe-dCA (10)  Prepared from NVOC-(2S,3S)-β-methylPhe 
cyanomethyl ester (9) by standard methods as for compound 24.  MALDI-MS calculated 
for [C39H47N10O20P2]+ ([M+H]+) 1037.24, found 1037.45. 
NVOC-(2S,3R)-β-methylPhe cyanomethyl ester (11).  Prepared from (2S,3R)-β-
methylPhe (generous gift from Victor Hruby, University of Arizona) by standard 
methods as for compounds 22 and 23.  1H NMR (300 MHz, CDCl3) δ 7.70 (s, 1H), 7.35-
7.19 (m, 5H), 6.93 (s, 1H), 5.50 (dd, J = 21, 15 Hz, 2H), 5.33 (d, J = 8.7 Hz, 1H), 4.64-
4.56 (m, 3H), 3.95 (s, 6H), 3.32 (m, 1H), 1.43 (d, J = 7.2 Hz, 3H). 
NVOC-(2S,3R)-β-methylPhe-dCA (12).  Prepared from NVOC-(2S,3R)-β-methylPhe 
cyanomethyl ester (11) by standard methods as for compound 24.  MALDI-MS 
calculated for [C39H47N10O20P2]+ ([M+H]+) 1037.24, found 1037.39. 
NVOC-(2S,3S)-β-methylTrp cyanomethyl ester (13).  Prepared from (2S,3S)-β-
methylTrp (generous gift from Victor Hruby, University of Arizona) by standard methods 
as for compounds 22 and 23.  1H NMR (300 MHz, CDCl3) δ 8.17 (s, 1H), 7.70 (s, 1H), 
7.62 (d, J = 7.9 Hz, 1H), 7.38 (d, J = 8.1 Hz, 1H), 7.22 (t, J = 7.6 Hz, 1H), 7.14 (t, J = 7.5 
Hz, 1H), 7.09 (d, J = 2.5 Hz, 1H), 6.91 (s, 1H), 5.52 (dd, J = 15, 15 Hz, 2H), 5.35 (d, J = 
8.7 Hz, 1H), 4.79-4.49 (m, 3H), 3.94 (s, 3H), 3.89 (s, 3H), 3.82 (m, 1H), 1.54 (d, J = 7.2 
Hz, 4H).  13C NMR (CDCl3) δ 170.58, 155.90, 153.77, 148.31, 139.82, 136.56, 127.85, 
126.41, 122.82, 122.13, 120.19, 118.94, 114.84, 113.93, 111.78, 110.08, 108.34, 64.30, 
58.96, 56.60, 56.56, 48.95, 34.18, 18.10. 
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NVOC-(2S,3S)-β-methylTrp-dCA (14).  Prepared from NVOC-(2S,3S)-β-methylTrp 
cyanomethyl ester (11) by standard methods as for compound 24.  MALDI-MS 
calculated for [C41H48N11O20P2]+ ([M+H]+) 1076.25, found 1076.29. 
Boc-indoleacrylic acid (15).  Trans-3-indoleacrylic acid (2 g, 10.7 mmol, 1 eq) was 
added to a solution of acetonitrile (20 mL) and water (1.5 mL) in a 100 mL round bottom 
flask.  Triethylamine (1.57 mL, 11.2 mmol, 1.05 eq) was added and all solids dissolved 
after several minutes of stirring.  4-Dimethylaminopyridine (131 mg, 1.07 mmol, 0.1 eq) 
was added, followed by Boc2O (2.58 mL, 11.2 mmol, 1.05 eq), added dropwise over ~2 
min, and the reaction solution was stirred at room temperature overnight.  Additional 
Boc2O (2.46 mL, 10.7 mmol, 1 eq) was added and the reaction was stirred at 45°C for 2 
hrs, after which the reaction was complete by TLC.  The reaction solution was diluted 
with 60 mL Et2O and washed with 1M aqueous KHSO4 (5x).  The organic layer was 
extracted with 5% aqueous NaHCO3 (5x) and the combined aqueous NaHCO3 layers 
were acidified with aqueous HCl to pH 1.5, then extracted with Et2O (5x) and these 
combined ether layers were washed with brine, dried over Na2SO4, and concentrated.  
The resulting solid was purified by flash chromatography (5:1 to 1:1 
dichloromethane/ethyl acetate), to give 2.15 g (~70% yield) of crude product, which was 
carried on to the next step without further purification.  1H NMR (300 MHz, CDCl3) δ 
8.21 (d, J = 7.9 Hz, 1H), 7.97-7.85 (m, 3H), 7.38 (m, 2H), 6.56 (d, J = 16.1 Hz, 1H), 1.70 
(s, 9H). 
 Boc-indoleacrylic acid-oxazolidinone (16).  Crude Boc-indoleacrylic acid 15 (1.5 g, 
~5.2 mmol, 1.3 eq) was dissolved in dry THF (20.2 mL) in a 250 mL oven-dried Schlenk 
flask under argon.  Triethylamine (1.41 mL, 10 mmol, 2.5 eq) was added, and the 
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reaction solution was cooled to ~-10°C.  Trimethylacetyl chloride (0.595 mL, 4.8 mmol, 
1.2 eq) was added dropwise, upon which a yellow precipitate formed, and the reaction 
suspension was stirred at -10°C for 1 hr.  Dry LiBr (0.384 g, 4.4 mmol, 1.1 eq) was 
added, followed by (S)-4-phenyl-2-oxazolidinone (0.656 g, 4.0 mmol, 1.0 eq), the 
reaction was warmed to room temperature, and stirred at room temperature for 4 hrs.  The 
reaction was quenched by addition of 0.2 M aqueous HCl (40 mL, 2 eq), and the THF 
was removed in vacuo, ethyl acetate was added, and this organic layer was washed with 
0.2 M aqueous HCl, then 1M aqueous NaHCO3 (2x), then brine, dried over Na2SO4, and 
concentrated.  The crude product was purified by flash chromatography (4:1 
hexanes/ethyl acetate) to yield compound 16 (1.51 g, 47% yield over 2 steps from trans-
3-indoleacrylic acid).  1H NMR (300 MHz, CDCl3) δ 8.19 (dd, J = 5.9, 3.3 Hz, 1H), 8.08 
(d, J = 15.8 Hz, 1H), 7.99-7.89 (m, 3H), 7.43-7.33 (m, 7H), 5.59 (dd, J = 8.7, 3.8 Hz, 
1H), 4.76 (t, J = 8.8 Hz, 1H), 4.33 (dd, J = 8.8, 3.8 Hz, 1H), 1.68 (s, 9H). 
(3R)-Boc-β-methylindolepropanoic acid-oxazolidinone (17).  A solution of 
methylmagnesium bromide (3M in Et2O, 1.75 mL, 5.24 mmol, 1.5 eq) in dry THF (18 
mL) and dimethyl sulfide (5.4 mL) in an oven-dried Schlenk flask was subjected to three 
freeze-pump-thaw cycles, placed under an atmosphere of argon, and cooled to 0°C.  
CuBrDMS (1.08g, 5.24 mmol, 1.5 eq) was added all at once and the solution was stirred 
for 30 min at 0°C.  A solution of Boc-indoleacrylic acid-oxazolidinone (16) in THF (10 
mL), which had also been subjected to three freeze-pump-thaw cycles, was added via 
cannula over 5 min.  The reaction solution was stirred at 0°C for 2 hrs, then at room 
temperature for 45 min, quenched by the addition of 30 mL saturated aqueous NH4Cl, 
and stirred at room temperature for 30 min.  The layers were partitioned and the organic 
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layer was washed with saturated aqueous NH4Cl (4x), then brine (2x), then dried over 
Mg2SO4 and concentrated.  The major diastereomer was isolated from the crude product 
by flash chromatography (5:1 hexanes/ethyl acetate) to yield compound 17 (1.12 g, 72% 
yield).  1H NMR (300 MHz, CDCl3) δ 8.12 (d, J = 7.3 Hz, 1H), 7.60 (d, J = 7.3 Hz, 1H), 
7.36-7.21 (m, 8H), 5.36 (dd, J = 8.7, 3.7 Hz, 1H), 4.58 (t, J = 8.8 Hz, 1H), 4.22 (dd, J = 
8.9, 3.8 Hz, 1H), 3.61 (dd, J = 13.9, 7.0 Hz, 1H), 3.47 (dd, J = 16.5, 7.1 Hz, 1H), 3.25 
(dd, J = 16.5, 7.2 Hz, 1H), 1.66 (s, 9H), 1.33 (d, J = 6.9 Hz, 3H).  13C NMR (75 MHz, 
CDCl3) δ 171.51, 153.84, 139.05, 129.68, 129.23, 128.78, 125.94, 125.04, 124.42, 
122.47, 121.80, 119.39, 115.44, 83.57, 70.05, 57.77, 42.24, 28.36, 26.97, 21.11. 
(2S, 3R)-Boc-β-methyl-α-azido-indolepropanoic acid-oxazolidinone (18).  (3R)-Boc-
β-methylindolepropanoic acid-oxazolidinone 17 (600 mg, 1.34 mmol, 1 eq) was 
dissolved in THF (7 mL) under argon in a 50 mL oven-dried Schlenk flask.  A solution of 
0.5 M KHMDS in toluene (2.94 mL, 1.47 mmol, 1.1 eq) was added to THF (5 mL) in a 
100 mL oven-dried Schlenk flask under argon.  Both flasks were cooled to -78°C and the 
solution of compound 17 was transferred to the KHMDS solution by cannula.  This 
solution was stirred at -78°C for 30 min.  Trisyl azide46,47 was dissolved in THF (5 mL) 
in a 100 mL oven-dried Schlenk flask under argon and cooled to -78°C.  The compound 
17/KHMDS solution was transferred to this flask via cannula transfer and the solution 
was stirred at -78°C for 5 min.  The reaction was quenched by addition of glacial acetic 
acid (0.368 mL, 6.44 mmol, 4.8 eq), and the solution was warmed to room temperature, 
and stirred at room temperature for 4 hrs.  This solution was diluted with Et2O and 1M 
aqueous sodium chloride and mixed.  The aqueous phase was extracted with 1:1 
Et2O/THF (3x) and the combined organics washed with 1M NaHCO3 (2x) then brine 
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(2x), dried over MgSO4, and concentrated.  The crude product was purified by flash 
chromatography (5:1 hexanes/ethyl acetate) to yield compound 18 (455 mg, 69% yield).  
1H NMR (300 MHz, CDCl3) δ 8.18 (d, J = 8.1 Hz, 1H), 7.65 (d, J = 7.4 Hz, 1H), 7.53 (s, 
1H), 7.36-7.26 (m, 5H), 7.18 (dd, J = 7.6, 1.8 Hz, 2H), 5.36 (d, J = 9.4 Hz, 1H), 4.79 (dd, 
J = 8.3, 2.9 Hz, 1H), 4.02 (dd, J = 8.8, 3.0 Hz, 1H), 3.85 (t, J = 8.6 Hz, 1H), 3.64 (dq, J = 
14.1, 7.0 Hz, 1H), 1.69 (s, 9H), 1.57 (d, J = 7.0 Hz, 3H).  13C NMR (75 MHz, CDCl3) δ 
169.63, 153.02, 149.58, 138.19, 135.25, 129.34, 129.26, 128.97, 125.77, 124.89, 124.11, 
122.76, 120.30, 119.40, 115.34, 84.13, 70.22, 63.64, 58.02, 32.84, 28.31, 17.98. 
(2S,3R)-Boc-β-methyl-α-azido-indolepropanoic acid (19).  (2S,3R)-Boc-β-methyl-α-
azido-indolepropanoic acid-oxazolidinone 18 (400 mg, 0.817 mmol, 1 eq) was dissolved 
in THF (10 mL) and H2O (10 mL).  This solution was cooled to 0°C and hydrogen 
peroxide (30% aqueous solution, 0.508 mL) was added dropwise over 1 min with stirring, 
then LiOHH2O (68 mg, 1.63 mmol, 2 eq) was added all at once, and the reaction 
solution was stirred at 0°C for 30 min, after which the reaction was complete by TLC.  
NaHSO3 (512 mg in 0.6 mL H2O, 4.92 mmol, 3 eq) was added at 0°C, followed by 
saturated aqueous NaHCO3 (10 mL), and the mixture was stirred at room temperature for 
30 min.  THF was removed in vacuo, Et2O (15 mL) was added and the layers were 
partitioned after mixing.  The organic layer was extracted with saturated aqueous 
NaHCO3 (3x) and the combined aqueous layers were acidified to pH = 1.5 with 1M HCl.  
The resulting suspension was extracted with ethyl acetate (4x) and these combined ethyl 
acetate layers were washed with H2O (2x) and brine (2x), dried over MgSO4, and 
concentrated to yield crude product 1.  The original Et2O organic layer was extracted 
again with saturated aqueous NaHCO3 (3x), acidified to pH = 1, and this suspension was 
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extracted with ethyl acetate (4x).  The combined organic layers were washed with brine 
(2x), dried over MgSO4, and concentrated to yield crude product 2.  Crude product 1 was 
partially purified by flash chromatography (1:1 ethyl acetate/hexanes, then 100% ethyl 
acetate, then 5% methanol and 1% acetic acid in ethyl acetate) to yield compound 19 (92 
mg, 33% yield).  1H NMR (300 MHz, CDCl3) δ 9.62 (s, 1H), 8.16 (d, J = 8.0 Hz, 1H), 
7.60 (d, J = 7.6 Hz, 1H), 7.54 (s, 1H), 7.31 (dt, J = 23.6, 7.0 Hz, 2H), 4.41 (d, J = 4.3 Hz, 
1H), 3.79-3.71 (m, 1H), 1.69 (s, 9H), 1.44 (d, J = 7.0 Hz, 3H).  13C NMR (75 MHz, 
CDCl3) δ 175.38, 149.84, 135.58, 129.21, 124.85, 123.65, 122.81, 121.07, 118.70, 
115.70, 84.12, 66.28, 33.07, 28.34, 14.87.  IR (NaCl) 2978 (m), 2928 (m), 2109 (s), 1733 
(s), 1370 (s), 1157 (s) cm-1. 
(2S,3R)-Boc-β-methyltryptophan (20).  (2S,3R)-Boc-β-methyl-α-azido-indolepropanoic 
acid 19 (81 mg, 0.235 mmol, 1 eq) was dissolved in THF (2 mL), trimethylphosphine 
(1M in THF, 0.47 mL, 0.47 mmol, 2 eq) was added, and the reaction solution was stirred 
at room temperature under argon for 1 hr.  H2O was added (0.1 mL, 5.6 mmol, 24 eq) and 
this solution was stirred at room temperature for 14 hrs, after which it was concentrated 
in vacuo.  The resulting solid was partially purified by flash chromatography (1% acetic 
acid in ethyl acetate to 5% acetic acid in 1:1 ethyl acetate/methanol) to give 18 mg (~24% 
yield) of crude product, which was carried on to the next step without further purification.  
1H NMR (300 MHz, CD3OD) δ 8.14 (d, J = 8.1 Hz, 1H), 7.81 (d, J = 7.9 Hz, 1H), 7.55 
(s, 1H), 7.34-7.26 (m, 2H), 3.98-3.89 (m, 2H), 1.68 (s, 9H), 1.41 (d, J = 7.1 Hz, 3H).  13C 
NMR (126 MHz, CD3OD) δ 178.44, 150.99, 130.48, 125.89, 124.69, 123.89, 121.97, 
120.16, 116.39, 85.05, 32.49, 28.40, 22.81, 13.03.  HRMS (APCI/ESI+) calculated for 
[C17H23N2O4]+ ([M+H]+) 319.1658, found 319.1663. 
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(2S,3R)-β-methyltryptophan (21).  Crude (2S,3R)-Boc-β-methyltryptophan 20 (18 mg, 
~0.058 mmol) was suspended in H2O and heated to 170°C for 3 min by microwave 
irradiation.  The resulting solution was lyophilized to give 15.2 mg crude compound 21, 
which was carried on to the next step without further purification.  1H NMR (300 MHz, 
CD3OD) δ 7.74 (d, J = 7.8 Hz, 1H), 7.37 (d, J = 7.9 Hz, 1H), 7.18 (s, 1H), 7.13 (t, J = 7.5 
Hz, 1H), 7.05 (t, J = 7.5 Hz, 1H), 4.01-3.95 (m, 2H), 1.39 (d, J = 6.6 Hz, 3H).  HRMS 
(APCI/ESI+) calculated for [C12H15N2O2]+ ([M+H]+) 219.1128, found 219.1148. 
NVOC-(2S,3R)-β-methyltryptophan (22).  Crude (2S,3R)-β-methyltryptophan 21 (15.2 
mg, ~0.07 mmol, 1 eq) and Na2CO3 (36.9 mg, 0.348 mmol, 5 eq) were dissolved in a 
solution of water (1 mL) and dioxane (1 mL).  This solution was cooled to 0°C, 6-
nitroveratryloxycarbonyl (NVOC) chloride (19.3 mg, 0.07 mmol, 1 eq) was added, and 
the reaction solution was stirred at room temperature for 3 hrs.  The reaction solution was 
poured into H2O (15 mL) and washed with Et2O (3x).  The aqueous layer was acidified to 
pH = 1.5 with 6M HCl, then extracted (4x) with Et2O.  These combined Et2O layers were 
dried over MgSO4 and concentrated.  The resulting solid was purified by flash 
chromatography (1% acetic acid in 1.5:1 dichloromethane/ethyl acetate) to give 12.7 mg 
crude compound 22, which was carried on to the next step without further purification.  
HRMS (APCI/ESI-) calculated for [C22H24N3O8]- ([M-H]-) 458.1558, found 458.1616. 
NVOC-(2S,3R)-β-methyltryptophan cyanomethyl ester (23).  Crude NVOC-(2S,3R)-
β-methyltryptophan 22 (12.7 mg, ~ 0.028 mmol, 1 eq) was dissolved in DMF (0.2 mL) 
and chloroacetonitrile (0.2 mL, 3.16 mmol, 113 eq) under argon.  Triethylamine (11.6 
µL, 0.083 mmol, 3 eq) was added and the reaction was stirred at room temperature for 2 
hrs, then concentrated in vacuo.  The resulting solid was partially purified by flash 
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chromatography (15:1 to 2.5:1 dichloromethane/ethyl acetate), and further purified by 
additional flash chromatography (1:10 to 1:2 ethyl acetate/hexanes), to yield compound 
23 (6.3 mg, 5% yield over 4 steps from compound 19).  1H NMR (300 MHz, CDCl3) δ 
8.17 (s, 1H), 7.70 (s, 1H), 7.60 (d, J = 7.8 Hz, 1H), 7.38 (d, J = 8.0 Hz, 1H), 7.22 (t, J = 
7.2 Hz, 1H), 7.13 (t, J = 7.4 Hz, 1H), 7.08 (d, J = 2.4 Hz, 1H), 6.91 (s, 1H), 5.56-5.38 (m, 
3H), 4.75 (dd, J = 8.7, 6.1 Hz, 1H), 4.56 (q, J = 15.6 Hz, 2H), 3.95 (s, 3H), 3.90 (s, 3H), 
3.72-3.63 (m, 1H), 1.52 (d, J = 7.2 Hz, 3H).  13C NMR (126 MHz, CDCl 3) δ 170.61, 
155.58, 153.76, 148.31, 139.83, 136.37, 127.83, 126.55, 122.71, 122.03, 120.05, 118.66, 
115.34, 113.88, 111.70, 110.13, 108.32, 64.23, 59.24, 56.60, 56.56, 48.75, 34.04, 17.18.  
HRMS (APCI/ESI+) calculated for [C24H25N4O8]+ ([M+H]+) 497.1667, found 497.1677. 
NVOC-(2S,3R)-β-methylTrp-dCA (24).  dCA2.2 TBA (10 mg, 8.6 µmol, 1 eq) and 
NVOC-(2S,3R)-β-methyltryptophan cyanomethyl ester 23 were dissolved in DMF (0.135 
mL) and stirred at room temperature for 40 hrs under argon.  The reaction was purified 
by HPLC to yield compound 24 (283 µg, 3% yield).  MALDI-MS calculated for 
[C41H48N11O20P2]+ ([M+H]+) 1076.25, found 1076.65. 
NVOC-tert-leucine cyanomethyl ester.  Tert-leucine (Aldrich) was NVOC-protected 
and activated as a cyanomethyl ester by standard procedures.  1H NMR (300 MHz, 
CDCl3) δ 7.71 (s, 1H), 6.96 (s, 1H), 5.52 (d, J = 3.6 Hz, 2H), 5.41 (d, J = 9.4 Hz, 1H), 
4.77 (dd, J = 53.3, 15.6 Hz, 2H), 4.25 (d, J = 9.4 Hz, 1H), 3.99 (s, 3H), 3.95 (s, 3H), 1.04 
(s, 9H).  13C NMR (126 MHz, CDCl3) δ 170.63, 155.74, 153.71, 148.33, 139.89, 127.74, 
113.89, 110.12, 108.31, 64.27, 62.18, 56.61, 56.55, 48.61, 34.94, 26.60. 
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NVOC-tert-leucine-dCA.   Prepared from NVOC-tert-leucine cyanomethyl ester by 
standard methods as for compound 24.  MALDI-MS calculated for [C35H47N10O20P2]+ 
([M+H]+) 989.24, found 989.68. 
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Chapter 4: Binding interactions to the complementary subunit of the 
α4β4 receptor* 
 
4.1  Abstract 
The agonist binding site of nicotinic acetylcholine receptors (nAChRs) spans an 
interface between two subunits of the pentameric receptor.  The principal component of 
this binding site is contributed by an α subunit, and it binds the cationic moiety of the 
nicotinic pharmacophore.  The other part of the pharmacophore – a hydrogen bond 
acceptor – has recently been shown to bind to the complementary, non-α subunit, via the 
backbone NH of a conserved Leu.  This interaction was predicted by studies of 
acetylcholine binding proteins (AChBPs) and confirmed by functional studies of the 
neuronal (CNS) nAChR, α4β2.  The AChBP structures further suggested that the 
hydrogen bond to the backbone NH was mediated by a water molecule, and that a second 
hydrogen bonding interaction occurs between the water molecule and the backbone CO 
of a conserved Asn, also on the non-α subunit.  Here we provide new insights into the 
nature of the interactions between the hydrogen bond acceptor of nicotinic agonists and 
the complementary subunit backbone.  We have studied both the nAChR of the 
neuromuscular junction (muscle-type) and a neuronal subtype, (α4)2(β4)3.  In the muscle-
type receptor, both acetylcholine (ACh) and nicotine show a strong interaction with the 
Leu NH, but the potent nicotine analog epibatidine does not.  This interaction is much 
attenuated in the α4β4 receptor.  Surprisingly, we find no evidence for a functionally 
significant interaction with the backbone carbonyl of the relevant Asn in either receptor 
with an array of agonists. 
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4.2  Introduction 
nAChRs are pentamers, composed of five subunits arranged symmetrically 
around a central ion-conducting pore.  Nicotinic agonists bind at subunit interfaces, and a 
combination of structure-function studies and structural studies of the acetylcholine 
binding proteins (AChBPs), which share considerable sequence homology with the 
ligand binding domain of the nAChR, have established a detailed binding model.1-3  The 
α subunits contribute the principal component of the agonist binding site, which binds to 
the cationic end of agonists.  This binding site is well-characterized, consisting of a 
cation-π interaction to one of several conserved aromatic residues and typically a 
hydrogen bond from the N+H of the drug to a backbone carbonyl.4-6  The natural agonist 
acetylcholine (ACh), which lacks the crucial N+H, does not participate in the latter 
interaction.   
The complementary component of the agonist binding site is formed by non-α 
subunits, and recent work has shown that it involves a hydrogen bonding interaction to 
the hydrogen bond acceptor of agonists (e.g., the C=O of ACh or the pyridine N of 
nicotine; Figures 4.1 and 4.2).  Crystal structures of AChBPs with several drugs bound 
produced a binding model in which two backbone features – a CO and an NH from 
amino acids that are 12 residues apart – coordinate a water molecule, which in turn 
hydrogen bonds to the hydrogen bond acceptor of agonists (Figure 4.1).2,7,8  In nAChRs 
the particular residues are an Asn and a Leu, and they are conserved across the family 
(Figure 4.3; they are a Leu and a Met, respectively, in the AChBP structure of Figure 
4.1A).  Since residue numbering varies among different receptors, we will refer to them 
simply as the Asn and the Leu sites, the former contributing a CO, the latter an NH to the  
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Figure 4.1. Proposed binding model for nicotine at nAChRs.  (A) Crystal structure of nicotine bound to 
AChBP (1UW6).  (B) Schematic of binding model, denoting key interactions probed here. 
 
Figure 4.2.  (A) Agonists used in this study.  (B) Illustration of amide-to-ester mutation.  Introduction of an 
α-hydroxy acid in place of an amino acid eliminates the hydrogen bond donor (backbone NH) of the i 
residue and attenuates the hydrogen bond accepting ability of the i-1 carbonyl.  In this figure, the attenuated 
hydrogen bond is represented by a dashed line. 
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Figure 4.3.  Sequences of the complementary subunits considered here. The hydrogen bond-donating Leu 
and hydrogen bond-accepting Asn are highlighted. The key residues are highly conserved in other 
orthologs. Residue numbering is for the β2 subunit. 
proposed hydrogen bonding array; specific residue numbers are noted in the experimental 
section.  Recent studies of the neuronal α4β2 nAChR confirmed that the Leu NH of the 
β2 subunit does hydrogen bond to the pyridine N of nicotine and to the carbonyl O of 
ACh.9  
The present work expands these studies of hydrogen bonding interactions 
involving the complementary subunit in two ways.  First, we consider two new receptor 
subtypes: a second neuronal form, (α4)2(β4)3, henceforth referred to as α4β4; and the 
form found at the neuromuscular junction of the peripheral nervous system, (α1)2β1γδ 
(fetal form; in the adult variant the ε subunit replaces γ), which we will refer to as the 
muscle-type receptor.  Note that the pharmacology of the muscle-type receptor is quite 
distinct from neuronal receptors such as α4β2 and α4β4, most importantly in the fact that 
nicotine is quite potent at these neuronal receptors but not at the receptors of the 
neuromuscular junction.  This distinction allows smokers to become addicted to nicotine 
without adverse peripheral effects.  Second, we evaluate the other component of the 
proposed hydrogen bonding model, the water-mediated hydrogen bond to the Asn 
carbonyl, in both the α4β4 and the muscle-type receptors.  Efforts to probe the Asn 
backbone carbonyl in the previously studied α4β2 receptor were thwarted by technical 
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issues; the nonsense suppression methodology necessary for these studies was not 
selective/efficient enough for the present purposes. 
Using unnatural amino acid mutagenesis we find key differences in the hydrogen 
bonding properties of specific drug-receptor combinations.  Interestingly, we find no 
evidence for a functionally significant hydrogen bond to the Asn backbone carbonyl. 
 
4.3  Results 
4.3.1  General strategy  
The two hydrogen bonding interactions being considered here both involve the 
protein backbone, and such interactions can be probed by incorporating α-hydroxy 
analogs of amino acids at appropriate locations (Figure 4.2B).  As a probe of the Leu NH 
the strategy is straightforward: the backbone NH is replaced by an O.  Concerning the 
backbone CO, α-hydroxy substitution attenuates the hydrogen bonding ability of the i-1 
carbonyl by converting it to an ester carbonyl.  It is well-established that the carbonyls of 
esters are much poorer hydrogen bond acceptors than those of amides.  Interestingly, in 
many studies, both quantitative and qualitative, it has been shown that the two effects 
associated with backbone ester incorporation – removal of the NH hydrogen bond donor 
and attenuation of the CO hydrogen bond acceptor – can have similar energetic 
consequences.10-14  As such, to perturb the Asn CO we actually mutate the i+1 residue, 
which is Leu in the α4β4 receptor and Val in the muscle-type receptor.  Backbone ester 
mutations can be efficiently incorporated site-specifically into nAChRs expressed in 
Xenopus oocytes by nonsense suppression methodology.15,16  Typical experimental traces 
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and dose-response relations for unnatural amino acid mutagenesis experiments with these 
receptors have been reported previously.6,17  
These studies use EC50, the effective agonist concentration needed to reach a half-
maximal response, as a read-out of the functional impact of each mutation.  It is well 
recognized that EC50 is a composite measure, reflecting multiple equilibria that include 
both “binding” events – drug entering/exiting the agonist binding site – and “gating” 
events – the equilibria between open and closed states of the channel.  It is typical in an 
EC50 study to note an ambiguity as to whether a given mutation affects binding or gating.  
We would argue that in the present system, as in many similar previous studies from our 
lab, the ambiguity is of a different kind.  Given the subtlety and precision of the 
modifications enabled by unnatural amino acid mutagenesis, combined with our 
structural knowledge of the binding site and the location of the mutations made, it is clear 
that we are perturbing a hydrogen bonding interaction between the drug and the receptor 
– a binding interaction.  In order to see a change in EC50, it must be true that the 
hydrogen bonding interaction is diminished (or enhanced) in one or more of the multiple 
equilibria noted above.  In the studies presented here, the ambiguity in the EC50 
measurement concerns which equilibrium is perturbed, not the nature of the perturbation, 
which is clearly an attenuated binding interaction.   
  Detailed kinetic analyses, typically at the single channel level, can often 
determine which equilibrium step(s) is being perturbed.  However, we consider EC50 to 
be an appropriate metric here for two reasons.  First, detailed, single-channel studies are 
not feasible for the large number of drug-receptor combinations that we have considered.  
This is especially so given the protein expression limitations that are sometimes seen with 
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unnatural amino acid mutagenesis.  More importantly, our goal is to make 
pharmacological comparisons among closely related systems in response to subtle 
structural changes.  We also wish to compare these results to those of previous studies on 
related systems.  EC50 is a good measure of pharmacological activity.  Given our 
experience with these systems and unnatural amino acid mutagenesis in particular, we 
consider EC50 differences of less than a factor of 2 to be not interpretable. 
For studies of the muscle-type receptor we use the known L9’S mutation in the 
M2 transmembrane helix of the β1 subunit (where 9’ is the ninth amino acid from the 
cytoplasmic end of the M2 α-helix).18,19  This mutation is introduced to generically 
increase the sensitivity of the protein to agonists, and it results in a systematic ~40-fold 
decrease in EC50.  Given that the 9’ position is ~60 Å away from the agonist binding site, 
this mutation is generally expected to primarily affect gating and not agonist binding, 
although complications can arise.20  We have performed backbone ester mutagenesis of 
the Leu NH in the muscle-type receptor both in the absence and presence of the L9’S 
background mutation, and similar shifts in EC50 were seen for ACh (Table 4.1).  This 
confirms the viability of this strategy in the present system.  The agonist concentrations 
that were required to obtain a dose-response relation for epibatidine, nicotine and choline 
in the absence of the L9’S mutation were high enough that channel block by the agonist 
became a problem with some mutants, so all comparisons for this receptor are done using 
the L9’S mutation.  An analogous mutation was also used in the studies of α4β2.5  No 
such modification was necessary for the α4β4 receptor.   
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Table 4.1.  Mutagenesis of the backbone NH (γL119/δL121 mutations) and backbone CO (γV108/δV110 
mutations) of the muscle-type nAChR.  EC50 and Hill coefficient (nH) are ± SEM for goodness of fit to the 
Hill equation. 
 Agonist EC50 (µM) Fold Shift nH 
wild type  ACh 16.0 ± 0.3  1.3 ± 0.1 
γL119Leu, δL121Leua ACh 16.0 ± 0.5  1.5 ± 0.1 
γL119Lah, δL121Lah ACh 230 ± 6 14 1.5 ± 0.1 
wild typeb ACh 0.61 ± 0.04  1.4 ± 0.1 
γL119Leu, δL121Leua,b ACh 0.31 ± 0.02  1.5 ± 0.1 
γL119Lah, δL121Lahb ACh 9.1 ± 0.7 29 1.6 ± 0.2 
wild typeb Choline 840 ± 20  1.6 ± 0.1 
γL119Leu, δL121Leua,b Choline 780 ± 30  1.7 ± 0.1 
γL119Lah, δL121Lahb Choline 1000.00 ± 0.05 1.3 1.8 ± 0.1 
wild typeb (±)-Epibatidine 0.32 ± 0.02  1.5 ± 0.1 
γL119Leu, δL121Leua,b (±)-Epibatidine 0.40 ± 0.02  1.5 ± 0.1 
γL119Lah, δL121Lahb (±)-Epibatidine 0.52 ± 0.03 1.3 1.6 ± 0.1 
wild typeb S-Nicotine 22.0 ± 0.8  1.6 ± 0.1 
γL119Leu, δL121Leua,b S-Nicotine 23 ± 0.7  1.7 ± 0.1 
γL119Lah, δL121Lahb S-Nicotine 230 ± 30 10 2.2 ± 0.5 
γV108Val, δV110Vala,b ACh 0.29 ± 0.01  1.3 ± 0.1 
γV108Vah, δV110Vahb ACh 0.41 ± 0.05 1.4 1.2 ± 0.2 
γV108Val, δV110Vala,b Choline 620 ± 20  1.4 ± 0.1 
γV108Vah, δV110Vahb Choline 790 ± 60 1.3 1.4 ± 0.1 
γV108Val, δV110Vala,b (±)-Epibatidine 0.230 ± 0.006  1.4 ± 0.1 
γV108Vah, δV110Vahb (±)-Epibatidine 0.240 ± 0.006 1.0 1.5 ± 0.1 
γV108Val, δV110Vala,b S-Nicotine 15 ± 1  1.2 ± 0.1 
γV108Vah, δV110Vahb S-Nicotine 33 ± 2 2.2 1.6 ± 0.1 
aExpression of the wild type receptor with the natural amino acid incorporated by nonsense suppression 
bReceptor contains the βL9’S mutation 
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Table 4.2.  Mutagenesis of the backbone NH (βL119 mutations) and backbone CO (βL108 mutations) of 
the (α4)2(β4)3 nAChR.  EC50 and Hill coefficient (nH) are ± SEM for goodness of fit to the Hill equation. 
 Drug EC50 Fold Shift Hill 
β4L119Leua ACh 15.0 ± 0.7  1.42 ± 0.08 
β4L119Lah  ACh 43 ± 4 2.9 1.5 ± 0.2 
β4L119Leua S-Nicotine 2.1 ± 0.2  1.3 ± 0.1 
β4L119Lah  S-Nicotine 5.8 ± 0.4 2.8 1.4 ± 0.1 
β4L119Leua (±)-Epibatidine 0.0055 ± 0.0001  1.80 ± 0.05 
β4L119Lah  (±)-Epibatidine 0.01018 ± 0.00009 1.9 1.63 ± 0.02 
β4L119Leua Varenicline 0.133 ± 0.002  1.37 ± 0.02 
β4L119Lah  Varenicline 0.050 ± 0.003 1 / 2.7 1.5 ± 0.1 
β4L119Leua (-)-Cytisine 0.229 ± 0.004  1.37 ± 0.02 
β4L119Lah  (-)-Cytisine 3.1 ± 0.1 14 1.37 ± 0.05 
β4L119Leua Choline 1400 ± 300  1.4 ± 0.2 
β4L119Lah  Choline 2000 ± 700 1.4 1.1 ± 0.2 
β4L108Leua ACh 15.2 ± 0.9  1.43 ± 0.09 
β4L108Lah ACh 13 ± 2 1 / 1.2 1.2 ± 0.2 
β4L108Leua S-Nicotine 1.9 ± 0.2  1.3 ± 0.1 
β4L108Lah S-Nicotine 1.7 ± 0.2 1 / 1.1 1.4 ± 0.1 
β4L108Leua (±)-Epibatidine 0.0050 ± 0.0002  1.70 ± 0.08 
β4L108Lah (±)-Epibatidine 0.0065 ± 0.0002 1.3 1.71 ± 0.08 
β4L108Leua Varenicline 0.120 ± 0.004  1.38 ± 0.05 
β4L108Lah Varenicline 0.24 ± 0.01 2.0 1.19 ± 0.05 
β4L108Leua (-)-Cytisine 0.227 ± 0.005  1.42 ± 0.04 
β4L108Lah (-)-Cytisine 0.139 ± 0.007 1 / 1.6 1.40 ± 0.08 
β4L108Leua Choline 1200  ± 70  1.62 ± 0.09 
β4L108Lah Choline 1100  ± 100 1 / 1.1 1.4 ± 0.1 
aExpression of the wild type receptor with the natural amino acid incorporated by nonsense suppression 
 
4.3.2  Mutagenesis studies of the Leu NH 
To probe for the presumed hydrogen bond to the Leu backbone NH, the leucine 
(γL119/δL121 in the muscle-type receptor, βL119 in the α4β4 receptor) was replaced 
with its α-hydroxy acid analog (leucine, α-hydroxy; Lah).  In the muscle-type receptor, 
ACh and nicotine both showed substantial increases in EC50, (Table 4.1) confirming that 
the backbone NH is important for receptor activation by these agonists.  Surprisingly, 
epibatidine, a nicotine analog that is quite potent at the muscle-type nAChR (although 
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~300-fold less so than at the α4β2 subtype), was unresponsive to the backbone ester 
mutation.  This contrasts the 5-fold increase in EC50 seen in the α4β2 receptor for the 
analogous mutation with epibatidine as agonist.  As expected, choline, which lacks the 
CO that serves as the hydrogen bond acceptor, was unresponsive to the backbone 
mutation, giving no shift in EC50 upon incorporation of the α-hydroxy acid. 
Surprisingly, the analogous Leu to Lah mutation in α4β4 showed small to 
negligible effects for ACh, nicotine, epibatidine, varenicline, and (as expected) choline 
(Table 4.2).  Cytisine does show a large response, establishing that the Leu NH can 
function as a hydrogen bond donor to an agonist in the α4β4 receptor. 
4.3.3  Mutagenesis studies of the Asn CO 
The second hydrogen bond predicted by the AChBP structures is to the backbone 
CO of a conserved Asn.  To probe for a hydrogen bond to this backbone CO, the i+1 
residue, γV108/δV110 in the muscle-type receptor and βL108 in α4β4, is replaced with 
its α-hydroxy acid analog (valine, α-hydroxy; Vah for Val or Lah for Leu).  As discussed 
above, this converts a backbone amide to a backbone ester, thereby attenuating the 
hydrogen bond-accepting ability of this moiety.   
Early efforts to probe the CO of the relevant Asn residue in the α4β2 receptor 
gave inconsistent results that led us to question whether we could reliably control the 
stoichiometry of the mutant receptor.21  Since the muscle-type receptor reliably assembles 
into just one stoichiometry ((α1)2β1γδ), we anticipated that comparable experiments 
would experience fewer complications, and, indeed, nonsense suppression studies at the 
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appropriate Val gave functional mutant receptors.  However, ACh, nicotine, epibatidine, 
and choline were not significantly impacted by the backbone ester mutation (Table 4.1). 
With the experience gained from the muscle-type receptor, we were able to probe 
the key Asn carbonyl in a neuronal receptor, α4β4.  Again, we find no evidence for a 
meaningful interaction with the carbonyl for the agonists ACh, nicotine, epibatidine, 
varenicline, cytisine, and choline (Table 4.2).   
 
4.4  Discussion 
In recent years, the well-studied nicotinic pharmacophore, comprised of a cationic 
N and a hydrogen bond acceptor,22 has been mapped onto specific binding interactions in 
the nAChR (Figure 4.1).  The cationic N binds to the principal component of the agonist 
binding site in the α subunit, and the hydrogen bond acceptor binds to the complementary, 
non-α subunit.  Guided by structures of AChBP, backbone mutagenesis studies 
established a hydrogen bond between the pharmacophore acceptor (pyridine N of 
nicotine; carbonyl O of ACh) and a Leu backbone NH in the α4β2 neuronal nAChR.  It is 
important to note that it is not just the rise in EC50 resulting from backbone mutation that 
establishes a hydrogen bond.  In all cases, choline, which lacks the hydrogen bond 
acceptor of the other agonists, is unaffected by the backbone mutation, proving a direct 
link between the mutation and the hydrogen bond acceptor of agonists.  In our previous 
experiments with the α4β2 subtype, we also studied the nicotine analog S-N-methyl-2-
phenylpyrrolidine (S-MPP).9  In this structure, the pyridyl ring of nicotine is replaced 
with a phenyl ring, providing an alternative way to probe the hydrogen bond-accepting 
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pyridine N.  This is a more subtle probe than the ACh/Ch comparison, and it provided a 
compelling link between the hydrogen bond acceptor of nicotine and the backbone NH in 
the α4β2 receptor.  In the present systems, we were unable to perform comparable studies 
with S-MPP, because the low potency of this compound at the receptors considered here 
required agonist concentrations that produced competing channel block of the receptor in 
dose-response studies.  Nevertheless, the studies of the α4β2 receptor provide support for 
the notion that mutations of the Leu NH are perturbing a hydrogen bond to the agonist. 
It is worth emphasizing that, while we consider the present work to probe 
hydrogen bonding interactions, we are in fact probing the functional significance of 
particular hydrogen bonds.  Thus, it is possible that a structural study could show the 
presence of a hydrogen bond, but if deleting/attenuating that hydrogen bond has no 
functional consequence, it would show up as no hydrogen bond in our assay.  We first 
discuss our findings concerning the contribution of the Leu backbone NH. 
ACh and nicotine both show a strong hydrogen bonding interaction with the Leu 
backbone NH in the muscle-type receptor.  Nicotine shows very poor potency at the wild-
type muscle receptor, and so we were surprised to find that nicotine is very sensitive to 
the Leu backbone ester mutation, more sensitive than it is to the corresponding mutation 
in α4β2, where nicotine is a very potent agonist.  This mutation also impacted ACh 
potency much more in the muscle-type receptor than in the α4β2 receptor.  We have 
performed similar backbone mutations at locations throughout the nAChR to probe for 
various hydrogen bonds, and we typically see informative, but modest increases in EC50 
of ~5-20-fold.  The 29-fold increase in EC50 seen for ACh in the muscle-type receptor is 
among the largest responses we have seen for a backbone ester mutation.  It is also much 
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larger than the 7-fold increase that was seen for the equivalent mutation in the α4β2 
receptor.9  These results may suggest that the hydrogen bond to the Leu NH is stronger in 
the muscle-type receptor, and it is possible that ACh and nicotine sit more closely to this 
residue in the muscle-type receptor than they do in the α4β2 subtype.  As expected, 
choline as an agonist is unresponsive to this mutation. 
Surprisingly, epibatidine, a potent agonist at the muscle-type receptor, is 
unresponsive to the Leu backbone NH mutation.  In crystal structures of AChBP binding 
nicotine or epibatidine, the relative positioning of all relevant atoms – the pyridine N and 
the backbone NH and CO – are essentially identical.  As such, it has been assumed that 
these two closely related molecules bind in the same way, even though the bridging water 
is not observable in the epibatidine structure, presumably because is it not ordered 
enough for the relatively low resolution structure.   
One possible explanation for the lack of a functionally significant hydrogen 
bonding interaction with the pyridine N of epibatidine in the muscle-type receptor is that 
the N is a relatively poor hydrogen bond acceptor.  When considering closely related 
systems, pKa is an excellent predictor of hydrogen bonding ability.  Pyridine, a good 
model for nicotine, has a pKa of 5.2, but 2-chloropyridine, a model for epibatidine, has a 
much lower pKa of 0.5.23  Thus, epibatidine is expected to be a poorer base than nicotine 
by ~5 orders of magnitude, and it is safe to conclude that epibatidine would also be a 
much poorer hydrogen bond acceptor.  Recently we have showed that varenicline, the 
smoking cessation compound marketed as Chantix®, is similarly unresponsive to the 
analogous backbone NH mutation in the α4β2 receptor.24  The quinoxaline nitrogens of 
varenicline have a pKa of 0.8, quite similar to that for epibatidine.  Thus, in these two 
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very potent nicotinic agonists – epibatidine and varenicline – the strength of the hydrogen 
bond acceptor is expected to be greatly attenuated, and our functional assay for this 
hydrogen bond appears to reflect this property. 
When we probe the Leu backbone NH interaction in the α4β4 receptor, we find a 
much smaller impact of the backbone mutation.  ACh and nicotine show meaningful, but 
much smaller effects than is usual; in α4β2 receptors the effect ranged from 5.6- to 8.5-
fold for the same agonists.  Again, epibatidine shows no meaningful effect and 
varenicline actually shows a small gain of function.  Cytisine, another compound that is 
marketed for smoking cessation under the brand name Tabex®, shows a large effect.  The 
hydrogen bond acceptor in cytisine is not a pyridine-type N, but is rather the O of an 
amide carbonyl.  Amides are much stronger hydrogen bond acceptors, and, indeed, we 
saw very large effects for cytisine at the α4β2 receptor.  For the two stoichiometries of 
α4β2 – 2:3 and 3:2 – the backbone NH mutation led to perturbations of 62- and 14-fold, 
respectively, with cytisine as the agonist. 
The second component of the interaction with the hydrogen bond acceptor of 
nicotinic agonists predicted by AChBP structures is the water-mediated hydrogen bond to 
the Asn backbone CO.  Using the backbone ester strategy to perturb this proposed 
interaction, we measured 9 different drug-receptor interactions involving two different 
receptors, and in no case do we see a meaningful interaction (not including choline, for 
which no effect is expected).  The strongest effects are for varenicline at α4β4, with a 
ratio of 2.0, and for nicotine at the muscle-type receptor, with a ratio of 2.2, barely what 
we consider to be meaningful.  All other effects are less than a factor of two.   
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Note that the strategy employed here to probe a hydrogen bond to a backbone 
carbonyl can produce large effects.  In nicotinic receptors when we use the strategy to 
probe the interaction of the N+H of the drug to the backbone carbonyl of the key Trp 
residue of the binding site (Figure 4.1), we see EC50 shifts ranging from 9- to 27-fold for 
potent drug-receptor combinations. 
We thus conclude that the water-mediated interaction between the hydrogen bond 
acceptor of agonists and the Asn backbone CO seen in AChBP structures is not 
functionally significant in nAChRs in general.  We note that there is a fundamental 
distinction between the two hydrogen bonds seen in AChBP.  If the water molecule were 
not present, the Leu backbone NH could donate a hydrogen bond directly to the hydrogen 
bond acceptor of agonists.  In contrast, the Asn backbone CO is itself a hydrogen bond 
acceptor, and so it can interact with the hydrogen bond acceptor of agonists only through 
an intermediary water.  Our results thus open up the possibility that the water molecule 
that is seen in essentially all AChBP structures is not present in actual receptors.  
Whether the water molecule is or is not present, we find that perturbing its putative 
hydrogen bonding partner has little consequence on receptor function. 
In the pharmacology of nicotinic receptors, it has often been suggested that the 
non-α, complementary subunit plays a key role in establishing subtype selectivity for 
various drugs.  We have now probed the complementary binding site for four nicotinic 
subtypes (muscle-type, α4β4, and both stoichiometries of α4β2), and see interesting 
variations for particular drug-receptor combinations.  We believe this information will be 
of value to efforts to develop more selective drugs that target nicotinic receptors.   
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We have shown that ACh and nicotine both engage in a functionally important 
hydrogen bond to the complementary subunit Leu backbone NH in the muscle-type 
nAChR, but the nicotine analog epibatidine does not.  In the α4β4 receptor, interactions 
with the Leu backbone NH are surprisingly weak.  We also find no evidence for a 
functionally important water-mediated hydrogen bond to the Asn backbone CO.  Our 
results highlight the necessity of functional studies on intact receptors to probe 
interactions suggested by structural studies of model systems. 
 
4.5  Experimental 
4.5.1  Mutagenesis 
Nonsense suppression was performed using techniques described previously on 
the mouse muscle embryonic nAChR, (α1)2β1γδ, in the pAMV vector5 and human 
(α4)2(β4)3 receptor in the pGEMhe vector.  For nonsense suppression experiments, a 
TAG (for mutation at γV108/δV110) or TGA stop codon (for mutation at γL119/δL121, 
β4L108, and β4L119) was introduced at the site of interest by the standard Stratagene 
QuickChange protocol and verified through sequencing.  The β1 subunit contains a 
background mutation in the transmembrane M2 helix (β1L9’S) that is known to lower 
whole-cell EC50 values.  The α1 subunit contains a hemagglutinin epitope in the M3-M4 
cytoplasmic loop that does not alter EC50 values in control experiments.  cDNA was 
linearized with the restriction enzyme NotI for muscle-type receptor subunits and NheI 
for α4 and β4.  mRNA was prepared by in vitro transcription using the mMessage 
Machine T7 kit (Ambion).   
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4.5.2  Microinjection 
Stage V-VI Xenopus laevis oocytes were injected with mRNA in a 10:1:1:1 or 
1:1:5:5 ratio of α1:β1:γ:δ for wild-type/conventional mutagenesis or nonsense 
suppression experiments, respectively, on the muscle-type receptor.  An mRNA ratio of 
1:20 (α4:β4) was used for nonsense suppression experiments on the (α4)2(β4)3 receptor.  
Control nonsense suppression experiments confirmed that this ratio ensures a 2:3 subunit 
stoichiometry.  α-Hydroxy acids and amino acids were appended to the dinucleotide dCA 
and enzymatically ligated to the truncated 74-nucleotide amber suppressor tRNA THG73 
or opal suppressor tRNA TQOpS’ as previously described.5  For wild-type or 
conventional mutagenesis experiments on the muscle-type receptor, 1-2 ng of mRNA was 
injected per oocyte in a single 75 nL injection.  For nonsense suppression experiments on 
the muscle-type receptor, each cell was injected with 75 nL of a 1:1 mixture of mRNA 
(20-25 ng of total mRNA) and tRNA (10-25 ng).  For nonsense suppression experiments 
on the (α4)2(β4)3 receptor, each cell was injected with 50 nL of a 1:1 mixture of mRNA 
(50 ng total) and tRNA (~25 ng).  Amino acids bearing a 6-nitroveratryloxycarbonyl 
protecting group were deprotected prior to injection via irradiation with a 500 W Hg/Xe 
arc lamp, filtered with WG-334 and UG-11 filters prior to injection.  Oocytes were 
incubated at 18 °C for 16-20 or 24-48 hours after injection for the wild-type/conventional 
mutagenesis or nonsense suppression experiments, respectively, on the muscle-type 
receptor.  Oocytes were incubated for 48 hours after injection for nonsense suppression 
experiments on the (α4)2(β4)3 receptor.  Wild-type recovery control experiments 
(injection of tRNA appended to the natural amino acid) were performed to evaluate the 
fidelity of the nonsense suppression experiments.  In additional control experiments on 
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the muscle-type receptor, injections of mRNA only and mRNA with 76-mer THG73 or 
TQOpS’ gave minimal currents in electrophysiology experiments (~100 nA or less for 
controls compared to >>2 µA for nonsense suppression experiments).  For the (α4)2(β4)3 
receptor, injections of mRNA with 76-mer TQOpS’ gave no detectable currents. 
4.5.3  Electrophysiology 
Two-electrode voltage clamp electrophysiology was used to measure the 
functional effects of each mutation.  Electrophysiology recordings were performed after 
injection and incubation as described above using the OpusXpress 6000A (Axon 
Instruments) at a holding potential of −60 mV.  The running buffer was a Ca2+ free ND96 
solution (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, and 5 mM HEPES, pH 7.5).  Agonist 
doses in Ca2+-free ND96 were applied for 15 s followed by a 116 s wash with the running 
buffer.  Acetylcholine chloride, (−)-nicotine tartrate, and (−)-cytisine were purchased 
from Sigma-Aldrich/RBI, (±)-epibatidine was purchased from Tocris, and varenicline 
tartrate was a generous gift from Pfizer.  Dose-response data were obtained for ≥ 8 
agonist concentrations on ≥ 8 cells.  Dose-response relations were fit to the Hill equation 
to obtain EC50 and Hill coefficient values, which are reported as averages ± standard 
error of the fit.   
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Chapter 5: An unusual pattern of ligand-receptor interactions for the 
α7 nicotinic acetylcholine receptor, with implications for the binding of 
varenicline* 
 
5.1  Abstract 
The α7 nicotinic acetylcholine receptor shows broad pharmacology, complicating 
the development of subtype-specific nicotinic receptor agonists.  Here we use unnatural 
amino acid mutagenesis to characterize binding to α7 by the smoking cessation drug 
varenicline (Chantix), an α4β2-targeted agonist that shows full efficacy and modest 
potency at the α7 receptor.  We find that unlike binding to its target receptor, varenicline 
does not form a cation-π interaction with TrpB, further supporting a unique binding mode 
for the cationic amine of nicotinic agonists at the α7 receptor.  We also evaluate binding 
to the complementary face of the receptor’s binding site by varenicline, the endogenous 
agonist acetylcholine, and the potent nicotine analog epibatidine.  Interestingly, we find 
no evidence for functionally significant interactions involving backbone NH and CO 
groups thought to bind the canonical agonist hydrogen bond acceptor of the nicotinic 
pharmacophore, perhaps reflecting a lesser importance of this pharmacophore element for 
α7 binding.  We also show that the Trp55 and Leu119 side chains of the binding site’s 
complementary face are important for the binding of the larger agonists epibatidine and 
varenicline, but dispensable for binding of the smaller, endogenous agonist acetylcholine. 
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5.2  Introduction 
The α7 nicotinic acetylcholine receptor (nAChR), a member of the Cys loop 
(pentameric) family of ligand-gated ion channels, is one of the principal mediators of 
synaptic transmission in the central nervous system.  It has attracted significant interest as 
a therapeutic target for Alzheimer’s disease, schizophrenia, and inflammation,1-3 and a 
number of α7-directed compounds are currently in the clinic for treatment of these 
disorders.4 
 Pharmacology of the α7 nAChR has revealed a wide range of structures capable 
of activating the receptor,5 contributing to the challenge of advancing selectivity among 
receptor subtypes in CNS drug development.  Varenicline, a potent partial agonist of the 
α4β2 receptor currently prescribed as a smoking cessation therapy (Chantix),6 has also to 
been demonstrated to be a full agonist of α7 with modest potency.7  Adverse 
neuropsychiatric effects of this drug have led to speculation that varenicline therapy 
could have off-target activity on α7 receptors.8 
 Despite a large and growing body of pharmacological data, our knowledge of the 
functionally important ligand-receptor interactions of the α7-binding site remains limited.  
The receptor has five identical agonist binding sites, located at each subunit-subunit 
interface.  While no direct structural data yet exist for this receptor, a large number of 
crystal structures of snail acetylcholine binding proteins (AChBPs), homologous to the 
extracellular domain of nAChRs, provide a useful guide for the binding site. 9,10  Two 
chimeras of the α7 extracellular domain and an AChBP have recently been reported, one 
with the Aplysia californica AChBP in complex with the antagonist MLA11 and another 
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Figure 5.1.  Two views of the nAChR agonist binding site.  (A) Crystal structure of the Ls-AChBP/α7 
chimera with epibatidine bound (3SQ6).12  The water molecule shown (red sphere) is not seen in this 
particular structure, but has been placed in the position seen in other structures.  All side chains shown in 
this structure are identical to the actual receptor residues studied except for Leu107, which instead is Asn.  
(B) Schematic of the agonist binding site, showing the key noncovalent interactions considered here.  
Varenicline is shown as the agonist so that all interactions considered in text can be illustrated.  Solid 
purple lines: cation-π interactions; dashed red lines: hydrogen bonds.  In both images, green residues are 
from the primary face; blue residues are from the complementary face. 
 
 
  
	  
115 
with the Lymnaea stagnalis AChBP (Ls-AChBP) in complex with the agonist 
epibatidine.12  Including all native α7 binding site residues and a bound agonist, the Ls-
AChBP/α7 chimera provides an excellent starting place to identify important agonist-
receptor interactions (Figure 5.1A).  Recent unmodified AChBP structures in complex 
with varenicline also suggest a ligand binding mode for this agonist.13,14  As for all other 
nicotinic receptors, the chief feature of the α7 binding site is an “aromatic box” defined 
by four residues (TyrA, TrpB, TyrC1, and TyrC2) contributed by its “principal” face and 
one (TrpD) contributed by its “complementary” face on the adjacent subunit (Figure 
5.1).15  This motif accommodates the positive charge common to all orthosteric nicotinic 
agonists, the principal component of the classical nicotinic pharmacophore.16  
The remainder of the binding site is contributed by the adjacent subunit.  This 
complementary face of the binding site is thought to recognize the hydrogen bond 
acceptor moiety of the classical nicotinic pharmacophore.  Various AChBP structures 
suggest that this hydrogen bonding partner is a water molecule held between the 
backbone NH of Leu119 and the backbone CO of Asn107.14,17-20  The proposed water 
molecule is not always evident in the structures, but the positioning of the key protein 
residues, including Leu119 and Asn107, is consistent in all structures, and so the water 
molecule is assumed to be present.  As such, in Figure 5.1 we have added the proposed 
hydrogen bonding water molecule to the Ls-AChBP/α7 chimera structure.  In previous 
work, we have used unnatural amino acid mutagenesis to establish that the backbone NH 
of Leu119 does have a hydrogen bonding interaction with agonists in the α4β2 and 
muscle-type nicotinic receptors, but the interaction is attenuated in the α4β4 receptor.21  
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In contrast, similar evaluation of the Asn107 backbone CO in the muscle-type and α4β4 
receptors did not reveal a functionally significant hydrogen bonding interaction.22 
Several side chains on the complementary face of the binding site are also 
positioned to form possible ligand contacts.  Recent crystal structures of AChBP in 
complex with varenicline have indicated that side chains corresponding to α7 residues 
Trp55, Leu109, Gln117, and Leu119 all contact this ligand (Figure 5.1A).13,14  Both the 
Trp55 and Leu119 side chains have recently been implicated in ligand binding for the α7 
receptor.23 
We have previously characterized a unique binding mode for the endogenous 
agonist ACh and the potent nicotine analog epibatidine to the aromatic box residues of 
the α7 receptor.24  As expected, the cationic moiety of the agonist binds via a cation-π 
interaction.  Surprisingly, however, the residue involved was found to be either TyrA, for 
ACh, or TyrC2, for epibatidine – all other nicotinic receptor/agonist combinations we 
have examined involve a cation-π interaction to TrpB.25-27  Additionally, a strong 
hydrogen bond from TrpB’s backbone carbonyl to the agonist N+-H (for agonists 
possessing this moiety), which has been seen in the α4β2 and α4β4 neuronal receptors 
24,26 and the muscle-type receptor,28 appears to be weak or absent for epibatidine at the α7 
receptor. 
In the present work, we use unnatural amino acid mutagenesis to evaluate binding 
of the fully efficacious and moderately potent agonist varenicline to the aromatic box 
residues of the α7 receptor’s principal face. We also evaluate interactions to the 
receptor’s complementary face for the agonists ACh, epibatidine, and varenicline.  Like 
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ACh and epibatidine, varenicline does not form a cation-π interaction to TrpB.  This 
observation further supports a unique binding mode to the aromatic box for agonists in α7.  
We also find that these three agonists are largely insensitive to backbone mutations to 
both the NH and CO groups thought to recognize the hydrogen bond acceptor of the 
nicotinic pharmacophore.  By conventional mutagenesis of complementary face residues 
proposed to contribute to the binding site, we have identified side chains that are 
functionally important for the agonists epibatidine and varenicline, but not for the smaller 
agonist ACh. 
 
5.3  Results 
5.3.1  Experimental design 
 Recently, we have shown that the α7 nAChR is amenable to unnatural amino acid 
mutagenesis by nonsense suppression in Xenopus oocytes – electrophysiology yields 
reproducible dose-response relationships when incorporating a wide panel of unnatural 
side chains (representative dose-response curves from this study are shown in Figure 
5.2).24  We coexpress the rat α7 nAChR with the human RIC-3 protein to overcome poor 
receptor expression.  All mutant receptors studied include the T6’S background mutation 
in the transmembrane domain, which limits the rapid desensitization associated with the 
α7 receptor while minimally perturbing receptor pharmacology.29 
In the present study we measure the functional impact of each mutation using 
EC50, the effective agonist concentration that gives a half-maximal response.  EC50 is a 
composite measure that reflects multiple equilibria: both “binding” events – drug  
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Figure 5.2.  Representative traces and dose-response curves.  (A) Representative current traces for 
incorporation of Trp by nonsense suppression at the TrpB (Trp149) site.  Bars indicate application of 
varenicline (in µM) at concentrations noted.  (B) Dose-response curve and fit to the Hill equation for 
normalized varenicline responses for Trp incorporation at the TrpB site.  Error bars indicate SEM (n = 17). 
entering/exiting the agonist binding site – and “gating” events – the equilibria between 
open and closed states of the channel.  Without detailed kinetic analyses, typically at the 
single channel level, it is not possible to parse which equilibria are perturbed by a given 
mutation.  For example, a mutation affecting a binding interaction could affect a gating 
equilibrium if the drug binds more tightly to the open state of the channel than the closed 
state (or vice versa).  The primary tool used here is unnatural amino acid mutagenesis, 
which allows precise, chemically well-defined modifications to the agonist binding site.  
We would argue that while the identity of the equilibrium step(s) being perturbed for 
each mutation in this study is unknown, we can confidently assign the nature of the 
perturbation: an attenuated ligand binding interaction.  Our structural knowledge of the 
binding site has guided the location of mutations made, and previous studies on this and 
related systems demonstrate ligand-specific EC50 shifts consistent with specific binding 
interactions.  Further, unnatural amino acid mutagenesis allows for subtle and precise 
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modifications to protein structure that target the interaction of interest.  This argument is 
less compelling when more perturbing, conventional amino acid mutagenesis is 
employed, but studies of that kind reported here can provide guidance for further 
investigation. 
We consider EC50 to be the appropriate metric here for two reasons.  First, 
detailed, single channel studies are not feasible for the large number of drug-receptor 
combinations that we have considered.  This is especially so given the protein expression 
limitations that are sometimes seen with unnatural amino acid mutagenesis.  Second and 
more importantly, our goal is to evaluate the pharmacology of the α7 receptor and 
compare these results to those of previous studies on related systems.  EC50 is a good 
measure of pharmacological activity.  Given our experience with this system, we 
generally do not ascribe specific structural interactions to EC50 differences that are less 
than a factor of 2. 
5.3.2  Unnatural amino acid mutagenesis to probe cation-π interactions and hydrogen 
bonds to the protein backbone 
To determine whether varenicline forms a cation-π interaction to one or more of 
the aromatic residues on the binding site’s principal face, we incorporated unnatural 
aromatic amino acid analogs with attenuated cation-π binding ability and probed for a 
concomitant reduction in receptor function (Figure 5.3B).  In particular, systematic 
fluorination of an aromatic side chain is diagnostic for a cation-π interaction.  Comparing 
EC50 shifts for the highly deactivating cyano (CN) substituent and the sterically similar 
but much less deactivating bromo (Br) substituent is also instructive.  
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We probe hydrogen bonding to the protein backbone with α-hydroxy acid 
mutagenesis, replacing the native amide peptide bond with an ester (Figure 5.3C).  This 
mutation has two effects: most obviously, the hydrogen bond donor NH is deleted.  
Second, the ester carbonyl is well-established as a poorer hydrogen bond acceptor than 
the native amide carbonyl, so hydrogen bonds to this group will be attenuated.  Note that 
a backbone carbonyl is modulated by mutating the i+1 residue to an α-hydroxy acid. 
 
Figure 5.3. (A) Agonists considered here.  (B) Aromatic unnatural amino acids employed here.  (C) The α-
hydroxy acid strategy for evaluating backbone hydrogen bonding.  The hydrogen bond is stronger (solid 
line) on the left than on the right (dashed line). 
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5.3.3  Varenicline interactions with the binding site’s principal face 
 At the TrpB site, the varenicline EC50 for F3-Trp is not significantly shifted from 
wild type, while F4-Trp shows a modest 3.8-fold shift (Table 5.1), substantially smaller 
than we have observed for agonists forming a cation-π interaction with this side chain in 
other receptors.  For comparison, a 16-20-fold shift was seen for the corresponding F4-
Trp mutation with varenicline at its targeted α4β2 receptor.25  Further, for α7 we found 
that the highly deactivating cyano substituent has no functional effect, confirming that 
varenicline does not form a cation-π interaction to TrpB. 
 The remaining aromatic residues of the principal face, TyrA, TyrC1, and TyrC2, 
were also probed for cation-π binding to varenicline.  Interrogation of tyrosine presents 
an additional challenge: fluorination of this aromatic system progressively lowers the pKa 
of the hydroxyl group.  This effect is substantial enough that tetrafluorotyrosine (pKa ~5.3 
vs 10 for tyrosine) will likely be deprotonated under physiological conditions, 
confounding interpretation of EC50 shifts.30  We circumvent this complication by first 
evaluating the function of phenylalanine and then proceeding with fluorinated 
phenylalanine derivatives. 
 As we had previously observed for ACh and epibatidine, phenylalanine produces 
a substantial EC50 shift at TyrA for varenicline, while 4-MeO-Phe produces a wild-type 
EC50, possibly indicating the need for a hydrogen bond acceptor and/or steric placeholder 
at the 4-position (Table 5.1).  F2-Phe and F3-Phe gave small, but detectable, responses at 
high varenicline doses.  Full dose-response curves, however, were obscured by the 
response of naïve oocytes to varenicline at concentrations ≥ 1 mM.  Without these data it 
is not possible to rule on a cation-π interaction at TyrA, although losses of function for 4-
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Br-Phe and more so for 4-CN-Phe do suggest an important role for side chain 
electrostatics (Figure 5.4). 
Table 5.1.  Wild type and mutations to the binding site’s principal face.  EC50 and Hill coefficient (nH) are 
± SEM for goodness of fit to the Hill equation. 
Mutation Agonist EC50 (µM) Fold Shift nH n 
wt ACh 99 ± 3  2.7 ± 0.2 16 
wt Varenicline 1.99 ± 0.03  2.8 ± 0.1 15 
wt Epibatidine 0.34 ± 0.01  3.0 ± 0.2 13 
TyrA      
Y93 Tyra Varenicline 2.21 ± 0.05  3.0 ± 0.2 7 
Y93 Phe Varenicline 126 ± 5 57 2.4 ± 0.2 9 
Y93 4-F1-Phe Varenicline 34 ± 3 15 2.0 ± 0.3 11 
Y93 F2-Phe Varenicline >100b   8 
Y93 F3-Phe Varenicline >100b   8 
Y93 4-Br-Phe Varenicline 12 ± 1 5.4 3.1 ± 0.6 7 
Y93 4-CN-Phe Varenicline 33 ± 2 15 2.5 ± 0.4 10 
Y93 4-MeO-Phe Varenicline 2.19 ± 0.05 0.99 2.3 ± 0.1 6 
TrpB      
W149 Trpa Varenicline 2.5 ± 0.1  2.1 ± 0.1 17 
W149 F3-Trp Varenicline 4.1 ± 0.1 1.6 2.3 ± 0.1 15 
W149 F4-Trp Varenicline 9.6 ± 0.8 3.8 2.0 ± 0.2 15 
W149 5-CN-Trp Varenicline 2.1 ± 0.1 0.84 2.6 ± 0.4 12 
TyrC1      
Y188 Tyra Varenicline 2.23 ± 0.08  2.4 ± 0.2 8 
Y188 Phe Varenicline >100b   6 
TyrC2      
Y195 Tyra Varenicline 2.12 ± 0.02  2.76 ± 0.06 8 
Y195 Phe Varenicline 2.28 ± 0.09 1.1 3.1 ± 0.4 6 
Y195 3-F1-Phe Varenicline 5.1 ± 0.07 2.4 1.9 ± 0.02 12 
Y195 4-F1-Phe Varenicline 1.53 ± 0.05 0.72 3.4 ± 0.3 9 
Y195 F2-Phe Varenicline 16.3 ± 0.7 7.7 2.4 ± 0.2 12 
Y195 F3-Phe Varenicline 16 ± 1 7.5 2.6 ± 0.3 7 
Y195 4-Br-Phe Varenicline 3.48 ± 0.07 1.6 3.6 ± 0.2 5 
Y195 4-CN-Phe Varenicline 21 ± 1 9.9 3.8 ± 0.9 11 
Y195 4-MeO-Phe Varenicline 2.42 ± 0.09 1.1 2.8 ± 0.3 11 
TrpB+1      
S150 Thr Varenicline 0.81 ± 0.04  2.2 ± 0.2 11 
S150 Tah Varenicline 2.4 ± 0.1 3.0 from Thr 2.2 ± 0.2 15 
Lys145      
K145A ACh N.R.    
K145Q ACh 590 ± 20 6.0 2.5 ± 0.1 8 
K145Q Varenicline 9.4 ± 0.2 4.7 1.6 ± 0.2 7 
K145R ACh 1600 ± 100 16 2.6 ± 0.3 6 
K145R Varenicline 61.6 ± 0.2 31 3.19 ± 0.03 9 
aExpression of the wild type receptor with the natural amino acid incorporated by nonsense suppression 
bResponse of naïve oocytes to varenicline doses ≥ 1mM obscures complete dose-response data 
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Figure 5.4.  Cation-π binding plot for TyrA, in which log[EC50(mutant)/EC50(wt)] is plotted versus 
quantitative cation-π binding energies;27,31 a strong linear correlation would suggest a cation-π interaction.  
Phe (open circle) is not included in the fit. 
 In previous work on the α7 receptor, we assigned a cation-π interaction between 
ACh and TyrA.24 However, a recent Ls-AChBP/α7 chimera crystal structure suggests that 
TyrA may actually form an intra-protein cation-π interaction with the Lys145 side chain 
(Figure 5.1B).12  We neutralized this Lys side chain to Gln and found only a modest 4-6-
fold loss of function for Var and ACh (Table 5.1), suggesting that the much larger EC50 
shifts for poor cation-π-binding Phe analogs at TyrA largely reflect a weakened ligand 
binding interaction instead. 
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 At TyrC2 the Phe mutant and 4-MeO-Phe are essentially wild type.  We do 
observe a loss of receptor function for varenicline with Phe analogs possessing attenuated 
cation-π binding ability (Table 5.1).  However, EC50 shifts are modest.  For example, we 
see a 7.5-fold shift for the highly deactivating F3-Phe mutation, while the same mutation 
for epibatidine (which does form a cation-π interaction with TyrC2) gave a nearly 50-fold 
shift.24  Further, the EC50s have only a weak linear dependence on cation-π binding 
energy (Figure 5.5).  4-F1-Phe unexpectedly gave a gain of receptor function, though 
shifting the fluorine to the 3-position produces a modest loss of function.  TyrC1 was too 
sensitive to phenylalanine substitution to even yield a measurable EC50, preventing the 
study of this residue (Table 5.1). 
 
Figure 5.5.  Cation-π binding plot for TyrA, in which log[EC50(mutant)/EC50(wt)] is plotted versus 
quantitative cation-π binding energies;27,31 a strong linear correlation would suggest a cation-π interaction.  
3-F1-Phe and 4-F1-Phe (open circles) are not included in the fit. 
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Finally, we probed the TrpB backbone carbonyl for a functionally significant 
hydrogen bond to the agonist, as has been observed in other receptors with agonists 
possessing an N+-H group.  We find that mutation of Ser150 (i+1 relative to TrpB) to 
threonine, α-hydroxy (Tah) produces a three-fold shift relative to the conservative 
mutation S150Thr, potentially indicating a weak hydrogen bond (Table 5.1). 
5.3.4  Probing the canonical hydrogen bond of the nicotinic pharmacophore between 
agonists and the complementary subunit 
 To test for the functional importance of interactions with the hydrogen bond 
acceptor group on the agonist, we evaluated residues that contribute to the water-
mediated hydrogen bonding array of Figure 5.1.  The Leu119 backbone NH and the 
Asn107 backbone CO were evaluated by α-hydroxy acid mutagenesis.  The L119Lah 
mutation, which deletes the Leu119 backbone NH, had little functional effect on the 
agonists ACh and varenicline, with EC50 shifts less than 2-fold, and produced a 2.6-fold 
shift for epibatidine (Table 5.2).  We probed the Asn107 CO by mutating its i+1 residue, 
Val108, to valine, α-hydroxy (Vah), attenuating the hydrogen bond accepting ability of 
the backbone CO of interest.  We saw little functional effect for ACh and epibatidine, 
with EC50 shifts less than 2-fold, and a modest 4.3-fold shift for varenicline. 
5.3.5  Functional importance of side chains on the complementary face of the binding site 
 To complete our survey of ligand-receptor interactions, we tested the functional 
effect of alanine mutations on residues of the binding site’s complementary face that are 
proposed to contact these agonists: Trp55, Leu109, Gln117, and Leu119.12-14  Of these 
mutations, L109A and Q117A produced modest shifts of 3.1-fold or less for all three 
agonists tested (Table 5.2).  Interestingly, the mutants W55A and L119A showed little, if 
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any, effect on ACh, but large shifts of 9-fold or greater for the larger agonists epibatidine 
and varenicline. 
Table 5.2.  Mutations to the binding site’s complementary face.  EC50 and Hill coefficient (nH) are ± SEM 
for goodness of fit to the Hill equation. 
Mutation Agonist EC50 (µM) Fold Shift nH n 
V108 Vala ACh 103 ± 2  2.9 ± 0.2 10 
V108 Vah ACh 184 ± 9 1.8 2.3 ± 0.2 10 
V108 Vala Varenicline 2.3 ± 0.1  4 ± 1 8 
V108 Vah Varenicline 10.0 ± 0.5 4.3 2.5 ± 0.3 9 
V108 Vala Epibatidine 0.396 ± 0.005  3.02 ± 0.09 7 
V108 Vah Epibatidine 0.64 ± 0.04 1.6 3.4 ± 0.5 11 
L119 Leua ACh 120 ± 6  2.5 ± 0.3 9 
L119 Lah ACh 180 ± 8 1.5 2.4 ± 0.2 6 
L119 Leua Varenicline 2.26 ± 0.02  2.76 ± 0.05 7 
L119 Lah Varenicline 3.15 ± 0.08 1.4 2.2 ± 0.1 9 
L119 Leua Epibatidine 0.290 ± 0.005  3.3 ± 0.1 8 
L119 Lah Epibatidine 0.75 ± 0.01 2.6 3.4 ± 0.1 10 
N107L ACh 350 ± 3 3.5 2.48 ± 0.05 5 
N107L Varenicline 2.77 ± 0.05 1.4 2.6 ± 0.1 4 
N107L Epibatidine 1.37 ± 0.02 4.0 2.44 ± 0.06 4 
W55A ACh 134 ± 8 1.4 1.9 ± 0.2 8 
W55A Varenicline 67.6 ± 0.9 34 2.95 ± 0.09 11 
W55A Epibatidine 5.8 ± 0.3 17 2.2 ± 0.2 10 
L109A ACh 303 ± 7 3.1 2.4 ± 0.1 9 
L109A Varenicline 0.53 ± 0.01 0.27 3.3 ± 0.2 12 
L109A Epibatidine 0.282 ± 0.008 0.83 2.8 ± 0.2 9 
Q117A ACh 180 ± 4 1.8 2.7 ± 0.1 10 
Q117A Varenicline 4.85 ± 0.06 2.4 2.88 ± 0.09 12 
Q117A Epibatidine 0.90 ± 0.05 2.6 3.0 ± 0.4 11 
L119A ACh 210 ± 9 2.1 2.3 ± 0.2 11 
L119A Varenicline 41 ± 1 21 2.6 ± 0.2 11 
L119A Epibatidine 3.20 ± 0.09 9 3.0 ± 0.2 10 
aExpression of the wild type receptor with the natural amino acid incorporated by nonsense suppression 
bResponse of naïve oocytes to varenicline doses ≥ 1mM obscures complete dose-response data 
 
5.4  Discussion 
This work expands our survey of ligand-receptor interactions for ACh and 
epibatidine at the α7 nAChR and examines the yet-uncharacterized binding of varenicline.  
We have previously investigated binding of these ligands to other nAChRs, allowing for 
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comparisons to be drawn among these receptors with superficially similar binding sites, 
but distinct pharmacologies.   
5.4.1  Cation-π interactions to the “aromatic box” residues of the principal face 
The “aromatic box” is conserved across all nicotinic binding sites and is 
comprised of identical residues: three tyrosines (A, C1, and C2) and two tryptophans (B 
and D).  The present study of varenicline’s interactions with these side chains 
corroborates our earlier findings for the binding of ACh and epibatidine to the α7 
receptor: TrpB is not engaged in a cation-π interaction with the agonist.24  This contrasts 
a large number of studies of other nAChRs, including the muscle-type receptor, the α4β4 
receptor, and both stoichiometries of the α4β2 receptor, as well as other Cys-loop 
receptors such as the 5-HT3A receptor, the glycine receptor, and the GABAc receptor, all 
of which involve cation-π interactions to TrpB or another aromatic residue at that site.24-
27,31-33   
Instead, TyrA and TyrC2 of the α7 receptor form cation-π interactions with the 
agonists ACh and epibatidine, respectively.24  We were able to evaluate a number of 
TyrC2 mutants. We find a modest effect when substituting poor cation-π binding side 
chains and only a weak correlation of cation-π binding energy with EC50 (Figure 5.5).  
We conclude that TyrC2 does not form a strong cation-π interaction with varenicline.  At 
the TyrA site we do observe a suggestive electrostatic trend with varenicline for the Phe 
analogs incorporated (Figure 5.4), but we lack data for F2-Phe and F3-Phe, hampered by 
EC50 values beyond our measurable range. On the basis of the Ls-AChBP/α7 chimera 
structure a cation-π interaction between TyrA and Lys145 has been proposed. However, 
we find that the K145Q produces a smaller effect than the 4-F and 4-CN mutations of 
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TyrA (Table 5.1), which is not consistent with this model.  For α7, as for other nicotinic 
receptors we have investigated, extreme sensitivity of TyrC1 to mutagenesis has 
prevented further study of this residue.   
5.4.2  Hydrogen bonding and steric effects on the principal face 
It is worth emphasizing that, while we consider the present work to probe 
hydrogen bonding interactions, we are in fact probing the functional significance of 
particular hydrogen bonds.  Thus, it is possible that a structural study could show the 
presence of a hydrogen bond, but if deleting/attenuating that hydrogen bond has no 
functional consequence, it would show up as no hydrogen bond in our assay. 
We find evidence for only a weak hydrogen bond between the TrpB backbone 
carbonyl and the N+-H of varenicline, as we had observed for epibatidine (Table 5.1).24  
The hydroxy acid mutation that here produced a 3-fold EC50 shift gave much larger 14-
19-fold shifts for varenicline at its targeted α4β2 receptor.25  Indeed, comparably large 
shifts have been measured for all agonists bearing this N+-H that we have characterized to 
date at the α4β2 and α4β4 neuronal receptors, all of which also bind the TrpB side chain 
with a cation-π interaction.24-26  It is perhaps not surprising, then, that this hydrogen bond 
would be attenuated if the agonist has moved its cation-π interaction to other residues of 
the aromatic box. 
Various AChBP crystal structures suggest a hydrogen bond between the side 
chain –OH of TyrA and the N+-H of agonists such as nicotine (1UW6), varenicline 
(4AFT), cytisine (4AFO), and epibatidine (2BYQ, 3SQ6), as shown in Figure 
5.1.12,14,17,18  The large loss of function for deleting the –OH by mutation to Phe is 
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consistent with this model (Table 5.1).  In addition, 4-MeO-Phe, which can serve as a 
hydrogen bond acceptor like Tyr, shows wild type behavior.  4-F1-, 4-CN-, and 4-Br-Phe 
are all preferable to Phe, suggesting there could also be a steric component involving the 
4 position of TyrA. 
For TyrC2, mutation to Phe yields a receptor with wild type function for 
varenicline (Table 5.1): neither a steric nor a more specific hydrogen bonding role for this 
side chain –OH seems plausible.  Recent AChBP-varenicline crystal structures show a 
potential hydrogen bond between the TyrC2 –OH and one of varenicline’s quinoxaline 
nitrogens.13,14  Our data indicate that any such interaction in the α7 receptor is not 
functionally important.  Interestingly, the Phe mutant did have a significantly shifted 
EC50 for ACh and for epibatidine (6-fold and 11-fold, respectively),24 so varenicline 
evidently interacts with this side chain differently than these other agonists.  Generally, 
mutations at this site do not strongly impact varenicline function, and there are no 
obvious trends in the data.  
5.4.3  Hydrogen bonding to the complementary face 
 In addition to a cationic group, the classical nicotinic pharmacophore includes a 
hydrogen bond acceptor approximately 4-6 Å away,16 a feature shared by all three 
agonists tested in this study.  AChBP crystal structures show agonist hydrogen bond 
acceptor groups directly contacting a water molecule, which in turn is held by a backbone 
NH and backbone CO of the complementary subunit (Figure 5.1).  Mutant cycle analyses 
of the α4β2 receptor confirm a hydrogen bonding role for the Leu119 backbone NH for 
both nicotine and ACh as agonists, consistent with the AChBP structures.  In α4β2, the 
L119Lah mutant (which removes this residue’s backbone NH) produced a 7-fold EC50 
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shift for ACh and for nicotine.21  We now find that the corresponding backbone mutation 
of Leu119 in the α7 receptor has minimal  functional effects on ACh and varenicline and 
only a 2.6-fold shift for epibatidine (Table 5.2). Evidently, the Leu119 NH does not form 
a functionally important interaction in the α7 receptor, perhaps reflecting either a 
reshaping of the binding site or a repositioning of agonists relative to their binding mode 
in the other receptors.  A subtly different ligand binding mode might be expected given 
the use of TyrA and TyrC2 for cation-π interactions in α7, rather than TrpB.  Functional 
importance of the Leu119 NH in other nicotinic receptors is mixed: it forms important 
contacts to ACh and nicotine for the muscle-type nAChR, but significantly weaker 
interactions in the neuronal α4β4 receptor.22   
  The other proposed hydrogen bonding partner of the binding site’s 
complementary face is the Asn107 backbone CO, which accepts a hydrogen bond from 
the water molecule that also binds to the Leu119 NH and the drug hydrogen bond 
acceptor.  We find that, in the α7 receptor, ACh and epibatidine are largely insensitive to 
the V108Vah mutation that attenuates the hydrogen bond acceptor ability of the Asn107 
CO, with EC50 shifts < 2-fold (Table 5.2).  This group may have a modest functional 
relevance for varenicline, as we did record a 4.3-fold loss of function for that drug.  Note 
that both the CO on the protein backbone and the quinoxaline N on varenicline can only 
act as hydrogen bond acceptors, so this hydrogen bond would need to be mediated by a 
water molecule, as observed in AChBP.  Analogous hydroxy acid mutations modulating 
this CO in the muscle-type and α4β4 receptors did not affect agonist EC50.22  Note that α-
hydroxy acid mutations probing backbone CO hydrogen bonding can produce large EC50 
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shifts, an example being the TrpB backbone CO, where we have seen shifts as large as 
20-30-fold in other receptors.25,26 
 Taken together, it is possible that the α7 receptor either engages the agonist 
hydrogen bond acceptor with other groups or lacks energetically significant contacts with 
it.  Regarding the former possibility, other candidate hydrogen bonding partners expected 
to lie near the agonist include the Gln117 and Asn107 side chains.  Mutation of these to 
side chains without the potential to form hydrogen bonds has only modest functional 
effects of 4-fold or smaller, indicating that no critical interactions are present (Table 5.2).  
Without direct structural data for the α7 binding site, it is unclear exactly where these and 
other potential hydrogen bonding groups lie relative to the agonist. 
Regarding the possibility that this hydrogen bond acceptor group does not form 
functionally important receptor contacts, it is worth remembering that 
tetramethylammonium (TMA), a much simpler structure that, of course, cannot 
participate in the hydrogen bonding interactions being probed here, has virtually the same 
potency and efficacy as ACh for the α7 receptor.5,34  Heteromeric neuronal nAChRs and 
the muscle-type receptor also respond to TMA, but with substantially elevated EC50s 
and/or reduced efficacies.5,34  As such, it appears that the minimal requirements for 
agonist binding are more relaxed for α7.  Indeed, the homomeric α7 receptor, which is 
phylogenetically more ancestral than the subunits of heteromeric receptors,35 appears to 
have a less specialized binding site with broad pharmacology.5  While most characterized 
agonists for the α7 receptor do posses a hydrogen bond acceptor moiety consistent with 
the canonical nicotinic pharmacophore, some α7-specific agonists lack this feature.5  
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Diminished importance of hydrogen bonding interactions for α7 relative to other nAChRs 
may underlie this specificity. 
5.4.4  Interactions with complementary face side chains 
 With the critical positively charged “head group” of agonists buried within the 
aromatic box of the binding site’s principal face, the remaining features of larger ligands 
might be expected to make significant receptor contacts to side chains on the 
complementary face of the binding site.  In crystal structures of varenicline bound to 
AChBP, the side chains corresponding to Trp55 (the sole complementary face contributor 
to the aromatic box), Leu109, Gln117, and Leu119 all contact the ligand.13,14  We find 
that the endogenous ligand ACh is minimally perturbed by alanine mutations to each of 
these residues (Table 5.2).  The largest loss of function for ACh is observed for the 
L109A mutation (3.1-fold), which interestingly caused a modest gain of function (3.8-
fold) for the larger varenicline ligand and a wild type EC50 for epibatidine.  Steric 
compensation between the ligand and side chain could explain this observation.  The 
Q117A mutant had only a small effect on all three agonists, with EC50 fold shifts of 1.8 to 
2.6.  The W55A and L119A mutations, however, were highly detrimental to epibatidine 
and varenicline, but unperturbing to ACh.  These residues, more highly conserved than 
Leu109 and Gln117 among subunits forming the complementary face of nicotinic 
binding sites, could form hydrophobic interactions with larger ligands, but do not affect 
ACh. 
 The Trp55 and Leu119 side chains were previously shown to play an important 
functional role in the α7 receptor, with modifications to these side chains selectively 
affecting larger agonists.23  Strikingly, the W55A mutation has only a small effect on 
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EC50, but increases the relative efficacy of varenicline from 15% to 125% in the α4β2 
receptor, this drug’s intended target.13  The substantial increase in EC50 we observe for 
W55A in the α7 receptor represents a dramatically different phenotype and indicates that 
this residue makes different contributions to receptor function for α7 versus α4β2.  These 
findings suggest that avoiding agonist interactions with Trp55 could be a strategy to 
improve α4β2 selectivity over α7. 
 
5.5  Conclusions 
Our survey of potential agonist-receptor contacts for the α7 receptor reveals a 
unique pattern of interactions compared to other nAChRs.  Differing roles for conserved 
binding site residues across nAChRs underscore the challenge of rationalizing subtype 
selectivity and the critical importance of functional evaluation of interactions suggested 
by structural models.  Despite these challenges, the growing body of knowledge on 
subtype-specific drug-receptor interactions holds promise for advancing selectivity in 
drug design. 
 
5.6  Experimental 
5.6.1  Molecular biology 
cDNA for the rat α7 T6’S receptor and for human RIC-3 were in the pAMV and 
pGEM plasmids, respectively.  Site-directed mutagenesis was performed using the 
QuikChange protocol (Agilent Technologies, Santa Clara, CA).  For nonsense 
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suppression experiments, the site of interest was mutated to the amber stop codon, with 
the exception of Val108 and Leu119, which were mutated to the opal stop codon.  
Circular α7 and hRIC-3 DNA were linearized with NotI and XhoI restriction enzymes, 
respectively.  After purification (Qiagen, Hilden, Germany), linearized DNA was used as 
a template for runoff in vitro transcription using the T7 mMessage mMachine kit (Life 
Technologies, Carlsbad, CA). The amber suppressor tRNA THG7336 was used for 
nonsense suppression at all sites except Val108 and Leu119, for which the opal 
suppressor TQOpS’37,38 was used. 
α-Hydroxy or amino acids were appended to the dinucleotide dCA and 
enzymatically ligated to the appropriate truncated 74mer suppressor tRNA as previously 
described.39,40  Crude tRNA-amino acid or tRNA-hydroxy acid product was used without 
desalting, and the product was confirmed by MALDI-TOF MS on a 3-hydropicolinic acid 
matrix.  tRNA-amino acids bearing a 6-nitroveratryloxycarbonyl protecting group were 
deprotected prior to injection via irradiation with a 500 W Hg/Xe arc lamp, filtered with 
WG-334 and UG-11 filters prior to injection. 
5.6.2  Microinjection 
Stage V–VI Xenopus laevis oocytes were harvested and injected with RNAs as 
described previously.40  5–25 ng of α7 mRNA was co-injected with ~20 ng of RIC-3 
mRNA per oocyte.  For all of the suppression experiments, ~15 ng of tRNA per cell was 
used.  Each oocyte was injected with 50 nL of RNA solution and incubated for 24–48 hrs 
before recording.  In the case of low maximal currents sometimes observed in nonsense 
suppression experiments, presumably due to low expression, a second RNA injection was 
required 24 hrs after the first injection.  As a negative control for suppression 
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experiments, unacylated full length tRNA was co-injected with mRNA in the same 
manner as charged tRNA.  These control experiments yielded negligible responses for all 
sites studied. 
5.6.3  Electrophysiology 
Receptor function was assayed using the OpusXpress 6000A (Molecular Devices, 
Sunnyvale, CA) in two-electrode voltage clamp mode.  The oocytes were clamped at a 
holding potential of -60 mV.  1 mL of each drug solution was applied for 15 s, followed 
by a 5-min wash step with ND96 buffer (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, 1.8 
mM CaCl2, 5 mM HEPES) between each concentration.  Acetylcholine chloride was 
purchased from Sigma-Aldrich (St. Louis, MO), (±)-epibatidine was purchased from 
Tocris (Bristol, United Kingdom), and varenicline tartrate was a generous gift from Pfizer.  
Drug dilutions were prepared in ND96 buffer.  Dose-response data were obtained for at 
least six concentrations of agonist and for a minimum of four oocytes.  The EC50 and Hill 
coefficient (nH) values for each condition were obtained by fitting the averaged, 
normalized dose-response data to the Hill equation. 
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Chapter 6: Efforts toward single molecule fluorescence imaging of 
nAChRs 
 
6.1  Abstract 
Fluorescence studies probing conformational changes in nAChRs upon activation 
have the potential to bridge a wealth of functional data on these receptors from 
electrophysiology with emerging structural models for activation.  Incorporation of 
fluorophores as unnatural amino acid side chains by nonsense suppression is an attractive 
option for selective labeling of these receptors for fluorescence studies.  This chapter 
describes efforts to replicate and expand upon an earlier report from our group in which 
single nAChRs bearing a BODIPY fluorophore as an amino acid side chain were imaged 
in the membrane of Xenopus laevis oocytes.  Progress was hampered by high levels of 
background fluorescence.  Several approaches to circumvent this issue are described, 
including improved sample preparation, dye conjugation, and the use of a fluorescent 
tRNA with partially quenched fluorescence. 
 
6.2  Introduction 
 Our understanding of nAChR gating motions lags far behind our functional 
understanding of these receptors from electrophysiology.  Opening of the ion-conducting 
pore 60 Å away from the ligand binding site is thought to occur through closure of the C 
loop around the agonist and twisting of the entire extracellular domain coupled to tilting 
of TM2 and TM3.1  Computational studies, x-ray crystallography of homologous 
bacterial channels, and cryo-EM structures of acetylcholine-bound and agonist-free 
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nAChRs corroborate some of these proposed gating motions. 2-6  However, many 
question remain: How large are the gating motions in the actual receptor?  Are motions 
symmetric throughout the five subunits of the channel?  What are the structures of 
desensitized and “uncoupled” states?  Fluorescence studies on functional receptors in 
native cell membranes have the potential to address these questions. 
 To answer these sorts of detailed structural questions, small molecule 
fluorophores are highly preferred over fluorescent proteins due to their greater brightness, 
greater photostability, and most of all, small size.  The tradeoff, of course, is the 
significant challenge of specific attachment of the fluorophore to the protein, especially 
in vivo.  Incorporating the fluorophore as the side chain of an unnatural amino acid is an 
especially attractive option, and this approach has previously been used to incorporate 
single fluorophores into membrane proteins in vivo.7,8  This approach obviates the need 
for the attachment site to be solvent accessible, and also ensures site-selective labeling. 
 Previously, the Dougherty and Lester labs reported the successful incorporation of 
a BODIPY fluorophore into the nAChR by nonsense suppression in Xenopus oocytes, 
and single molecule imaging of these fluorescent receptors.9  The fluorophore used was 
BODIPYFL, which was conjugated to a lysine side chain (Figure 6.1A).  This side chain 
was incorporated into the β19’ site of the muscle-type nAChR, and the presence of 
functional receptors at the cell membrane was confirmed by electrophysiology.  
Fluorescence imaging was conducted on devitellinized oocytes using total internal 
reflection fluorescence (TIRF) microscopy.  TIRF, in which only molecules less than 
~100 nm from the glass surface the cell membrane is resting against are illuminated, was 
critical to enable fluorescent imaging at the membrane, given the high autofluorescence 
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of the oocyte interior10 and a large excess of fluorescent tRNA-Lys-BODIPY injected 
into the cell. 
Figure 6.1.  (A) Structure of Lys-BODIPYFL.  (B) Structure of Lys-BODIPY558.   
 A logical extension of this work is the incorporation of two different fluorophores 
site-specifically into the nAChR to enable Förster resonance energy transfer (FRET) 
studies.  A recently expanded toolkit of tRNAs for nonsense suppression in Xenopus 
oocytes enables the incorporation of multiple unnatural amino acids simultaneously.11  
Walrati Limapichat laid much of the groundwork for incorporation of multiple 
fluorophores into the nAChR, including the preparation of Lys-BODIPYFL and Lys-
BODIPY558 (Figure 6.1) conjugated to dCA (which are used in the experiments 
described below), screening of sites for fluorophore incorporation, and preliminary 
imaging experiments.12  These fluorophores have been incorporated into calmodulin as 
amino acid side chains by nonsense suppression in vitro and have a Förster radius (R0) of 
60Å.13 
 This work aims to optimize the expression and TIRF imaging of fluorescent 
amino acids in nAChRs in vivo to enable two-color FRET experiments.  Progress was 
	  	  
142	  
hampered by high background from fluorescent tRNA injected into the cell.  Efforts are 
described to minimize this fluorescence background, including different membrane 
preparations and the preparation of a tRNA-Lys-BODIPYFL with partially quenched 
fluorescence.  Analysis of single puncta simultaneously at two wavelengths is also 
discussed. 
 
6.3  Results and Discussion 
6.3.1  Background fluorescence from tRNA-BODIPY 
 As a starting point, visualization of receptors bearing a single Lys-BODIPYFL 
was attempted, under similar conditions to those used by Pantoja and co-workers in our 
lab’s earlier report on receptor single molecule imaging.9  The β70 site was chosen for 
Lys-BODIPYFL incorporation, as this position is known to be permissive to the 
incorporation of large side chains.14  The amber suppressor tRNA TQAS was chosen for 
these experiments, as it shows low levels of reacylation in Xenopus oocytes.15  As a 
control, TQAS tRNA acylated with Lys-BODIPYFL (TQAS-BODIPYFL) was injected 
into cells alone to assess the level of background fluorescence from intracellular tRNA.  
High levels of fluorescence were seen for both β70 mRNA + TQAS-BODIPYFL and 
tRNA only conditions (Figure 6.2).  Some cell-to-cell variability was seen for both 
conditions.  Overall the two conditions were indistinguishable from each other, indicating 
that background fluorescence from tRNA-BODIPY was too high to permit visualization 
of fluorescent receptors.  Conditions were not identical to those used by Pantoja9, but 
differences are not expected to affect the background fluorescence levels (conditions used 
here: 20 ng total of 2:5:1:1 α/β70TAG/γ/δ mRNA mix, 10 ng of TQAS-BODIPYFL  
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Figure 6.2.  TIRF images and average whole cell currents from Xenopus laevis oocytes incubated for 24 
hrs after the injection condition noted over each panel.  Panels are representative images from the same cell 
batch that the electrophysiology recordings were made on.  Imax values are for a saturating ACh 
concentration (1000 µM).  Receptor density on the cell surface is predicted from macroscopic currents 
observed from that cell batch, using previously reported assumptions.9  Brightness range for all panels is 
100 counts (black) to 3000 counts (white). 
tRNA, 24 hr incubation.  Pantoja conditions: 25 ng total of 2:5:1:1 α/β19’GGGU/γ/δ 
mRNA mix, 12.5 ng of YFaFSAAAC-Lys-BODIPYFL tRNA, 24 hr incubation).  
Subsequent imaging using the same tRNA employed by Pantoja (YFaFSAAAC-Lys-
BODIPYFL tRNA) gave similar background fluorescence levels. 
 The fluorescence observed has a relatively uniform, granular appearance (Figure 
6.2) that is completely stationary, inconsistent with freely diffusing fluorophores within 
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the cytosol.  We speculate that the fluorophores are most likely either embedded in the 
plasma membrane, with minimal lateral diffusion, or are adhered to the glass coverslip.   
 In the Pantoja and co-workers report, some background fluorescence was 
observed from cells injected with tRNA-BODIPYFL alone, but this was observed at 
significantly lower puncta densities than the mRNA + tRNA-BODIPYFL conditions 
(0.007 ± 0.002/µm2 for tRNA alone, compared with 0.021 ± 0.003/µm2 for mRNA + 
tRNA).9  The fluorescence observed in the images obtained here (tRNA only and tRNA + 
mRNA conditions) was too dense for individual puncta to be counted. 
Surface expression of receptors incorporating Lys-BODIPYFL was confirmed by 
electrophysiology (Figure 6.2).  High levels of reacylation and/or readthrough are seen 
for nonsense suppression at this site, as indicated by a control in which unacylated 76mer 
tRNA is injected in place of tRNA-Lys-BODIPYFL.  Assuming a typical average plasma 
membrane surface area of an oocyte and uniform membrane adhesion to the glass 
coverslip under imaging conditions, and using the known single channel conductance for 
this receptor, receptor density on the plasma membrane can be estimated from whole cell 
current magnitudes.9  These estimates (Figure 6.2) indicate that when currents from 
reacylation are subtracted, densities on the order of 0.2 receptors/µm2 are expected for 
receptors bearing Lys-BODIPYFL under these conditions.  While Pantoja only observed 
puncta at ~1/3 the density predicted by whole-cell currents, the larger currents observed 
here should still yield greater puncta densities than the 0.021 ± 0.003/µm2 observed by 
Pantoja, with approximately the same amount of tRNA injected.  While our failure to 
distinguish between tRNA only and tRNA + mRNA images is apparently due to high 
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background fluorescence from tRNA, we are not experiencing uniquely low levels of 
receptor expression relative to the quantity of fluorescent tRNA injected. 
 A more sensitive CCD camera was used for these experiments than in the Pantoja 
study, leading us to wonder whether the higher background fluorescence levels we 
observed were simply due to greater camera sensitivity, such that brighter punctate 
features were not visible over the high background observed.  However, no new image 
features emerged (punctate or otherwise) when imaging at lower excitation laser 
intensities or shorter image integration times: we simply obtained dimmer images with 
the same uniform granular fluorescence pattern.  To help reference the fluorescence 
intensities we observed, we labeled cells expressing wild type receptors with Alexa488-
labeled α-bungarotoxin (αBtxAlexa488, from Life Technologies).  This conjugate has 
approximately one dye per α-bungarotoxin molecule9, and there are two α-bungarotoxin 
binding sites per receptor.  Alexa488 has a similar fluorescence emission profile as 
BODIPYFL and was reported to have approximately three times the brightness of 
BODIPYFL when each dye was conjugated to streptavidin.16  Some punctate 
αBtxAlexa488 background labeling was seen on uninjected cells (Figure 6.2), but more 
punctate fluorescence was seen for labeled cells expressing wild type receptors (Figure 
6.2).  These puncta are dimmer than the fluorescence background seen in cells injected 
with tRNA-Lys-BODIPYFL, indicating that imaging fluorescent receptors against this 
background will not be possible. 
 We wondered if optimizing the amount of mRNA and tRNA injected might yield 
conditions under which fluorescent receptors could be resolved above the background.  
As expected, the level of background fluorescence is dependent on the amount of tRNA  
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Figure 6.3.  TIRF images from oocytes injected with varying amounts of TQAS-BODIPYFL. Brightness 
range for all panels is 100 counts (black) to 1500 counts (white). 
 
 
 
 
 
 
Figure 6.4.  Whole cell currents from cells injected with various quantities of mRNA and tRNA.  
Incubation time is 24 hrs.  (A) tRNA titration; all cells injected with 20 ng β70TAG mRNA mix and the 
indicated quantity of tRNA.  (B) mRNA titration; all cells injected with 37.5 ng TQAS-BODIPYFL and the 
indicated quantity of β70TAG mRNA mix. 
injected (Figure 6.3).  Surface expression levels (judged by measuring whole-cell 
currents) increase when injecting 10 ng rather than 1 ng of mRNA, but do not get any 
larger with 100 ng of mRNA (Figure 6.4A).  Expression levels continually increased over 
the entire range of tRNA injection amounts tested (Figure 6.4B).  These data suggest that 
tRNA is the limiting factor for receptor expression, and unfortunately it must be supplied 
at an enormous excess: a rough estimate of surface expression levels from macroscopic 
currents suggest that 3 x 104 tRNA molecules were injected per receptor ultimately 
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present on the cell surface.  This estimate is for 24 hrs after injection of 20 ng total 
β70TAG mRNA and 10 ng TQAS-BODIPYFL tRNA.  Comparison of absorbance values 
at 260 nm (λmax for RNA) and 510 nm (λmax for BODIPYFL) on TQAS-BODIPYFL 
tRNA using known molar absorptivity values indicate a 1:3 molar ratio of BODIPYFL to 
tRNA.  This confirms that there is not an excess of BODIPY fluorophores in the tRNA 
solution and is consistent with the presence of some unacylated tRNA in the TQAS-
BODIPYFL solution. 
 We wondered whether the background fluorescence we observed was from free 
BODIPY fluorophores, from Lys-BODIPY that had hydrolyzed off of the tRNA, or from 
fluorophores still attached to tRNA.  The free backbone amine of Lys-BODIPY on the 
tRNA was protected with an NVOC group to minimize hydrolysis of the amino acid from 
the tRNA during preparation and storage, and was photolyzed immediately prior to 
oocyte injection.  We compared fluorescence from oocytes injected under standard 
conditions to injection of tRNA-Lys-BODIPYFL-NVOC (i.e., the NVOC group was not 
photolyzed prior to injection) (Figure 6.5).  Fluorescence was comparable for both  
Figure 6.5.  TIRF images from oocytes injected with various BODIPYFL species.  All cells were injected 
with 0.1 pmol of the indicated species (= 2.5 ng TQAS-BODIPYFL).   In the first panel TQAS-BODIPYFL 
was NVOC-deprotected by photolysis.  All other samples were injected without photolysis.  The common 
dark spot and interference pattern observed in all images is due to irregularities in the TIRF illumination 
field.  Brightness range for all panels is 100 counts (black) to 3000 counts (white). 
	  	  
148	  
deprotected and NVOC-protected tRNA.  We anticipate that much less of the Lys-
BODIPYFL will hydrolyze from the tRNA in its NVOC-protected form, so background 
fluorescence from free Lys-BODIPYFL is not anticipated to be the issue.   
To assess whether the nature of the moiety BODIPY is appended to changes the 
background signal, we also examined fluorescence from cells injected with the 
dinucleotide dCA appended to Lys-BODIPY (dCA-Lys-BODIPYFL-NVOC) and 
fluorescence from free BODIPYFL.  Interestingly, somewhat less fluorescence was seen 
for dCA-BODIPY than for tRNA-BODIPY and less fluorescence still was seen for free 
BODIPY.  It is possible that the hydrophobic BODIPY fluorophore partitions to the lipid-
rich yolk of the oocyte unless tethered to a large hydrophilic moiety such as tRNA. 
 Cursory investigations using a different objective lens (100x, 1.65NA) and 
imaging on a different fluorescence microscope (Olympus IX81) also revealed similar 
images for tRNA-BODIPY only and for tRNA-BODIPY + mRNA conditions.  These 
results suggest that optical issues (i.e., laser focusing, TIRF illumination, collection of 
fluorescence by the objective lens) were not likely to be the source of the background 
observed.   
6.3.2  Optimization of vitelline membrane removal 
 Oocytes imaged by TIRF microscopy were first stripped of their vitelline 
membrane, a protein-rich layer of extracellular matrix surrounding the plasma membrane.  
Using a standard technique, this membrane was removed manually with forceps after 
osmotic shrinking of the oocyte.  The plasma membrane of Xenopus laevis oocytes is 
heavily studded with microvilli extending through the extracellular matrix,17 and previous 
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studies imaging devitellinized oocytes have suggested that the microvilli may be sheared 
during the standard manual devitellinization protocol.18  We wondered whether the high 
fluorescent background observed could have been due to fluorophore leakage out of the 
oocyte via tears in the plasma membrane caused by devitellinization.   
 Other protocols have been reported for vitelline membrane removal that aim to 
preserve plasma membrane integrity.  Two of these methods were investigated for their 
ability to reduce background fluorescence in this system.  Both protocols were originally 
reported to improve the reliability of high-resistance seal formation for single channel 
patch clamp experiments.  The first method aims to remove adhesions between the 
plasma membrane and vitelline membrane by enzymatic digestion.19  For 60 min, cells 
are exposed to 4 mg/mL collagenase and 4 mg/mL hyaluronidase, after which cells are 
shrunk by exposure to hypertonic media.  Upon shrinking, the vitelline membrane 
(“detached,” though still intact) appears separated from the plasma membrane, while in 
the absence of enzymatic treatment the vitelline membrane wrinkles and shrinks together 
with the plasma membrane.  This enzymatic treatment was conducted immediately prior 
to manual devitellinization and imaging. 
In the second method, the vitelline membrane is completely digested 
enzymatically, so that manual stripping is unnecessary.20  Digestion is achieved by 
protease treatment (0.05 mg/mL, Type VIII, Sigma) with gentle shaking.  Swelling 
followed by disappearance of the vitelline membrane can be seen by light microscopy.  
While the literature report of this protocol cites complete digestion of the vitelline 
membrane within 3-4 min, we found that 30 min was required.  To test whether 
membrane-expressed receptors are affected by the protease treatment, we performed 
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electrophysiology (2-electrode voltage clamp) immediately following digestion on 
oocytes expressing the wild-type muscle nAChR.  We recorded an EC50 for ACh (17.4 ± 
0.7 µM), only slightly shifted from untreated cells (23.2 ± 0.9 µM, from the same cell 
batch), and observed similar current magnitudes, suggesting that receptors are still 
functional. 
These two devitellinization conditions were compared with standard manual 
devitellinization by imaging cells injected with the small organic dye fluorescein (1 
pmol/oocyte – we inject approximately this molar quantity of tRNA per oocyte in 
standard experiments).  Fluorescence from standard devitellinization conditions and the 
collagenase/hyaluronidase reduced adhesion method gave similar, moderate levels of 
fluorescence (Figure 6.6A, B).  The protease devitellinization condition, however, gave 
Figure 6.6.  TIRF images from oocytes prepared under various devitellinization conditions.  In top panels 
cells were injected with 0.1 pmol fluorescein and devitellinized by the method indicated.  In the bottom 
panel the cell was injected with nAChR mRNA tagged with GFP on the β subunit.  Brightness range for all 
panels is 100 counts (black) to 4000 counts (white). 
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very low fluorescence levels across many cells, consistent with less leakage of the dye 
from the oocyte (Figure 6.6C).  To confirm that the plasma membrane was indeed 
exposed and adhered to the coverslip in the protease-digested cells, we imaged protease-
treated cells expressing nAChRs with GFP appended to the β1 subunit (Figure 6.6D).  
Indeed, we observed patches of fluorescence from these cells.  Of note, inspection in 
brightfield mode (data not shown) suggested that these crisply delineated bright patches 
likely correspond with adhered sections of membrane. 
With respect to delineated regions of fluorescence, the opposite result was 
observed in images from select oocytes prepared either by standard manual 
devitellinization or hyaluronidase/collagenase treatment prior to manual stripping.  In 
isolated cases, regions where the plasma membrane did not appear tightly adhered to the 
glass coverslip (by inspection in brightfield mode) had higher fluorescence levels than 
adjacent regions that appeared to be adhered (Figure 6.7).  The inverse is expected for 
TIRF imaging of the membrane, as only fluorophores within ~100 nm of the coverslip 
Figure 6.7.  TIRF images from oocytes injected with 10 ng TQAS-BODIPYFL and 10 ng α70TAG mRNA 
mix, imaged at apparent boundaries of plasma membrane adhesion to the glass coverslip.  Adhesion to the 
coverslip is inferred from inspection under bright field illumination (not shown).  (A) Oocyte devitellinized 
manually after hyaluronidase/collagenase treatment.  Top of this field (dark region) appears adhered to the 
coverslip, while the bottom (brighter region) does not.  (B) Oocyte devitellinized by standard manual 
technique without enzymatic treatment.  Bottom of this field (darker region) appears adhered to the 
coverslip, while the top (brighter region) does not. Brightness range for both panels is 100 counts (black) to 
4000 counts (white). 
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surface will be illuminated.  This could be consistent with leakage of fluorophores from 
the cytosol into the space between the coverslip and plasma membrane, whereas diffusion 
of fluorophores into adhered regions is more restricted. 
The protease condition seems promising for reducing background fluorescence.  
However, when imaging protease-treated cells injected with tRNA-BODIPY alone or 
with tRNA-BODIPY + mRNA, no difference was observed; both yielded comparable 
levels of punctate fluorescence (Figure 6.8), albeit with lower levels of background 
fluorescence than in earlier attempts (i.e., Figure 6.2).   
 
Figure 6.8.  TIRF images from cells subjected to protease devitellinization conditions.  Injection conditions 
are indicated above panels. Brightness range for both panels is 500 counts (black) to 3000 counts (white). 
It should be noted that after significant practice at the standard technique using 
forceps to manually strip the vitelline membrane, low background fluorescence levels 
were sometimes obtained (Figure 6.9) – roughly at the same low background 
fluorescence levels seen in the protease digestion experiments.  Good oocyte health may 
also be critical for this result, though this was not investigated systematically.  With 
extremely precise technique, it is plausible that this method could yield satisfactorily low 
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levels of fluorescence, as were evidently obtained in the Pantoja et al. study.9  However, 
even at the low background fluorescence levels sometimes obtained in the experiments 
described here, no difference was ever observed between tRNA only and tRNA + mRNA 
conditions, as the Pantoja study describes. 
 
Figure 6.9.  TIRF images showing low background from standard manual devitellinization conditions. 
Injection conditions are indicated above panels. Brightness range for all panels is 250 counts (black) to 
3500 counts (white). 
 
6.3.3  Two-color imaging and single puncta analysis 
 As receptors could not be convincingly visualized above fluorescent background 
in the single color imaging experiments described above, we turned to two-color FRET 
imaging.  FRET should allow a means to distinguish receptors from background as it 
should only be observed from receptors bearing two fluorophores.  In these experiments, 
we used Alexa488-labeled α-bungarotoxin to label receptors with this donor fluorophore, 
which could be excited by the same 488 nm laser used for the BODIPYFL experiments.  
The acceptor fluorophore used was BODIPY558 (Figure 6.1), incorporated as a Lys-
BODIPY558 side chain at the γ70 site.  Here we used the opal suppressor tRNA 
TQOpS’.15,21 In these experiments, oocytes expressing γ70Lys-BODIPY558 are labeled 
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with Alexa488-α-bungarotoxin immediately prior to imaging.  It should be noted that 
there are two α-bungarotoxin binding sites on the muscle-type nAChR: at α/γ and α/δ 
interfaces.  This leads to a complex FRET scenario with the potential for two donor 
fluorophores and a single acceptor.  Based on rough modeling from the torpedo nAChR 
structure,22 these two donor-acceptor distances are expected to be roughly 40 Å and 60 Å.  
However, only 74% of α-bungarotoxin molecules are reported to be Alexa488-labeled in 
the supplied conjugate, and some of these donor fluorophores are likely bleached during 
sample handling and focus, such that 48% of Alexa488-α-bungarotoxin labeled receptors 
are reported to give only a single photobleaching step under similar conditions to those 
used here.9  Hence, some receptors will be expected to have two Alexa488 donor 
fluorophores, while many should have only one. 
 Two-color imaging is enabled by use of the OptoSplit II image splitter, which 
allows side-by-side imaging of the same field at two wavelengths.  Excitation is identical 
to the experiments described above: a 488 nm laser is used to excite donor fluorophores.  
The fluorescence emission light path is split by a dichroic mirror and the two resulting 
light paths transit different bandpass filters, allowing for selection of the donor and 
acceptor emission wavelengths of interest, which are projected side-by-side onto the 
camera.   
 Corresponding puncta in the two channels were identified using IDL scripts 
written by Taekjip Ha’s lab at the University of Illinois (details in Methods section), 
allowing the intensity of a given punctum in both channels to be determined as a function 
of time.  Puncta with step-like fluorescence intensities were considered for further 
analysis.  For all conditions, cells were labeled with Alexa488-α-bungarotoxin.  For a 
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control in which cells are injected with γ70TGA mRNA and unacylated 76mer tRNA, 
fluorescence in the donor channel is generally consistent with single step photobleaching, 
with little or no fluorescence in the corresponding acceptor channel (Figure 6.10).  These 
donor fluorophores are likely the result of both nonspecific labeling of Alexa488-α-
bungarotoxin and of labeling “background” receptors generated from nonsense 
suppression by tRNA acylated in vivo.   
 
Figure 6.10.  Two-color fluorescence image and fluorescence traces from selected puncta of a cell injected 
with unacylated TQOpS’ 76mer tRNA and labeled with αBtxAlexa488.  Entire fluorescence image is 
shown with the same “heatmap” false-color scheme.  Donor channel and acceptor channel represent the 
same field of view imaged at different emission wavelengths.  Fluorescence traces show donor channel 
intensity (green) and acceptor intensity (red) for the same punctum.  Horizontal axis is time (s) and vertical 
axis is intensity (counts).  Note the small degree of spectral bleedthough of donor fluorescence into the 
acceptor channel (visible in both images and in traces). 
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Cells injected with γ70TGA mRNA and tRNA-BODIPY558 do have puncta with 
fluorescence in both donor and acceptor channels, as would be expected for FRET 
(Figure 6.11).  No clear hallmarks of single molecule FRET were observed however, 
such as anticorrelated donor and acceptor fluorescence intensities – specifically a jump in 
donor fluorescence intensity upon acceptor blinking or bleaching.   
 
Figure 6.11.  Two-color fluorescence image and fluorescence traces from selected puncta of a cell injected 
with TQOpS’-BODIPY558 tRNA and γ70TGA mRNA mix and labeled with αBtxAlexa488.  Puncta 
recognized by IDL scripts are surrounded by red circles in this image.  Entire fluorescence image is shown 
with the same “heatmap” false-color scheme.  Donor channel and acceptor channel represent the same field 
of view imaged at different emission wavelengths.  Fluorescence traces show donor channel intensity 
(green) and acceptor intensity (red) for the same punctum.  Horizontal axis is time (s) and vertical axis is 
intensity (counts).   
    
	  	  
157	  
Critically, very similar fluorescence traces were seen for puncta from control cells 
injected with tRNA-BODIPY558 only (no receptor mRNA) (Figure 6.12).  For this 
condition, sparse Alexa488 donor fluorophores are likely present from nonspecific 
labeling by Alexa488-α-bungarotoxin.  High background from BODIPY558 in the 
acceptor channel raises the possibility of nonspecific spatial overlap of fluorophores.  
However, fluorescence intensities in the donor and acceptor channels are correlated in 
many cases, suggesting either specific association of α-bungarotoxin and BODIPY558 (a  
 
Figure 6.12.  Two-color fluorescence image and fluorescence traces from selected puncta of a cell injected 
with TQOpS’-BODIPY558 tRNA and labeled with αBtxAlexa488.  Entire fluorescence image is shown 
with the same “heatmap” false-color scheme.  Donor channel and acceptor channel represent the same field 
of view imaged at different emission wavelengths.  Fluorescence traces show donor channel intensity 
(green) and acceptor intensity (red) for the same punctum.  Horizontal axis is time (s) and vertical axis is 
intensity (counts).   
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mechanism for this is unknown) or presence of another species with a broad fluorescence 
spectrum that spans both wavelength windows (inconsistent with either Alexa488 or 
BODIPY558).  Local “breathing” of the plasma membrane in the vertical plane – in and 
out of TIRF illumination – is also plausible.  Regardless of the origin of this effect, these 
control results suggest that the γ70TGA mRNA + tRNA-BODIPY558 two-color 
fluorescence traces cannot be trusted as FRET.  Presumably, “background” fluorescence 
from injected tRNA-BODIPY is once again the issue. 
 6.3.4  Attempts at fluorophore conjugation by azide-alkyne cycloaddition 
In an effort to circumvent the high background fluorescence levels seen from 
injected tRNA-BODIPY, we attempted dye conjugation to surface-expressed receptors in 
a labeling step.  The desired attributes of labeling were high specificity for the desired 
nAChR site and low nonspecific labeling of the cell surface.  We selected copper-
catalyzed azide-alkyne cycloaddition (“click chemistry”) as the ligation chemistry, which 
has extensive precedent for the labeling of biological samples.23  In the envisioned 
ligation scheme, the alkyne is incorporated site-specifically into the nAChR as an 
unnatural amino acid side chain.  Propargyl glycine (Pra), which is commercially 
available, (Figure 6.13A) was chosen and was ligated to tRNA by standard methods.  
This amino acid was effectively incorporated at the nAChR α70 site (data not shown), 
which is known to be solvent-accessible.14 
 A principal concern when conducting copper-catalyzed click chemistry in vivo is 
the toxicity of copper to cells.  We first sought to assess copper toxicity in our system 
before actually attempting the coupling reaction since, to our knowledge, copper- 
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Figure 6.13.  (A) Structures of propargyl glycine (Pra), Azide-Fluor 488, and Alexa Fluor 488 Azide.  (B) 
TIRF images of oocytes labeled with azido dyes.  In the top two panels, oocytes were simply incubated 
with the azido dye in ND96 solution.  In the bottom three panels, oocytes were exposed to copper click 
conditions (Table 6.1 Condition 1) in the presence of azido dye in ND96. 
Table 6.1.  Analysis of cell health by whole cell electrophysiology after 1 hr exposure to copper-catalyzed 
azide-alkyne cycloaddition conditions. 
 Untreated Condition 1 Condition 2 
Additives to ND96 
incubation buffer  
100 µM CuSO4 
500 µM THPTA 
2.5 mM Na Ascorbate 
1 mM CuSO4 
500 µM THPTA 
2.5 mM Na Ascorbate 
Resting potential (mV) -68 ± 3 -27 ± 1 
Leak Current (mA) -0.008 ± 0.001 -0.13 ± 0.03 
EC50 (µM ACh) 23.9 ± 0.6 27.9 ± 0.6 
Cells appear swollen, 
~1/3 ruptured after 1 hr 
(not analyzed by 
electrophysiology) 
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catalyzed click chemistry has not been reported on Xenopus oocytes.  Oocytes expressing 
the wild type nAChR were exposed to standard click conditions for a typical reaction 
time of 1 hr (Table 6.1).24  In these conditions, the copper is supplied as Cu(II), which is 
reduced to the active Cu(I) species in situ by ascorbate in the presence of the tris(3-
hydroxypropyltriazolylmethyl)amine (THPTA) copper ligand.24  While a reduction of the 
negative membrane resting potential and an increase in the leak current after incubation 
suggest some reduction in cell health, these cells survived a 40 min series of ACh 
applications to yield a dose-response curve with an EC50 only modestly shifted from wild 
type.  Tenfold higher concentrations of copper, however, result in cell death.  These 
results suggest that cells could still be viable for in vivo imaging after exposure to 
standard copper click conditions, though some reduction in cell health is expected. 
 Next we assessed the viability of labeling by exposing oocytes to azide-
conjugated dyes.  We initially selected a commercially available rhodamine-derived 
azido dye, Azide-Fluor 488 (Figure 6.13A).  High fluorescence levels were seen after 
exposing uninjected oocytes to a standard labeling concentration (50 µM) for 45 min, 
even after copious washes (5x) with buffer.  A tenfold lower concentration of dye (lower 
than what is ideal for in vivo labeling) also gave appreciable levels of fluorescence 
(Figure 6.13B).  We reasoned that a charged, more hydrophilic dye might give less 
nonspecific labeling, so we tested another commercially available azido dye, AlexaFluor 
488-Azide (Figure 6.13B).  Unfortunately we also observed high levels of background 
fluorescence for this dye.  Indistinguishable fluorescence levels were seen for α70Pra-
expressing cells treated with this dye in a labeling solution (Table 6.1, Condition 1) and 
for identically treated cells injected with α70TAG mRNA and unacylated 76mer tRNA 
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(Figure 6.13B).  We conclude that these azido dyes give unacceptably high levels of 
nonspecific labeling to be viable in this system.  
6.3.5  Design and synthesis of a fluorescence-quenched tRNA 
Pursing the original scheme of fluorophore incorporation by nonsense suppression, 
we sought an alternative approach to reduce high background fluorescence from injected 
fluorescent tRNA.  We reasoned that we might modify the tRNA-BODIPY in such a way 
that the BODIPY’s fluorescence was quenched until the dye is incorporated into the 
protein of interest.  Toward this end, we employed a “dark quencher” – a molecule that 
efficiently dissipates energy nonradiatively, and in this application acts as a FRET 
acceptor for a donor fluorophore.25 
 Positioning of this quencher on the tRNA is expected to be critical: it must be in 
sufficiently close proximity to the BODIPY fluorophore at the tRNA’s 3’ terminus to 
efficiently quench its fluorescence, yet it must be in a position tolerated by the ribosome 
during translation.  We reasoned that the 5’ terminus of the tRNA was a sensible site for 
quencher incorporation, allowing for relatively facile quencher incorporation and close 
proximity to BODIPY (Figure 6.14).  Tolerance of a large structural modification to this 
region was largely unexplored, but at least modest changes are tolerated: removal of a 
native tRNA’s 5’ phosphate has a small effect on the rate of translation,26 and we 
routinely use suppressor tRNAs bearing an unnatural 5’ triphosphate.27 
 The Iowa Black FQ quencher, a dark quencher available from Integrated DNA 
Technologies, was selected for these experiments.  The structure of this quencher has not 
been released by the manufacturer, but it is reported to have a molecular weight of 442.4  
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Figure 6.14.  Schematic of Q-TQAS-BODIPYFL quenched fluorescent tRNA.  Dashed line: disconnection 
of 16mer and 57mer component fragments.  Black oval: Iowa Black FQ dark quencher.  Green star: Lys-
BODIPYFL. 
g/mol and an absorbance maximum at 531 nm, which is appropriate for good spectral 
overlap with BODIPYFL fluorescence emission.  To assemble a tRNA bearing this 
quencher group, we obtained a custom 16mer oligoribonucleotide corresponding to the 
first 16 bases of the TQAS suppressor tRNA’s 5’ terminus with the Iowa Black FQ 
quencher appended to it’s 5’ end (Integrated DNA Technologies).  This oligo was then 
ligated to a transcribed 57mer oligo comprising the remainder of TQAS, minus the final 
two 3’ nucleotides, to yield the quencher-tagged “74mer.”  Prior to the ligation, the 
57mer was treated with phosphatase to remove its 5’ triphosphate, then treated with 
polynucleotide kinase to add a single 5’ phosphate, rendering this oligo competent for 
ligation to the 16mer by T4 RNA ligase.  The ligation product was purified by 
preparative polyacrylamide gel electrophoresis (PAGE).  This “74mer” could then be 
ligated to aminoacylated dCA by standard methods.27  In this fashion, full length “76mer” 
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TQAS tRNA bearing a 5’ Iowa Black FQ quencher and acylated at its 3’ end with Lys-
BODIPYFL (Q-TQAS-BODIPYFL) was prepared, as was 76mer tRNA bearing a 5’ 
quencher, but no 3’ amino acid (Q-TQAS 76mer) for use in control experiments.  Identity 
of the products was confirmed by MALDI-MS and also by UV-Vis absorption spectra 
(Figure 6.15).  These spectra confirm that the Iowa Black FQ quencher absorbance 
should have good spectral overlap with BODIPYFL emission (~515 – 560 nm). 
 
Figure 6.15.  UV-Vis spectra of tRNAs 
Next we sought to assess the translational competence of tRNA bearing a 5’ 
quencher.  Q-TQAS-BODIPYFL tRNA was evaluated for nonsense suppression at the 
β70 site.  Encouragingly, we observed appreciable expression of receptors by 
electrophysiology when using this tRNA, though the expression level was reduced 
relative to the condition for regular TQAS-BODIPYFL tRNA lacking the quencher 
(Figure 6.16).  Q-TQAS 76mer conditions showed significantly less expression than 
those for acylated tRNA, suggesting that reacylation still low for tRNA with a 5’ 
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quencher.  In another experiment, we observed that Q-TQAS-Trp tRNA was competent 
for tryptophan incorporation by nonsense suppression at the αW149 site (data not shown). 
Figure 6.16.  Maximal whole cell currents from cells injected with 10 ng β70TAG nAChR mRNA mix and 
10 ng of the specified tRNA.  Cells were incubated for 24 hrs after injection and assayed with a saturating 
concentration of ACh (1000 µM). 
 
Table 6.2.  tRNA fluorescence readings.  All samples are 16 µM in 1 mM NaOAc buffer (pH 4.5).  
Fluorescence readings were taken on 5 µL samples using the Flexstation III fluorescent plate reader with 
excitation at 485 nm and emission filtered to 520 nm. 
 520 nm fluorescence (RFU) 
Buffer  0.413 
TQAS-BODIPYFL 1840 
Q-TQAS-BODIPYFL 512 
TQAS 76mer 2.33 
Q-TQAS 76mer 0.531 
 
The efficiency of fluorescence quenching by Iowa Black FQ on the Q-TQAS-
BODIPYFL tRNA was assessed using the Flexstation III fluorescent plate reader.  We 
measured BODIPYFL fluorescence for tRNA samples and observed a 72% reduction in 
fluorescence for Q-TQAS-BODIPYFL relative to TQAS-BODIPYFL (Table 6.2).  These 
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results do suggest fluorescence quenching of BODIPYFL by Iowa Black FQ on the 
tRNA, though appreciable fluorescence remains.  To confirm that fluorescent impurities 
were not present (for example, RNAs with BODIPY but lacking the quencher), we 
performed fluorescence imaging of tRNA samples run out on a denaturing PAGE gel 
(Figure 6.17).  For both TQAS-BODIPYFL and Q-TQAS-BODIPYFL tRNAs, we see 
only a single fluorescent species with emission at BODIPYFL wavelengths (515-545 nm), 
consistent with the anticipated tRNA species.  Ethidium bromide staining allows for 
visualization of all nucleic acid species using a distinct fluorescence window (560-580 
nm).  This fluorescence window indicates multiple RNA species in both of these samples, 
which may account for hydrolysis of Lys-BODIPYFL off of the tRNA (this species is 
seen as a minor product by MALDI-MS).  However, imaging of this gel suggests that 
there are not any other fluorescent species present in the sample that would account for 
“unquenched” fluorescence from Q-TQAS-BODIPYFL. 
Figure 6.17.  (A) Fluorescence image of an ethidium bromide-stained denaturing polyacrylamide gel of 
tRNA species.  Lanes:  (1) 50 bp DNA ladder; (2) TQAS 76mer; (3) TQAS-BODIPYFL; (4) Q-TQAS-
BODIPYFL; (5) Q-TQAS 76mer.  0.2 µg RNA was loaded into each lane.  Green false color is BODIPYFL 
fluorescence (515-545 nm) and red false color is ethidium bromide fluorescence (560-580 nm).  (B) 
Ethidium bromide fluorescence channel (red border) and BODIPYFL fluorescence channel (green border) 
for Q-TQAS-BODIPYFL (Lane 4). 
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It is plausible that the quencher and BODIPY are too distant from each other on 
the tRNA for highly efficient quenching.  In a representative tRNA (yeast Phe), the 5’ 
phosphate and 3’ hydroxyl groups are 24 Å distant from each other.28  The 5’ quencher 
and 3’ BODIPY fluorophore will be more distant still – perhaps another 10 – 15 Å, if the 
Lys side chain and (unknown) quencher tether are included.  The Förster radius of the 
BODIPYFL/Iowa Black FQ pair has not been reported, though it is plausible that at the 
~25-40 Å separation of the BODIPY and Iowa Black on the tRNA, quenching by FRET 
may be in the 70% range suggested by our fluorescence measurements (Table 6.2). 
 Finally, we imaged oocytes injected with Q-TQAS-BODIPYFL.  These oocytes 
were devitellinized by the standard manual method.  At standard injection amounts (10 
ng tRNA), we observed high levels of fluorescence for the tRNA-only condition and no 
discernible difference in fluorescence for tRNA + β70TAG mRNA (Figure 6.18A).  
Hence the original aim of the quenched tRNA to reduce background fluorescence levels 
to the extent that receptors can be distinguished from background has not been met.  We 
also imaged cells injected with far less tRNA (0.2 ng) such that (background) 
fluorescence would be sparse and punctate.  Again, we saw comparable levels of 
fluorescence (now punctate) for conditions with and without receptor mRNA (Figure 
6.18B).  Investigation of individual puncta brightness revealed similar values whether the 
cells were injected with Q-TQAS-BODIPYFL or TQAS-BODIPYFL (~3000 - 4000 
counts).  This is surprising, given the 72% reduction in bulk fluorescence measured for 
the quencher-bearing tRNA (Table 6.2).  One explanation could be high levels of Lys-
BODIPYFL hydrolysis off of the tRNA or some other form of tRNA degradation that 
liberates BODIPY from the quencher. 
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Figure 6.18.  TIRF images of oocytes injected with fluorescence-quenched tRNA.  (A) Q-TQAS-BODIPY 
tRNA still gives appreciable levels of background fluorescence.  Brightness range: 400 counts (black) to 
2000 counts (white).  (B) TIRF images of cells injected with low amounts of tRNA.  Puncta from all 
conditions have comparable brightness (~3000 – 4000 counts).  Image brightness range: 100 counts (black) 
to 4500 counts (white). 
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6.4  Conclusions 
 Despite various efforts to circumvent background fluorescence from injected 
tRNA, we were unable to identify conditions in which fluorescent receptors could be 
visualized above background.  Background fluorescence will be an inherent issue for in 
vivo imaging with fluorophore incorporation by nonsense suppression.  TIRF microscopy 
offers a reduction of intracellular fluorescence seen, but in the experiments described in 
this chapter, background fluorescence, apparently at or near the glass surface, was still 
unmanageably high. 
 For future efforts on this project, several areas seem promising for improvements.  
First, clean plasma membrane preparation will likely be facilitated by only selecting cells 
of excellent health and by taking special care to use meticulous manual devitellinization 
technique.  Second, dyes other than BODIPY that have greater photostability could be 
explored.  A literature search revealed no studies using BODIPY dyes for single molecule 
FRET, likely due to the their limited photostability.  Cy3 and Cy5 are the most widely 
used FRET pair for single molecule imaging,29 and could be viable alternatives to 
BODIPY, though their slightly larger size could limit the efficiency of their incorporation 
into proteins by nonsense suppression.  Finally, click chemistry conjugation of dyes could 
be viable using recently developed “turn on” fluorophores whose fluorescence intensity 
increases dramatically upon conjugation.  This could offer a work-around for the high 
levels of nonspecific dye labeling observed in the fluorophore conjugation attempts 
described above.   
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6.5  Experimental 
6.5.1  Molecular biology and in vivo expression 
Nonsense suppression was performed using techniques described previously on 
the mouse muscle embryonic nAChR, (α1)2β1γδ, in the pAMV vector.30  Stage V-VI 
Xenopus laevis oocytes were injected with 1 ng total mRNA in a 2:1:1:1 ratio of 
α1:β1:γ:δ for wild-type experiments.  For nonsense suppression experiments, oocytes 
were typically injected with 10 ng tRNA and 10 ng total mRNA in a 10:1:1:1 ratio of 
α1:β1:γ:δ for suppression in the α subunit, in a 2:5:1:1 ratio for suppression in the β 
subunit, or in a 2:1:5:1 ratio for suppression in the γ subunit.  tRNAs bearing a 6-
nitroveratryloxycarbonyl protecting group were deprotected prior to injection via 
irradiation with a 500 W Hg/Xe arc lamp, filtered with WG-334 and UG-11 filters prior 
to injection.  Deprotection was carried out for 4 min only to limit the amount of BODIPY 
photobleaching.12  Oocytes were injected for 24-48 hrs prior to imaging or 
electrophysiology. 
6.5.2  Electrophysiology 
Electrophysiology recordings were performed using the OpusXpress 6000A 
(Axon Instruments) at a holding potential of −60 mV.  The running buffer was a Ca2+ free 
ND96 solution (96 mM NaCl, 2 mM KCl, 1 mM MgCl2, and 5 mM HEPES, pH 7.5).  
Agonist doses in Ca2+-free ND96 were applied for 15 s followed by a 116 s wash with the 
running buffer.  Dose-response relations were fit to the Hill equation to obtain EC50 and 
Hill coefficient values, which are reported as averages ± standard error of the fit.   
6.5.3  Oocyte membrane preparation 
 The oocyte vitelline membrane was removed prior to imaging.  Under standard 
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conditions (used unless specified otherwise), oocytes were incubated in hypertonic media 
(220 mM Na aspartate, 10 mM EDTA, 2 mM MgCl2, and 10 mM HEPES, pH 7.4) for 5–
15 min.  Under a dissecting microscope, the vitelline membrane, which was visible over 
the underlying plasma membrane, was manually removed using forceps.  In one 
alternative condition,19 cells are incubated in ND96 solution containing 4 mg/mL 
collagenase (Sigma, Type IA) and 4 mg/mL hyaluronidase (Sigma, Type IV-S) for 60 
min, after which cells are exposed to hypertonic media and manually stripped of their 
vitelline membrane, as described above.  In another alternative condition,20 complete 
digestion of the vitelline membrane is achieved by protease treatment (0.05 mg/mL in 
ND96, Type VIII, Sigma) with gentle shaking for 30 min.  Digestion of the vitelline 
membrane is visualized under light microscopy.  After any devitellinization procedure, 
the oocyte is immediately transferred to a glass-bottom petri dish (MatTek) for TIRF 
imaging.  Oocytes were typically placed on the dish with their animal pole facing down, 
as the vegetal pole generally shows higher autofluorescence. 
6.5.4  Total internal reflection fluorescence (TIRF) imaging 
TIRF microscopy was conducted on an Olympus IX81 inverted microscope.  A 
JDS Uniphase 2219 488 nm argon ion laser was coupled to the microscope via a fiber 
optic.  Through-objective TIRF imaging was conducted using an Olympus 100x 1.45-NA 
objective lens.  Images were captured using an Andor iXon 897 electron-multiplying 
charge coupled device (EMCCD) camera.  Typical image integration time was 0.2 s.  
Andor iQ2 software was used to acquire the data, which were analyzed using ImageJ 
(National Institutes of Health).  A region of interest on the cell was selected to establish 
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focus on the membrane and the TIRF condition.  Imaging was conducted elsewhere on 
the cell, to limit the effect of photobleaching on measurements.   
6.5.5  Azido dye labeling under copper-catalyzed click conditions 
 In tests to assess cell viability under conditions for copper-catalyzed azide-alkyne 
cycloaddition, Xenopus oocytes were exposed to a solution of ND96 buffer containing 
100 µM CuSO4, 500 µM tris(3-hydroxypropyltriazolylmethyl)amine ligand (a gift from 
Lan Ban, Hsieh-Wilson lab, Caltech), and 2.5 mM sodium ascorbate.  For labeling 
attempts using an azido dye conjugate, oocytes were incubated in the above solution 
additionally containing 50 µM azido dye (either Azide-Fluor 488 [Click Chemistry 
Tools] or AlexaFluor 488-Azide [Life Technologies]) for 45 – 60 min.  Next cells were 
rinsed three times with ND96 buffer, incubated in ND96 for 15 min, rinsed again with 
ND96, and finally incubated another 15 min in ND96.  Cells were then devitellinized 
using the standard manual devitellinization method and imaged.  
6.5.6  Two-color TIRF imaging and image analysis 
 For all two-color TIRF imaging experiments, cells expressing the appropriate 
receptors of interest were labeled with Alexa488-labeled α-bungarotoxin (αBtxAlexa488, 
Life Technologies).  Cells were incubated in 20 nM αBtxAlexa488 for 6.5 hrs at 18°C, 
then rinsed twice with ND96, incubated in 5 mg/mL BSA in ND96 for 10 min, then 
rinsed with ND96 and incubated for 30 min and rinsed again with ND96 and incubated 
for 30 min.  Cells were then devitellinized using the standard manual devitellinization 
method and imaged. 
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 For these experiments, an Optosplit II (Cairn Research) beam splitter was 
installed in the fluorescence emission light path directly in front of the camera.  In our 
configuration of this device, incident light is split by a 560 nm dichroic mirror.  Reflected 
light (“donor channel”) passes through a 500-550 nm bandpass filter and transmitted light 
(“acceptor channel”) passes through a 575-615 nm bandpass filter.  These paths are 
focused side-by-side on the camera.  In our experiments, intensity of the donor channel 
was significantly higher than intensity of the acceptor channel, so a neutral density filter 
was placed in the donor channel path.   
 IDL scripts written by Taekjip Ha’s lab at the University of Illinois were used for 
single puncta data analysis.31  Using a MATLAB script, TIFF files obtained from the 
Andor iQ2 acquisition software were converted to PMA files for further analysis.  In 
order to correlate puncta in the donor channel to corresponding puncta in the acceptor 
channel, a mapping file was created using images of fluorescent beads collected on our 
TIRF microscope in two-color mode.  The beads (Duke Scientific G100 green fluorescent 
beads) were sparsely distributed on a glass bottom dish identical to those used for oocyte 
imaging and a new mapping file was created for each imaging session, in case of 
variation in optical alignment of the two channels.  This mapping file was applied to the 
actual movies of interest and fluorescence traces for each punctum identified by the script 
were extracted from both donor and acceptor channels.  These traces were analyzed and 
plotted in MATLAB. 
6.5.7  tRNA synthesis and characterization 
TQAS-BODIPYFL and TQAS-BODIPY558 tRNAs were synthesized by standard 
methods, ligating dCA-Lys-BODIPYFL or dCA-Lys-BODIPY558 to 74mer TQAS.27  
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dCA-Lys-BODIPYFL and dCA-Lys-BODIPY558 were prepared by Walrati 
Limapichat.12 
Q-TQAS-BODIPYFL tRNA was synthesized by ligation of a transcribed 57mer 
oligoribonucleotide (3’ portion) to a 16mer oligoribonucleotide (5’ portion) to yield 
“74mer” TQAS tRNA.  The 16mer oligoribonucleotide GUCCCUAUAGUAUAGC (all 
sequences are written 5’ to 3’) with a Iowa Black FQ quencher appended to its 5’ 
terminus was purchased from Integrated DNA Technologies.  The 57mer of the sequence 
GGUUAGUACUGGGGACUCUAAAUCCCUUGACCUGGGUUCGAAUCCCAGUA
GGGCCGC was prepared by runoff transcription of a modified DNA oligonucleotide 
bearing 2’ OMe groups on its two terminal 5’ nucleotides.  To render the 57mer 
competent for ligation to the 16mer, its 5’ triphosphate was removed using calf intestinal 
alkaline phosphatase (New England Biolabs), with purification by PCI extraction.  The 
resulting product was treated with T4 polynucleotide kinase (New England Biolabs), with 
purification by PCI extraction, to yield the desired 57mer with a 5’ monophosphate.  
16mer and 57mer were ligated to each other using T4 RNA ligase 1 (New England 
Biolabs).  16mer and 57mer were mixed in a 2:1 molar ratio, annealed by heating to 90°C 
for 2 min and then cooling to room temperature, and then subjected to standard T4 RNA 
ligase ligation conditions.27  The crude product of the ligation reaction was isolated by 
PCI extraction.  This product was purified by preparative acrylamide gel electrophoresis 
(PAGE) on a denaturing TBE 15% urea gel (Life Technologies).  Finally, the “74mer” 
oligonucleotide was ligated to dCA-Lys-BODIPYFL by standard methods27 to yield Q-
TQAS-BODIPYFL tRNA.  Control unacylated Q-TQAS 76mer tRNA was synthesized 
by ligating the 74mer to unacylated dCA.  The identity of RNA products throughout the 
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synthesis was confirmed by matrix-assisted laser desorption-ionization time-of-flight 
mass spectrometry on a 3-hydroxypicolinic acid matrix.  Final tRNA products were also 
characterized by UV-Vis on a Nanodrop 2000 spectrophotometer (Thermo Scientific). 
 Final tRNA products were also characterized by denaturing PAGE on a 15% TBE 
urea gel (Life Technologies).  0.2 µg of each tRNA was loaded onto the gel, which was 
stained with ethidium bromide after running.  The gel was imaged on a Typhoon FLA 
9000 imager (GE Healthcare Life Sciences) both at 473 nm excitation with a 515-545 nm 
bandpass emission filter and at 532 nm excitation with a 560-580 nm bandpass emission 
filter. 
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Chapter 7: Attempts to develop a FRET assay for the GPCR-G protein 
interaction 
 
7.1  Abstract 
 The interaction between GPCRs and their cognate G proteins is the critical 
junction between sensing a stimulus from the extracellular environment and intracellular 
signaling.  The atomic-level details of this interaction and the mechanism by which an 
active GPCR induces G protein activation are poorly understood.  An assay was devised 
to probe this interaction by unnatural amino acid mutagenesis, which would allow 
detailed chemical-scale insights into the processes.  The proposed assay is based on GTP-
induced dissociation of a stable GPCR-G protein complex on isolated plasma membranes.  
A fluorescence readout was chosen drawing on precedent for detecting receptor-G 
protein interactions by FRET between fluorescent protein fusions.  Fluorescent protein 
fusions were constructed of the β2 adrenergic receptor, D2 dopamine receptor, and a 
variety of G protein subunits.  When expressed in Xenopus laevis oocytes and assayed at 
the plasma membrane by fluorescence lifetime imaging microscopy (FLIM), no 
interaction between receptors and G proteins was detected, and the assay was not pursued 
further. 
 
7.2  Introduction 
 While our knowledge of atomic-scale details of ligand binding to GPCRs is 
rapidly expanding, a similar understanding of the interaction between the receptor and the 
G protein lags far behind.  The association of the active receptor with the G protein is the 
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key event relaying agonist binding to induction of a cellular response.  The active 
receptor effectively catalyzes G protein activation – that is, the exchange of GDP for 
GTP that induces dissociation of Gα from Gβγ (Figure 7.1).  
Figure 7.1.  Cycle of G protein (αβγ) activation by an activated GPCR (R*) 
In a landmark achievement, Kobilka and coworkers in 2011 obtained a crystal 
structure for the intermediate in this process: the complex of a nucleotide-free G protein 
(Gs) in complex with an active, agonist-bound GPCR (the β2 adrenergic receptor, β2AR) 
(Figure 7.2).1  This structure should provide a starting point for well-informed structure-
function studies of the receptor-G protein interface.  
 
 
Figure 7.2.  Crystal structure of the β2 adrenergic 
receptor (green) in complex with Gαs (blue), Gβ1 
(yellow), and Gγ2 (orange) 
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 Many intriguing questions remain with regard to G protein-receptor coupling.2  
Most fundamentally, it is largely unknown which residues mediate functionally important 
interactions across the protein-protein interface.  Second, the determinants of receptor 
specificity for a particular G protein are not well defined.  A fascinating additional layer 
to this problem exists for receptors able to activate more than one type of G protein.  In a 
principle known as signaling bias, different ligands can preferentially activate one 
signaling partner (G protein, arrestin, kinase, etc.) over another.3 Unnatural amino acid 
mutagenesis of the receptor-G protein interface would be a powerful tool to tackle these 
issues at a chemical scale, but an assay is not readily available to probe this interaction. 
Assay considerations and proposed design 
 An ideal assay would isolate G protein activation from the larger signaling 
cascade of ligand binding, receptor activation, and G protein activation of cellular targets.  
An attractive in vitro system has been described involving a GPCR (the β2AR) and its 
cognate G protein (Gs) reconstituted into a nanodisc4 (a small protein-ringed patch of 
lipid bilayer).5  The receptor and G protein form a stable complex when all GDP and 
GTP is removed from the system by treatment with apyrase, a nonspecific nucleotide 
phosphatase.6  This complex (Figure 7.1, boxed species) essentially represents the 
“transition state” for G protein activation – GDP has been expelled from the G protein’s 
nucleotide binding site.  This is the state that was captured in the β2AR-Gs crystal 
structure; apyrase digestion was required to form a stable receptor-G protein complex for 
crystallography.1  In a cellular context this would be a transient intermediate: GTP binds 
next, inducing dissociation of the G protein from the receptor and the Gα subunit from 
Gβγ (Figure 7.1).  In the nanodisc system, the G protein can be dissociated from the 
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receptor by addition of GDP or the nonhydrolyzable GTP analog GTPγS in a dose-
dependent fashion (Figure 7.3).  In the general scheme envisioned for the desired assay, 
the GTPγS EC50 for dissociation of the nucleotide-free complex is measured: loss of 
function mutations destabilizing the complex will lower the EC50, while mutations 
stabilizing the complex will raise it. 
Figure 7.3.  Dissociation of the nucleotide free nanobody-supported β2AR-Gs complex by GDP or GTPγS.  
Dissociation is monitored by fluorescence intensity of a bimane fluorophore on the β2AR.  Reproduced 
from Yao et al. (2009), copyright (2009) by the National Academy of Sciences. 
 An ideal assay for structure-function studies will allow for unnatural amino acid 
mutagenesis of the receptor and of the G protein.  In vivo expression of both receptor and 
G protein in Xenopus laevis oocytes is attractive, as this system is well suited to GPCR 
unnatural amino acid mutagenesis by nonsense suppression.7-9  The assay proposed in 
this chapter involves GTPγS dissociation of a receptor-G protein complex in plasma 
membranes derived from Xenopus laevis oocytes. FRET between fluorescent protein (FP) 
fusions of the receptor and the G protein could afford a readout for dissociation of the 
complex.  Of course, the large size of FPs is undesirable, but FP fusions of both GPCRs 
and G proteins are well documented and several sites for FP incorporation are reported 
that permit receptor activation of the G protein.10-12 
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Figure 7.4.  Hypothetical fluorescence decay traces.  (A) Fluorescence decay of an isolated fluorophore.  
(B) Fluorescence lifetime shortened by the presence of a FRET acceptor.  (C) Fluorescence decay of a 
mixed population of fluorophores A and B. 
Fluorescence lifetime imaging microscopy (FLIM) will be the principle method 
used to probe for an association between FP-tagged receptors and G proteins.  FLIM 
exploits the fact that a donor fluorophore participating in FRET has its fluorescence 
lifetime shortened relative to an isolated donor fluorophore (Figure 7.4).13  A 
fluorophore’s fluorescence decay as a function of time, F(t), is described by: 
€ 
F(t) = Ae−
t
τ  
Where t is time, A is the fluorescence peak amplitude, and τ is the fluorescence lifetime.  
FRET will decrease the value of τ and the FRET efficiency is conventionally given by:  
€ 
FRET efficiency =1− τFRET
τD
 
Where τFRET is the fluorescence lifetime corresponding to the FRET condition and τD is 
the fluorescence lifetime corresponding to a donor fluorophore in the absence of a FRET 
acceptor.   
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 A significant advantage of the FLIM technique compared to other methods for 
FRET measurement is the ability to discriminate populations of donor fluorophores 
participating in FRET from non-interacting donors in a mixed population (and to 
determine the FRET efficiencies for each population).13  In a two-component sample 
(Figure 7.4 C) the fluorescence decay is simply fit to a double exponential and the size of 
each population is given by their relative peak amplitudes, A1 and A2.  In the desired 
FRET assay for dissociation of a nucleotide-free G protein/receptor complex, most donor 
fluorophores will initially participate in FRET, and the interacting population will 
decrease as GTPγS is added. 
 In the assay envisioned, plasma membrane sheets from oocytes expressing FP 
fusions of a receptor and a G protein are immobilized on a glass surface, exposing the 
intracellular side of the membrane to solution.  The sheets are treated with apyrase to 
form stable receptor-G protein complexes, the initial FRET reading is established, and the 
sheets are subsequently treated with GTPγS to dissociate the complexes.  Such glass-
immobilized sheets of Xenopus lavevis membranes have previously been reported for 
fluorescence imaging of membrane proteins. 14,15  FLIM imaging of the membrane sheets 
using a confocal fluorescence microscope can be used to detect the receptor-G protein 
interaction by FRET.  The receptor-G protein system chosen for these experiments is the 
β2 adrenergic receptor with Gαs, Gβ1, and Gγ2 – the same proteins crystallized in the β2 
adrenergic receptor-G protein structure.1  The D2 dopamine receptor paired with Gαi2 
was also explored, as this receptor has been amenable to expression and characterization 
in Xenopus oocytes in our hands. 8,16 
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7.3  Results and Discussion 
7.3.1  Construction of Fluorescent Protein Fusions 
 Sites for fluorescent protein fusion to the receptors and G proteins were selected 
based on literature reports of maintained function and of positioning that yields FRET in 
vivo. 10,12  The chosen sites (Figure 7.5) have direct precedent for the β2 adrenergic 
receptor,10 D2 dopamine receptor,17 Gβ1,10 and Gγ2. 10,12  For Gαi2 and Gαs, the FP was 
inserted into a site that yielded robust FRET with a GPCR, though for a different G
Construct Protein Insertion Site Linker 
β2AR-FP human β2 adrenergic receptor 
 
C terminus -AGS- 
D2DR-FP human D2 dopamine receptor, long isoform  
C terminus -AGS- 
Gαs-FP human Gαs, short (isoform 3) 
 
loop between helices A and B 
(residues 99 and 100) 
-AGSG-,   
-GSGA- 
Gαi2-FP human Gαi2, isoform 1 
 
loop between helices A and B 
(residues 91 and 92) 
-AGSG-,   
-GSGA- 
FP-Gβ1 bovine Gβ1 
 
N terminus -GSGA- 
FP-Gγ2 human Gγ2 
 
N terminus -GSGA- 
Gγ2-FP human Gγ2 
 
C terminus -AGSG- 
Figure 7.5.  Fluorescent protein fusions created.  Each fusion noted was made for EmGFP, EYFP, and 
mCherry.  Approximate locations for fluorescent protein insertion are denoted by colored stars on the 
crystal structure of the β2AR-Gs complex. 
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protein (Gαi1). 11  All genes were subcloned into the pGEMhe vector for optimal 
expression in Xenopus laevis oocytes.18  For a wide range of options for FRET pairs, 
every fusion was prepared with each of three different fluorescent proteins: engineered 
monomeric green fluorescent protein (EmGFP), engineered yellow fluorescent protein 
(EYFP), and monomeric Cherry (mCherry).  Both EmGFP and EYFP can serve as FRET 
donors for mCherry.  
Several previous studies provide guidance on which construct combinations 
should afford the most robust FRET signals.  Michel Bouvier and co-workers have 
studied associations between FP-tagged G proteins and GPCRs by FRET, principally 
using the FRET pair of Luciferase (a protein yielding bioluminescence when supplied 
with the substrate coelenterazine) as the donor and GFP as the acceptor. 10,11  This 
technique is termed bioluminescence resonance energy transfer (BRET) as donor 
emission occurs via bioluminescence. For each condition they quantify a BRET value: 
the ratio of GFP emission intensity to Luciferase emission intensity.  All measurements 
were made in vivo in human embryonic kidney 293 cells.  They quantified a modest 
BRET value of 0.15 for β2AR-GFP coexpressed with Gαi1-Luciferase (same insertion 
sites as in Figure 7.5),11 and a more robust BRET value of 0.4 for β2AR-Luciferase with 
GFP-Gγ2.10  Both measurements were made in the presence of agonist, but only modestly 
lower values were measured under ligand-free conditions.  A strong BRET value of 0.4 
was measured for both α2A-adrenergic receptor-GFP/Gαi1-Luciferase and α2A-
adrenergic receptor-Luciferase/GFP-Gγ2 combinations.11  It should be noted that these 
BRET values in vivo likely encompass receptors and G proteins in a variety of states – 
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perhaps precoupled receptor-G protein(GDP) complexes, nucleotide free receptor-G 
protein complexes, and unassociated receptors and G proteins.   
7.3.2  Tests of construct function in vivo 
 Several preliminary electrophysiology experiments were performed to confirm the 
function of these constructs when expressed in Xenopus laevis oocytes.  These tests are 
by no means exhaustive, but do confirm the function of some of the constructs.  The D2 
dopamine receptor has routinely been expressed in this system and assayed via activation 
of coexpressed GIRK channels.  Under standard expression conditions, the D2DR-
EmGFP construct activated GIRK1/4 channels in response to dopamine and yielded a 
dose-response curve with an EC50 of 55 nM, within the normal EC50 range for the wild 
type D2 receptor. 
 In an established electrophysiology assay for the β2 adrenergic receptor in 
Xenopus laevis oocytes, the receptor can activate a coexpressed chloride channel, the 
cystic fibrosis transmembrane conductance regulator (CFTR).19  This assay was 
attempted for both wild type and FP-fusion constructs of the β2 adrenergic receptor 
coexpressed with the CFTR (subcloned into the pGEMhe vector for Xenopus expression), 
but no responses were detected.  The reason for this assay’s failure is unknown, though 
the function of the CFTR construct had not been validated.  This assay was not pursued 
further.  Another electrophysiology assay has been reported for the β2AR in Xenopus 
oocytes involving GIRK activation, which is enhanced by coexpression of Gαs. 20,21  
While results were variable among cell batches, coexpression of β2AR, Gαs, and 
GIRK1/4 gave large leak currents and gave very large basal currents upon exposure to 
high K+ buffer, and exposure to the β2AR agonist isoproterenol gave an induced current 
 186 
above this basal current.  Coexpression of Gαs with GIRK1/4 or β2AR with GIRK1/4 
gave markedly smaller leak and basal currents, suggesting that β2AR was signaling 
through expressed Gαs.  Large basal currents and a measurable induced current from 
isoproterenol were measured when β2AR-EYFP and Gαs-mCherry were coexpressed 
with GIRK1/4, suggesting that these FP-tagged constructs are functional as well.   
  
Figure 7.6.  Average currents detected by electrophysiology from coexpression of G protein subunits with 
D2DR and GIRK1/4 in Xenopus laevis oocytes.  Equimolar amounts of each G protein mRNA were 
injected. 
Preliminary electrophysiology data for D2DR coexpressed with GIRK1/4 and 
various G protein subunits suggest that wild type Gαi2, Gβ1, and Gγ2 are likely 
functional in this expression system (Figure 7.6).  Coexpression of wild type Gβ1, and 
Gγ2 significantly increased basal currents in the D2DR/GIRK1/4 system, though 
 187 
elevation of basal currents was not significant when FP-tagged EmGFP-Gβ1 and 
mCherry-Gγ2 were expressed instead.  Also, coexpression of wild type Gαi2 with Gβ1 
and Gγ2 significantly reduced basal currents and caused a borderline significant increase 
of dopamine-induced currents.  While these data validate the function of the wild type G 
protein constructs in this system, they do not establish whether FP-Gβ1 and FP-Gγ2 are 
functional. 
7.3.3  Formation and fluorescence imaging of plasma membrane sheets 
 Several methods were investigated for the formation of glass-supported plasma 
membrane sheets.15,22 The cleanest and most reproducible was found to be the method of 
Singer-Lahat et al.,14 in which a devitellinized oocyte is laid on a glass cover slip in 
buffer, allowed to adhere, and then forcefully aspirated away.  This yields a patch of 
plasma membrane with its intracellular face exposed to solution, which can be imaged by 
fluorescence microscopy.   
All constructs tested (at least one FP fusion for each G protein or receptor) could 
be visualized in membrane patches by fluorescence microscopy, suggesting that they 
indeed express and are present in the plasma membrane. Representative images are 
shown in Figure 7.7.   
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Figure 7.7.  Fluorescence images of two different membrane patches, one expressing the D2DR-EmGFP 
construct and the other expressing the Gαi2-mCherry construct.  Membrane patch boundary is visible in the 
Gai2-mCherry image. 
7.3.4  Attempts to measure FRET between G protein and receptor 
 Several control experiments suggested that FLIM should be a viable assay for this 
system.  FLIM on membrane sheets from cells expressing the β2AR-EmGFP construct 
generally gave a single-component fluorescence decay with a lifetime of approximately 
2.5 ns (Table 7.1).  A positive control in which mCherry was fused directly to EmGFP 
(via a -AGS- linker) on the β2AR-EmGFP construct had an additional short component 
(approximately 1 ns) in its fluorescence decay, consistent with FRET between EmGFP 
and mCherry.  The fact that this shorter component comprised only half of the 
fluorescence amplitude probably indicates that approximately half of the mCherry 
molecules are “dark” – either unfolded or do not have mature chromophores.  This is 
consistent with an earlier report of a FLIM measurement in mammalian cells for this 
same FRET pair, which indicated that only 55% of mCherry chromophores were 
functional.23  Thus, the actual fraction of interacting donors should be approximately 
double that suggested by FLIM. 
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Table 7.1.  FLIM data from representative membrane sheets 
Construct Expressed Normalized A1 τ1  (ns) Normalized A2 τ2 (ns) 
β2AR-EmGFP 1 2.53 -- -- 
β2AR-EmGFP-mCherry 0.52 2.28 0.48 0.98 
 
Inspired by the high BRET signals reported for coexpressed β2AR-luciferase and 
GFP-Gγ2 by Bouvier and coworkers, the constructs EmGFP-Gγ2 and β2AR-mCherry 
were explored for FRET in the Xenopus membrane sheet system.  These constructs use 
the identical G protein and receptor as in the Bouvier system with fluorescent proteins 
appended at identical sites.  EmGFP-Gγ2 expressed alone gave a single exponential 
fluorescence decay of approximately 2.5 ns (Table 7.2).  Coexpression of β2AR-mCherry 
did not markedly change the fluorescence decay; no obvious second component was 
present.  When the decay traces were fit to a single exponential, the condition in which 
the β2AR-mCherry FRET acceptor was present gave a very slightly shorter lifetime 
(Table 7.2), perhaps reflecting a small degree of FRET between the two proteins.  If a 
shorter lifetime component was present at all it was too small to be reliably fit as a 
second component to the fluorescence lifetime, and thus not useful for a G protein-
receptor assay.  Note that for the oocytes from which these membrane sheets derived, a 
significant excess of the FRET acceptor β2AR-mCherry mRNA was injected, with the 
aim of minimizing the fraction of unpaired EmGFP-Gγ2 donor.  These measurements 
were made in the presence of apyrase (2U/mL) and the β2AR agonist isoproterenol (100 
µM), conditions that should promote formation of nucleotide free G protein-receptor 
complexes.  For the cells used in these experiments, wild type Gαs and Gβ1 were also 
coexpressed with the FP constructs EmGFP-Gγ2 and β2AR-mCherry, which Bouvier and 
coworkers found to modestly increase BRET efficiency.  A cursory attempt to measure 
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FRET by a ratiometric method instead (NFRET)24 – comparing donor and acceptor 
fluorescence emission intensities – also did not indicate FRET between EmGFP-Gγ2 and 
β2AR-mCherry. 
Table 7.2.  FLIM data for membrane sheets incubating in 2 U/mL apyrase and 100 µM of the β2AR 
agonist isoproterenol.  mRNA injection amounts were 0.25 ng EmGFP-Gγ2 and 10 ng β2AR-mCherry per 
oocyte.  Every oocyte was also coinjected with 0.25 ng Gαs and 0.25 ng Gβ1 mRNA.  All fluorescence 
decay traces were fit to a single exponential. 
Construct(s) Expressed τ (ns)  
EmGFP-Gγ2 2.49 ± 0.05 n = 9 
EmGFP-Gγ2 + β2AR-mCherry 2.37 ± 0.05 n = 9 
 
Myriad other conditions were tested, none of which yielded fluorescence decay 
traces consistent with FRET.  Similar traces were measured from intact cells imaged by 
FLIM: whole devitellinized oocytes were laid on glass coverslips and the portion of the 
cell directly contacting the coverslip was imaged.  FLIM experiments were also 
conducted in the absence of apyrase or agonist, and in the presence of GTPγS – none of 
which changed the fluorescence decays.  EYFP was also tried as a donor fluorophore 
instead of GFP (the excitation wavelength and emission filters used in the FLIM 
experiments are suitable for both fluorophores).  EYFP gave a slightly longer 
fluorescence lifetime than GFP (~2.8 ns), but no difference was observed between donor-
only conditions and conditions in which the FRET acceptor was also present. 
A second fluorescence lifetime component of small amplitude (often 
approximately 20% that of the principle component) and a shorter lifetime (1 - 1.6 ns) 
was occasionally detected.  However, this feature was not associated with any particular 
sample type or conditions: it was found in donor-only samples as well as samples in 
which both donor and accepter were present and also seen with both GFP and YFP as 
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donors.  The origin of this component is unknown; it is assumed to derive from 
background fluorescence in the membrane patch. 
Finally, a wide array of other FP construct combinations were expressed and 
imaged by FLIM, though none of these yielded fluorescence decay traces consistent with 
FRET either.  These combinations (Table 7.3), were not explored in as extensive detail as 
the EmGFP-Gγ2/β2AR-mCherry pair, but some conditions varied include ratios of 
mRNA injected and the presence of agonst, apyrase, or GTPγS – none of which altered 
the FLIM traces.  Additionally, a modified β2AR-EYFP was tested in which the C 
terminus of the receptor (to which EYFP is appended) was truncated by 48 residues 
(everything after amino acid 365 was removed).  This truncated version of the β2AR is 
known to be functional and is the form in which the receptor was co-crystallized with its 
G protein.1  It was hoped that having a shorter C terminus would position the appended 
YFP closer to the G protein, giving a higher FRET efficiency.  Unfortunately, no FRET 
was observed for this construct either.   
Table 7.3.  Other construct combinations tested for FRET 
Donor Acceptor 
β2AR-EYFP mCherry-Gγ2 
Gγ2-EYFP β2AR-mCherry 
D2DR-EYFP mCherry-Gγ2 
Gγ2-EYFP D2DR-mCherry 
D2DR-EYFP Gαi2-mCherry 
Gαi2-EYFP D2DR-mCherry 
β2AR-EYFP Gαs-mCherry 
β2AR[truncated]-EYFP mCherry-Gγ2 
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 One possible reason for the failure of these experiments is that the distances 
between fluorescent proteins in these G protein/receptor complexes are beyond the 
working distance of the donor/acceptor pairs chosen.  The Bouvier BRET experiments 
were conducted primarily using the Renilla luciferase/GFP10 BRET pair.  The Förster 
distance (R0) for this exact pair has not been reported in the literature, but luciferase 
paired with a related GFP analog (GFP2) has a R0 of 75 Å.25  In contrast, R0 for 
EmGFP/mCherry and EYFP/mCherry are 51 Å and 57 Å, respectively.  The shorter 
working distance of these pairs would result in lower FRET efficiencies, perhaps below 
the threshold of detection for this system. 
 
7.4  Conclusions 
As FRET was not convincingly observed between any receptor and G protein under 
any of the conditions tested, this assay for probing the interaction between GPCRs and 
their cognate G proteins was not pursued further.  As no conditions tested yielded a 
measurable amount of FRET, no starting point was found for further optimization, we 
can only speculate about the reasons for the failure of the assay.  FLIM, the method of 
FRET measurement, was validated by the positive control of EmGFP fused to mCherry, 
confirming that FRET can be detected by this experimental apparatus on fluorescent 
proteins expressed in these membrane patches.  The electrophysiology experiments 
described above suggest that at least some of the FP constructs tested are functional in the 
Xenopus system, though not all (and very few in combination with each other) were 
evaluated.  In literature reports, fluorescent protein fusions involving identical GPCRs 
and G proteins with (different) FPs placed at identical locations were functional and 
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yielded FRET in mammalian cells. 10,11  Most likely, either the fusions of receptors and G 
proteins interact differently in the Xenopus system - they do not readily couple to one 
another or interact more transiently – or the working distances of the fluorescent protein 
donor/acceptor pairs investigated here are too short for the interactions probed. 
 
7.5  Experimental 
7.5.1  Molecular biology and in vivo expression 
All constructs were in the pGEMhe vector.  Fluorescent protein fusions were 
assembled by PCR subcloning with correct insertions verified by sequencing.  cDNA was 
linearized with the appropriate restriction enzyme, purified (Qiagen), and used as a 
template for in vitro runoff transcription using the T7 mMessage mMachine Kit (Life 
Technologies).  Stage V–VI Xenopus laevis oocytes were harvested and injected with 
RNAs as described previously.7  Each oocyte was injected with 0.5–20 ng of each 
appropriate mRNA 24-72 hrs before recording or imaging. 
7.5.2  Electrophysiology 
Oocyte recordings were made in two-electrode voltage clamp mode using the 
OpusXpress 6000A (Axon Instruments).  Recording buffers were ND96 (96 mM NaCl, 2 
mM KCl, 1 mM MgCl2, 5 mM HEPES, 1.8 mM CaCl2, pH 7.5) and high K+ ringer (96 
mM NaCl, 24 mM KCl, 1 mM MgCl2, 5 mM HEPES, 1.8 mM CaCl2, pH 7.5). Solution 
flow rates were 2 mL min–1 and drug application flow rates were 2.5 mL min–1. Initial 
holding potential was −60 mV.  Cells were subjected to a ND96 pre-wash for 10 s, a high 
K+ application for 50 s to establish basal currents, and agonist (dopamine for D2DR, 
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isoproterenol for β2AR) application in high K+ ringer for 25 s, followed by high K+ and 
ND96 washings for 45 and 90 s in duration, respectively. Agonist-induced currents were 
measured over the basal K+ current as described previously.8 
7.5.3  Membrane preparation: 
Glass-supported plasma membrane sheets were prepared by the method of Singer-
Lahat et al.14  A devitellinized oocyte is laid on a glass cover slip embedded in a plastic 
petri dish in ND96 buffer for approximately 15 min.  The oocyte is forcefully aspirated 
into a Pasteur pipette, leaving behind a patch of membrane adhered to the cover slip, 
which is further aspirated and then forcefully rinsed with ND96 using a pipette.  
7.5.4  FLIM imaging: 
A commercial FLIM system (PicoQuant) was used, interfaced with a confocal 
fluorescence microscope (Nikon Eclipse TE 2000-U), and using a pulsed 488 nm 
excitation laser and a time-resolved single photon avalanche diode detector with filters 
suitable for both GFP and YFP emission.  In a typical experiment, a Xenopus oocyte 
plasma membrane sheet from an oocyte expressing FP constructs was imaged at 60x 
magnification and a fluorescence decay profile was generated for a region of strong 
fluorescence. 
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